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Abstract
Dialysis patients have higher rates of mortality than the normal population. The
increased mortality among dialysis patients is associated with age, presence of
comorbid conditions on starting dialysis, and poor nutritional status indicated by
several nutritional markers and inflammation. This project sought to analyse these
issues in a closely studied cohort of patients in South East Scotland.
In the first study subjective global assessment (SGA) of nutritional status was
interrogated as a possible independent risk factor for 122 prevalent dialysis patients.
The results showed age, comorbidity, SGA and C-reactive protein were associated
with patient survival, and that significant additional information was provided by
measuring SGA. In the second study factors associated with survival were examined
in 183 consecutive patients starting renal replacement therapy in South East Scotland
in 2003 and 2004. The results revealed that age, comorbidity, initial access and serum
cholesterol all affected patients survival. In the Third study this 2003 and 2004 cohort
was compared with a similar cohort commencing dialysis between 1997 and 2000 in
South East Scotland. The results showed that median age rose from 63 to 65 and
comorbidity increased but 2 year survival rate was unchanged and there was a
substantial reduction in hospitalisation. The reason for improvement can not be
identified with certainty but it could be because: between the two studies the unit
moved hospitals and gained more nephrologists; additional machines were introduced,
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1.1 Dialysis patients die early
Patients with end stage renal disease (ESRD) must be treated with dialysis or a
kidney transplant to extend their life expectancies. The principle of dialysis was
discovered in 1854 by Thomas Graham of Glasgow. Haemodialysis was performed
in man for the first time in 1924 by Hass. Willem Kolff developed the first
functioning artificial kidney in 1943-1945. Belding Scribner started the world's first
outpatient dialysis facility in 1962. Haemodialysis became a practical treatment for
kidney failure in 1960s, and is the most common method used to treat advanced and
permanent kidney failure. Peritoneal dialysis is the other modality of dialysis that
became more safe and convenient to use in the late 1970s and early 1980s
(edren.org).
Although maintenance dialysis prevents death from uraemia, patient's survival and
quality of life remain an important issue. Despite the improvement in dialysis
technology, the advances achieved in general nephrology, and overall improvements
in healthcare, dialysis patients carry higher rates of mortality than the normal
population. The mortality of dialysis patients is highly influenced by cardiovascular
disease (CVD), age, and comorbidity. According to reports from the United States
Renal Data System (USRDS), the first year mortality rate is still higher than 20% in
dialysis patients and 60% at 5 years. The five year mortality for young patients <65
years was 34% compared to 79% for patients at 56 years or over (USRDS, 2007).
The most recent figures of mortality excluding death during the first 90 days in the
UK was 19% at one year, and 55% at 5 years. The five year mortality was 35% for
young patients and 76% for patients at 65 years or older (Ansell et al., 2007). Foley
and colleagues (1998) compared the CVD mortality by age, race, and gender in the
general population and dialysis patients (Figure 1.1) and they showed that mortality




Figure. 1.1; Data from general population are from National Center for Health Statistics multiple cause
of mortality file 1993. Data from dialysis patients include haemodialysis and peritoneal dialysis
combined from USRDS 1994-1996. The cardiovascular mortality is defined as death due to
arrhythmias, cardiomyopathy, cardiac arrest, myocardial infarction, atherosclerotic heart disease, and
pulmonary oedema (from Foley et al., 1998).
1.2 Causes ofDeath
The major causes of death in haemodialysis patient are: cardiovascular disease,
infection, and withdrawal from dialysis (Bloembergen et al., 1994; Cohen et al.,
1995; Wallen et al„ 2001 & USRDS 2002).
1.2.1 Cardiovascular disease
Cardiovascular disease (CYD) is the leading cause of death in dialysis patients. It
accounts for approximately 50% of deaths in haemodialysis patients (Foley et al.,
1998). Cardiovascular mortality is 10 to 30 fold higher than that seen in general
population (Sarnak et al., 2000; Churchill et al., 1992). A dialysis patient aged 25 to
44 years is at similar absolute risk of death from cardiovascular disease as an
individual without renal disease aged over 75 years (Foley et al., 1998). The
increased cardiovascular risk in dialysis patients is not fully clear but it could be
explained by: -
1. Higher prevalence of traditional cardiovascular risk factors such as: -
3
I. About 40% of patients starting RRT are diabetic in the USA and 22% in the
UK (USRDS 2007; Ansell et ah, 2007).
II. Hypertension is present in about 50-90% of dialysis patients, whereas the
frequency of hypertension in age- and sex matched control subjects of the general
population does not exceed 25% (Zoccali 2000).
2. Increase occurrence of non traditional risk factors related to chronic kidney disease
including: -
I. Coronary arteries, heart valves and myocardium become calcified in
dialysis patients, which is associated with increased cardiovascular mortality (Braun
et al., 1996; Young et al., 2005).
II. Anaemia is a commonly present in patient starting dialysis treatment and
may contribute to development of left ventricular hypertrophy which was found an
independent risk factor for survival in dialysis patients (Harnett et al. 1994;
Silberberg et al., 1989).
III. Hyperhomocysteinemia in dialysis patients may contribute to increase
incidence of cardiovascular morbidity and mortality (Mallamaci et al., 2002; Botsom
et al., 1997; Moustapha et al., 1998).
However, hypertension, hypercholesterolemia and higher levels of homocysteine
may interact with other non traditional risk factors such as inflammation,
comorbidity and malnutrition, thereby altering their overall association with
cardiovascular disease in dialysis patients producing a concept known as reverse
epidemiology (discussed in 1.3.1.9.4).
3. Some have suggested that inflammation accelerate atherogenesis in dialysis
patients (Lindner et al., 1974; Amann et al., 2004). However, whether the
atherogenesis of dialysis patients is accelerated and whether the nature of
atherosclerosis is similar in haemodialysis patients and the general population remain
matters of debate.
4
4 Cardiovascular diseases may lead to renal hypoperfusion increasing the risk of
concurrent renal failure.
5. Factors that predispose to cardiac disease also confer susceptibility to ESRD,
therefore these diseases are most likely to co-exist.
1.2.2 Infections
Infections are responsible for approximately 15 to 20% of deaths and are usually due
to common organisms (such as staphylococcus aureus) and are often related to the
transcutaneous access necessary for both haemodialysis and peritoneal dialysis
patients (USRDS 2002; Ansell et al., 2003). An infectious aetiology was responsible
for 201 deaths, or 23.1% of all deaths in the HEMO study that included 1846
randomized chronic haemodialysis patients. 871 patients died in this study, providing
an annual death rate of 16.6%. The annual rate of infection-related death was 3.8%.
There were 1698 infection-related hospitalisations, yielding a 35% annual rate (Allon
et al., 2003). Increased infection rate in dialysis patients seems to be due to a variety
of predisposing factors including uremic immunosuppression malnutrition, and type
of vascular access (Allon et al., 2003)
1.2.3 Withdrawal from dialysis
Withdrawal of long term dialysis in patients with ESRD occurs frequently, and
accounts for approximately 15 to 25% of all yearly deaths among the chronic dialysis
population in the United States (USRDS 1995 & Cohen et al., 2003). It is the second
or third cause of death in such patients (Mailloux et al., 1993 & Bajwa et al., 1996).
Several patient factors are associated with the decision to withdraw from dialysis
including (Bajwa et al., 1996; Moss et al., 1994 & Leggat et al., 1997):
• Advanced age
• Diabetes mellitus and related vascular complications
• Extensive atherosclerotic disease




• Higher physical discomfort
• Higher educational level
Withdrawal rate is high among elderly dialysis patients. In one study, for example,
dialysis was discontinued in about 6% of patients younger than 65 years of age, but
in 14% of those over 65 years of age (Nelson et ah, 1994). In another report, 56% of
those over the age of 85 died because ofwithdrawal from chronic dialysis (Neu et ah,
1986).
1.3 Factors associated with survival of patients on dialysis
These can be divided into 2 groups of risk factors (Figure 1.2):
1. Risk factors not related to dialysis procedure
2. Risk factors related to dialysis procedure
Figure 1.2; Summary of factors associated with survival of patients on dialysis
HRQoL=health related quality of life, Ca-P04= calcium phosphate metabolism
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1.3.1 Risk factors not related to dialysis procedure
1.3.1.1 Age
Age is the most important of the demographic factors associated with increased
morbidity and mortality in ESRD. The mean age of new patients starting RRT is
between 60 and 65 years in the United States, Europe, Canada, and Japan. As
expected survival declines with increasing age, with patients under age 45 doing
best; this may be because with older age patients there is an increase in the
prevalence of comorbid diseases such as vascular disease and diabetes, which could
contribute to further increasing in the risk of cardiovascular death (Mailloux et al.,
1994; Charra et ah, 1992). An annual report from USRDS (2005) stated that
mortality rate of dialysis patients advances more dramatically with age than do the
rates of transplant, chronic kidney disease (CKD), and non CKD patients. The
European Renal Association-European Dialysis and Transplant Association (ERA-
EDTA) report (2004) compared the expected remaining lifetime in Europe and USA
whites among 3 different groups (general population, transplant, and dialysis
patients) and showed that the differences in life expectancy become less with
advanced age (Figure 1.2). The UKRR (2005) reported that for every 10 year
increase in patient age, there is an increase in the hazard of death in the year after 90
days of 41% (Ansell et ah, 2005).
Expected remaining lifetimes
ERA-EDTA Registry vs USA whites
years
Figure. 1.3; ERA-EDTA Registry report 2004
7
Mailloux and colleagues (1994) analysed the survival of 683 patients who started
renal replacement therapy (RRT) between 1970 and 1989, and found fourfold
increase in the risk of death between a starting age of 25 and 65 years, with median
survival decreasing from 122 months in the youngest to 29 months in the oldest age
group. Also an analysis of the survival of about 90.000 patients included in the
United States Medicare Program who began dialysis at age of 55 years or more
between 1982 and 1987 found that the benefit of chronic haemodialysis (defined as
years of extended life) diminished with advanced age, regardless of the cause of
renal failure (Byrne et al., 1994). Data from the Canadian Institute of Health
Information (1999) showed that the comorbidity rate increases with age and that 80%
of individuals more than 65 years of age have at least one other chronic illness at
time of initiation of RRT.
1.3.1.2 Race
Survival of patients in the United States varies with race. African-Americans and
Asian-Americans have a lower mortality rate than whites (USRDS, 2002; Wong et
al., 1999 and Tanna et al., 2000). In one study (based upon the 1995 USRDS report),
the survival rates of black, white and other races at five years were 35, 25 and 32
percent, respectively. Similar relative results were observed in a single centre, which
reported 47 and 36% survival rates at five years for black and white patients
respectively (Bleyer et al., 1996). The survival advantages persist after careful
adjustment for unique patient characteristics, comorbidities, and laboratory
abnormalities (Wong et al., 1999; Tanna et al., 2000; and Bleyer et al., 1996).
1.3.1.3 Underlying renal disease
Significant differences in outcome are associated with underlying disease. Five year
survival among dialysis patients is best with chronic glomerular disease and
polycystic kidney disease, intermediate with hypertension-induced renal disease, and
worst with diabetic nephropathy (Mailloux et al., 1994). Patients with renovascular
disease also have poor prognosis; the risk ofmortality in these patients is double that
of patients with other renal diseases (excluding diabetes), and the survival estimate at
5 and 10 years are 16 and 8 percent respectively (Mailloux et al., 1994).
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1.3.1.4 Comorbidity
In the HEMO study, comorbidity was defined as all medical problems other than the
cause of renal disease (Miskulin et al., 2001).
1.3.1.4.1. Comorbidity and outcome
Comorbid medical conditions are frequently seen in dialysis patients and have an
important effect on clinical outcomes, including death, hospitalisation, and quality of
life. The UKRR (2005) reported that comorbidity is a powerful predictor of early and
late mortality among patients starting RRT (Ansell et al., 2005). The influence of
comorbidity on outcomes in dialysis patients have been addressed in a number of
observational studies. Wright (1991) showed that survival in RRT was significantly
influenced by the presence of cardiovascular disease, diabetes mellitus, chronic
obstructive pulmonary disease and cancer. Davies and coworkers (1995) in a study of
97 peritoneal dialysis patients found a strong effect of comorbid disease on mortality.
Khan and colleagues (1996) also found that survival in 1407 patients in seven centres
in five European countries was similarly influenced by the presence of comorbidity.
Chandna and collaborators (1999) found that comorbid conditions are important in
predicting survival and morbidity of patients on dialysis. The presence of diseases
such as cardiac disease, cerebrovascular disease, diabetes, atherosclerosis, and
malignancy have been recognized to play a big role in increasing the mortality risk in
ESRD patients (Shapiro et al., 1983; Khan et al., 1993). Data from Dialysis Outcome
and Practice Pattern Study (DOPPS) (2003), which compared demographic
characteristics and comorbid conditions of 17236 haemodialysis patients across
Europe, Japan, and US, showed that increasing age and a variety of comorbid
conditions (coronary artery disease, congestive heart failure, diabetes mellitus,
peripheral vascular disease, cerebrovascular disease, lung disease, cancer,
gastrointestinal bleeding, HIV infection, neurologic disease and hepatitis) were
associated with higher mortality (Goodkin et al., 2003).
1.3.1.4.2 Comorbidity Assessment
There is no consensus on the measurement and grading of comorbid illnesses in
dialysis patients. However, several comorbidity indices have been developed and
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modified specifically for dialysis population. Each has been validated for outcome of
mortality in the dialysis population, with a graded increase in mortality risk predicted
per increment in instrument level (Charlson et al., 1987; Wright et al., 1991; Khan et
al., 1993; Nicolucci et ah, 1992; Beddhu et ah, 2000; and Davies et ah, 2002).
1.3.1.4.3 Charlson comorbidity index
The Charlson Comorbidity index (CCI) was developed in 1987 based on one year
mortality data from internal medicine patients. It was initially validated in a cohort of
patients with breast cancer. The index consists of 19 medical conditions which are
primarily defined using International Classification of Diseases Ninth Revision
diagnosis codes (ICD-9-CM); each condition is weighted 1-6 with total scores
ranging from 0-37 (Table.1.1). From the weighted conditions, a sum score represents
the total comorbidity score. To account for the effects of increasing age, one point
can be added to the CCI score for each decade of life over the age of 50 (Charlson et
al., 1987). CCI is a widely used tool in areas other than ESRD and has been found to
predict survival in patients treated both by peritoneal dialysis (Fried et ah, 2001), and
haemodialysis (Beddhu et ah, 2000).
Score Condition Score Condition
1 Myocardial infarct 2 hemiplegia
1 Congestive heart disease 2 Moderate or severe renal disease
1 Peripheral vascular disease 2 Diabetes with end organ damage
l Cerebrovascular disease 2 Any tumour
1 Dementia 2 Leukaemia
1 Chronic pulmonary disease 2 Lymphoma
l Connective tissue disease 3 Moderate or severe liver disease
1 Ulcer disease 6 Metastatic solid tumour
1 Mild liver disease 6 Acquired immunodeficiency syndrome AIDS
1 diabetes
Table.l. I; Charlson comorbidity scores
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1.3.1.4.4 Khan score
This is a combination of age and comorbidity, used to assign patients to one of three
risk groups; low, medium, and high risk (Khan et al., 1993). Patients over 80 years
are always classified in the high risk group. Patients between 70 and 80 years are
allocated to the medium or high risk group (Table 1.2) (Khan et al., 1993).
Grade-0 (low risk) Age<70 years and no comorbid disease
Grade-1 (medium risk) Age 70-80 years, or <70 years age with any one of the
following: Angina, previous myocardial infarction, cardiac
failure, chronic obstructive airway disease, pulmonary fibrosis,
or liver disease (cirrhosis, chronic hepatitis), peripheral
vascular and cerebrovascular diseases or <70 with diabetes
mellitus
Grade-2 (high risk) Age>80 years, or <80 years with two or more organ
dysfunction, cardiopulmonary disease, visceral malignancy, or
70-80 years with diabetes or cardiopulmonary disease.
Table. 1.2; Khan comorbidity risk groups
1.3.1.4.5 Davies score
This is based on the presence or absence of seven comorbid conditions (malignancy,
ischaemic heart disease, peripheral vascular disease, left ventricular dysfunction,
diabetes, systemic collagen vascular disease and pulmonary diseases) (Table 1.3),
also producing three risk groups (Davies et al., 1995 and 2002). Unlike other indices
age is not included in this index, because it was specifically designed to be used in
conjunction with age as an independent covariate. Patients without comorbid
conditions are classified as low risk, patients with one or two comorbid disease are
regarded as medium risk. Patients with three or more comorbid conditions are
classified as high risk patients (Davies et al., 1995 and 2002).
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Ischemic heart disease (defined as prior MI, angina, or ischemic changes on ECG)
Left ventricular dysfunction (defined as history of congestive heart failure, pulmonary





Other significant pathology (chronic obstructive pulmonary disease)
Table 1.3; Davies comorbidity conditions
van Manen and colleagues (2002) found that Charlson, Khan, and Davies indices had
similar prognostic value with respect to mortality in ESRD patients. Furthermore,
they found that a comorbidity index that included severity grading of several diseases
did not perform better than the Charlson, Khan and Davies indices. Also the same
group in the Netherlands Cooperative Study on Dialysis Adequacy (NECOSAD
study), an observational cohort study involving 1041 incident dialysis patients from
36 centers in the Netherlands, evaluated the accuracy of these indices when taking
the health status as an outcome measure and they found that the three indices
performed equally with respect to their association with health status. However, they
favoured the Davies index because it required the least variables to be recorded to
score it (van Manen et al., 2003).
1.3.1.5 Anaemia
Anaemia remains a common finding in dialysis patients. The UKRR (2005) reported
that 40% of individuals new to dialysis had a haemoglobin < 1 Og/dl (Ansell et al.,
2005). Haemodynamic changes in anaemia include increased preload, heart rate and
stroke volume as well reduced afterload all act to raise cardiac output (Duke et al.,
1969). Over time these compensatory mechanisms lead to eccentric left ventricular
hypertrophy.
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There is no convincing evidence for a specific target level of haemoglobin. The
appropriate target haemoglobin concentration has been debated almost since
recombinant human epoetin first became available.
The observational data suggest a high haemoglobin level (>13 g/dL) associated with
lower rates of hospitalisation and mortality (Collins et al., 2001; and Ma et al., 1999;
and Li et al., 2004) and haemoglobin level (<10 g/dL) [haematocrit <30%] increase
the risk of mortality (Madore et al. 1997; Locatelli et al., 1998; Ma et al. 1999; and
Locatelli et al., 2004). These observational studies have limitations because of their
retrospective design and the potential effect of confounding factors.
However, randomized controlled studies failed to show reduction in mortality when
aiming for a haemoglobin level of >12 g/dl. The CHOIR and CREATE randomized
trials included 1432 and approximately 600 patients with CKD respectively. They
showed either risk or no benefit with regard to cardiovascular outcomes aiming to
completely correct the haemoglobin in CKD patients (Singh et al., 2006; and Drueke
et al., 2006). Also the Canada-Europe study, which included 596 incident
haemodialysis patients, showed a higher rate of cerebrovascular acceident in the
higher haemoglobin group (13 g/dl) versus lower haemoglobin group (11 g/dl)
(Parfrey et al., 2005). However, normalization of haemoglobin was shown to be
associated with improved quality of life in terms of main physical symptoms, fatigue,
depression and frustration as evaluated by Kidney Disease Questionnaires (Furuland
et al., 2003; Drueke et al., 2006).
International guidelines have recommended different target haemoglobin
concentrations. The first National Kidney Foundation Kidney Disease Outcomes
Quality Initiative anaemia guidelines, published in 1997 (K/DOQI 1997a) and
updated in 2001 (K/DOQI 2001a), called for a 11-12 g/dl target haemoglobin range.
In May 2006 the guidelines were changed to an effective target range of 11-13 g/dl
(K/DOQI 2006). The European Best Practice Guideline 5 (2000) set a minimum
target of haemoglobin 11 g/dl, with an average value of 12-12.5g/dl. The UK Renal
Association recommended that individuals with chronic renal failure should achieve
haemoglobin of lOg/dl within 6 months of being seen by a nephrologist unless there
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is a specific reason why it could not be achieved. The above recommendation more
likely to be refined or changed as further big randomized controlled studies
examining the benefit of higher versus lower target haemoglobin concentrations are
published.
1.3.1.6 Diabetes Mellitus
The number of patients who have diabetes and ESRD and are being treated with
RRT is increasing dramatically, to the point that, during the past few years, in many
countries, diabetes has or will soon become the most frequent single cause of ESRD.
According to USRDS, the annual number of patients who have diabetes and are
admitted to RRT in the United States more than doubled between 1995 and 2000
(from 19155 to 41685 patients), and there was a striking increase in the percentage of
incident ESRD patients with diabetes as the primary renal diagnosis (30.4% in 1987,
36.3% in 1992, and 45.2% in 2000) (USRDS 2002). As a consequence of the
increasing number of patients who have diabetes and are being admitted to RRT and
their improved survival, the prevalence of RRT patients with diabetes has also
significantly increased worldwide; in the US, the proportion of RRT patients with
diabetes as the cause of ESRD increased from 26.9% in 1991 to 30.6% in 1995 and
36% in 2000 (USRDS 2002)
Patients with diabetes receiving RRT continue to do worse with respect to survival
and QoL than do non-diabetic patients (Wolfe et al., 1992; and USRDS, 2003).
According to USRDS (2002), the adjusted 5-year survival of patients who have
diabetes and started RRT in 1995 was 33.6% (it was 24.5% for patients who started
dialysis in 1985); significantly worse than that of patients in whom primary cause of
ESRD was hypertension (42%), glomerulonephritis (53%), or other renal disease
(43%). The main reason for such high mortality rates, which is of cardiovascular
origin in the majority of cases (Koch et al., 1993), is that the cardiovascular
conditions of patients with diabetes are already severely impaired when they start
RRT, as demonstrated by the high prevalence of coronary artery disease, stroke,
peripheral vascular disease, and amputations (Stack et al., 2001; and Eggers et al.,
1999). This explains why patients who have diabetes and are on RRT are at higher
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risk of developing de novo cardiovascular disease, particularly ischaemic heart
disease, which not only is more frequent but also has a more aggressive course than
in non-diabetic patients (Herzog et al., 1998). Survival also varies inversely with age,
being best in young diabetics with good blood pressure control and no clinically
evident cardiac disease (USRDS, 2003; and Locatelli et ah, 2003). The USRDS 2003
report showed that extended survival at 10 years appears to be less likely for diabetic
as compared to non-diabetic patients (4% versus 11 to 14%).
1.3.1.7 Hypertension
Hypertension is a common finding in dialysis patients. Based upon multiple studies,
over 50 to 60% of haemodialysis patients are hypertensive. These values are much
lower than the 80% incidence of hypertension at the initiation of dialysis, due largely
to better volume control in most patients (Zuccala et ah, 1988). The relationship
between blood pressure and mortality in dialysis patients remains controversial.
There has been considerable discussion regarding whether hypertension is a risk
factor for mortality, whether hypotension is associated with increased cardiovascular
mortality, and how much blood pressure must be lowered to minimize mortality.
High blood pressure in the general population is associated with increased
cardiovascular mortality and morbidity, and its control can reduce these adverse
consequences (Sytkowski et ah, 1996). Unlike the general population, observational
studies showed that haemodialysis patients have a higher mortality rate with a low
blood pressure whereas survival advantages shown to be associated with a high
blood pressure, what is termed as reverse epidemiology (Kalantar-Zadeh et ah,
2003b). One study of 5433 haemodialysis patients found that, low systolic blood
pressure <110 mmHg pre and post dialysis was associated with increased overall and
cardiovascular mortality (Zager et ah, 1998). Another report of nearly 4500
haemodialysis patients also found a significantly increased mortality risk among
patients with low pre-dialysis systolic blood pressure (110 mmHg) (Port et ah, 1999).
On the other hand, a relation between hypertension and increased mortality was
observed (Charra et ah, 1992; Fernandez et ah, 1992). in a study of 11142
haemodialysis patients from the USRDS dialysis morbidity and mortality waves 3
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and 4 study found that high post dialysis systolic blood pressure values were
associated with increased mortality and use of anti-hypertensive medication showed
a strong association with survival (Foley et al., 2002).
The inverse relation between blood pressure and mortality has resulted in questioning
whether treatment goals for hypertension control in dialysis patients should be
different from the general population. It would appear not reasonable to accept
uncontrolled hypertension in dialysis patients. Observational studies showed that
adequate blood pressure control may lead to reduction of cardiovascular events
especially congestive heart failure and regression of left ventricular hypertrophy
(Nakamura et al., 2005; London et al., 2001) and furthermore, optimal blood pressure
control is associated with high survival rates (Charra et al., 1992: Foley et al., 2002).
In general, treatment goals of hypertension should not based on observational
studies. Prospectiv e randomised studies are needed to compare the effect of different
blood pressure targets on outcome in dialysis patients.
1.3.1.8 Cardiovascular disease
At onset of dialysis heart disease is very common; around 44% (Foley et al., 1995).
Cardiac disease is the leading cause of death among prevalent maintenance dialysis
patients. About half the deaths in dialysis patients are attributed to CVD (USRDS,
1998). In addition, dialysis patients with cardiac disease have a higher case-fatality
rate than non dialysis patients with heart disease. Cardiovascular morbidity is also
high, accounting for about one third of the hospitalisations of dialysis patients
(USRDS, 1998). This excess in cardiovascular morbidity and mortality is, in part,
caused by high prevalence of cardiac disease before initiation of dialysis (Foley et
al., 1995), the high prevalence of cardiovascular risk factors in patients with
progressive CKD and to the contribution of diabetes and hypertension in the
aetiology of ESRD (USRDS 2003).
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1.3.1.8.1 Risk factors for cardiovascular morbidity and mortality
These can be divided into 2 major groups
1. Traditional risk factors (diabetes, hypertension, dyslipidemia, age and
smoking).
2. Factors related to chronic kidney disease (anaemia, abnormality of calcium-
phosphate metabolism [secondary hyperparathyroidism], and malnutrition)
1.3.1.8.1.1 Traditional risk factors
1.3.1.8.1.1.1 Diabetes Mellitus
In ESRD it is widely recognised that diabetic patients are at a very high
cardiovascular risk. At commencement of dialysis, diabetes was strongly associated
with concentric left ventricular hypertrophy, ischaemic heart disease, and cardiac
failure compared with non diabetics (Foley et al., 1997). In addition, it was
associated with the development of de novo ischaemic heart disease (Foley et al.,
1997) (diabetes was discussed more in 1.3.1.6)
1.3.1.8.1.1.2 Hypertension
Hypertension was discussed in 1.3.1.7.
1.3.1.8.1.1.3 Dyslipidemia
Disturbance in plasma lipoprotein metabolism is frequently observed among patients
with ESRD, particularly those on dialysis. The combination of dyslipidemia and
other co-existing risk factors such as hypertension and diabetes is likely to contribute
to a marked increase in the risk of cardiovascular morbidity and mortality in
individuals receiving dialysis (Foley et al., 1998).
Dyslipidemia in haemodialysis patients is characterized by: i) increased
concentration of plasma triglycerides rich apoB containing lipoproteins. They occur
preferentially in very low density lipoprotein (VLDL), intermediate density
lipoprotein (IDL), and low density lipoprotein (LDL). ii) Reduced concentration of
apoA containing lipoprotein mainly apoA-I and apoA-III. They occur preferentially
in high density lipoprotein (HDL), iii) Increase in apoC-III and apoE concentrations
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(Attman et al., 1999). The apolipoprotein profile of peritoneal dialysis patients is
characterized by a proportionately greater increase in the level of apoB, apoC-III,
and apoE than in haemodialysis patients (Johansson et al., 2000). The principal
disturbance of the lipoprotein metabolism appears to be a reduced catabolism and
clearance of triglyceride rich apoB containing lipoproteins (Attman et al., 1993).
Observational studies in dialysis patients have shown that low, rather high
cholesterol is a marker of high risk in these patients, possible because low cholesterol
reflects malnutrition (Lowrie et al., 1990). Liu and colleagues (2004) suggested that a
low cholesterol level is considered as a marker of malnutrition in dialysis patients as
they found that cholesterol levels are related to the nutritional status of dialysis
patients (Liu et al., 2004). Data from USRDS (2003) showed that low serum
cholesterol is associated with an increased risk of death. Also decreased cholesterol
may be a marker of inflammation (see section 1.3.1.9.2).
Statin treatment has been proven to reduce the mortality and morbidity in
cardiovascular disease in patients with normal renal function (4S, 1994; WOSCOPS,
1995; MRC/BHF, 2002). Meta-analysis of 14 trials including 90,000 participants
showed a clear benefit from statins for both primary and secondary prevention, but
too few patients with CKD were included in these trials (Baigent et al., 2005).
There is no definitive evidence that statins significantly reduce cardiac death in
patients on RRT. The Assessment of Lescol in renal transplantation (ALERT) study
compared Fluvastatin versus a placebo showed that there was no significant
reduction in cardiac death and myocardial infarction over 6 years follow-up (Holdaas
et al., 2001). The cholesterol and Recurrent events (CARE) study showed Pravastatin
40mg reduced further cardiac events in patients with previous myocardial infarction
and mild CKD (Tonelli et al., 2003). The Cerivastatin in Heart Outcomes in Renal
Disease: Understanding Survival study (CHORUS) was initiated using Cerivastatin
in haemodialysis patients, but stopped in 2001 when Cerivastatin was withdrawn
from the market.
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The Die Deutsche Diabetes Dialysis Study (4D study), a double blind controlled trial
randomised 1255 patients with type 2 diabetes receiving maintenance haemodialysis,
to receive 20 mg of atorvastatin per day or matching placebo showed surprising
results as the primary end point of cardiovascular death, was only reduced by 8%
which was not statistically significant. The 4 D investigators concluded that dialysis
patients mainly die from cardiovascular deaths other than due to coronary artery
disease precipitated by hypercholesterolemia, or the negative results might have been
due to the advanced cardiovascular diseases in the chronic haemodialysis patients,
and because statin therapy was initiated too late (Wanner et al., 2005). In contrast,
the CARDS trial (Collaborative Atorvastatin Diabetes Study) of 2838 patients with
type 2 diabetes who had not yet developed significant kidney disease to assess the
effectiveness of atorvastatin 10 mg daily for primary prevention of major
cardiovascular events showed that atorvastatin reduced the rate of acute coronary
events by 36%, coronary revascularization by 31%, stroke by 48%, and death by
27% (Colhoun et al., 2004). It is reasonable to continue using statin until further
evidence is available that confirms the results of the 4D study in larger numbers of
dialysis patients including those non diabetic and peritoneal dialysis patients.
Work to find a clear evidence of statins beneficial effect on survival of dialysis
patients is still ongoing. The Study of Heart and Renal Protection (SHARP) was
designed to assess the effects of lowering cholesterol on major vascular events, and
on the rate of progression to ESRD among patients with CKD. SHARP aims to
compare Ezetimibe (cholesterol absorption inhibitor)/Simvastatin (cholesterol
lowering therapy) versus placebo among 9000 patients with CKD (3000 on dialysis).
Results are expected in 2009. The AURORA study is evaluating the use of
Rosuvastatin (lOmg versus placebo) in 2700 regular haemodialysis patients and




Smoking is an important CVD risk factor. Recently, it has been implicated in the
progression of CKD in patients with severe hypertension (Regalado et al., 2000). The
Cardiovascular Risk Extended Evaluation in Dialysis (CREED) study, which
investigated the relationship between carotid atherosclerosis and some major
cardiovascular risk factors in patients on chronic dialysis, recruited 119 unselected
dialysis patients (89 on haemodialysis and 30 on peritoneal dialysis). In a detailed
echo-colour Doppler study of the carotid arteries of this cohort, they found that
arterial pressure and smoking were associated with carotid atherosclerosis,
independent of the other risk factors (Malatino et al., 1999). Smoking appears to be
especially harmful in diabetic ESRD patients. In one study it was associated with a
doubling of mortality rates (McMillan et al., 1990). In a study comparing survival
rate in 22 diabetic haemodialysis patients who smoked >10 cigarettes/day with that
in 30 non smoking haemodialysis diabetic patients, five year survival was 9% and
30% in the smokers and no smokers, respectively (Biesenbach et al., 1996).
1.3.1.8.1.2 Factors related to chronic kidney disease
1.3.1.8.1.2.1 Anaemia
Anaemia was discussed in 1.3.1.5.
1.3.1.8.1.2.2 Abnormality of calcium - phosphate metabolism
Renal osteodystrophy is a common complication of CKD and is believed to have its
origins early in the onset of renal impairment (Coburn 1980). Elevations of
parathyroid hormone (PTH) in serum have been reported in patients with only
slightly abnormal GFR of 60 to 80 ml/min (Slatopolsky et al., 1985 and Baker et al.,
1989). The skeletal manifestations vary from patient to patient, but essentially fall
into 2 groups [high-turnover lesions (osteitis fibrosa and mild hyperparathyroid
disease) and low-turnover lesions (osteomalacia and adynamic)], and, in children,
retardation of growth. Extra-skeletal manifestations of this syndrome, such as
myopathy, vascular and visceral calcification, and peripheral ischaemic necrosis, are
also well recognized (Block et al., 2004 and Young et al., 2005).
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However, over the past 10 years, it has become apparent that there is a strong
association between serum phosphate levels, vascular disease and increased mortality
in dialysis patients. Block and colleagues (2004) showed that hyperphosphataemia
and hyperparathyroidism were significantly associated with all-cause, cardiovascular,
and fracture-related hospitalisation in haemodialysis patients. Ganesh and
collaborates (2001) found that serum phosphate >2.10 mmol/L (6.5 mg/dl) phosphate
was significantly associated with increased relative risk of death from coronary
artery disease and sudden death. An observational study describes the significant
predictors, and consequences of abnormal calcium-phosphate metabolism in
representative groups of 307 haemodialysis facilities which enrolled 17236 patients
participating in the DOPPS study. This showed that all-cause mortality and
cardiovascular mortality were significantly associated with serum concentrations of
phosphate, calcium, calcium-phosphate product and PTH (Young et al., 2005). The
UK Renal association recommended serum phosphate maintained between 1.1 and
2 2
1.8 mmol/1 and calcium phosphate product should be kept below 4.8 mmol /L and
ideally below 4.2 mmol2/ L2. The K/DOQI guidelines (2003) recommended that
serum phosphate should be between 1.13 and 1.78 mmol/L (3.5 and 5.5mg/dL) and
calcium phosphate products upper limits of 55mg2/dL2.
Observational studies showed the association between serum calcium level and
increased morbidity and mortality. In a study of 433 patients commencing dialysis
(both haemodialysis and peritoneal dialysis) showed low calcium level (mean
calcium <2.2 mmol/L (8.8 mg/dL) was significantly associated with increased
mortality (RR 2.10). Morbidity was also increased. The relative risk associated with
calcium level of < 2.2 mmol/L was 5.23 for de novo ischaemic heart disease, 2.46 for
recurrent ischaemic heart disease and 2.64 for recurrent cardiac failure (Foley et al.,
1996b). The DOPPS study also showed that mortality of haemodialysis patients is
associated with serum calcium (Young et al. 2005). The UK Renal Association
recommended serum calcium maintained between 2.2 and 2.5 mmol/L whereas the
K/DOQI guideline is unique in recommending that serum calcium be maintained in
the lower half of the normal range (2.10 to 2.37mmol/L [8.4 to 9.5mg/dL]).
However, no randomized trials support the hypothesis that a decrease in serum
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phosphate or calcium levels toward the normal or target level might be associated
with decreased mortality. The long-term effects of this on serum PTH and mortality
are unknown and no randomized trial has ever tested the guideline.
1.3.1.8.1.2.3 Malnutrition
Malnutrition is discussed more in 1.3.1.10
1.3.1.9 Inflammation
Inflammation has been identified as an epidemiological^ important risk factor for
cardiovascular disease in the general population (Ridker et al., 1998). In CKD
patients elevated levels of inflammatory markers have been shown to be associated
with increased all cause and cardiovascular mortality (Zimmermann et al., 1999;
Yeun et al., 2000; Stenvinkel et al., 2002; Wang et al., 2003; Menon et al., 2005; and
Mallamaci et al., 2005). Several inflammatory biomarkers, such as serum albumin
(Lowrie et al., 1990), CRP (Zimmermann et al., 1999; and Yeun et al 2000),
interleukin (IL)-6 (Kimmel et al., 1998; Pecoits-Filho et al., 2002; and Rao et al.,
2005), intercellular adhesion molecule (ICAM)-l (Suliman et al., 2006), neutrophils
count (Pifer et al., 2002), IL-18 (Chiang et al., 2004), and fibrinogen (Zoccali et al.,
2003) predict hospitalisation and outcome in patients with ESRD.
1.3.1.9.1 C-reactive protein (CRP)
CRP is a well established acute phase reactant. It has a pentameric structure with a
molecular weight of 115 kDa. Its physiological function is not fully understood, but
it may play a role in the clearance of endotoxins and opsonized bacteria. It increases
during many conditions such as infections and recent surgery.
In the general population CRP is found to be related to the risk of myocardial
infarction, stroke and sudden death (Ridker et al., 1997). Since the Bergstrom and
colleagues report (1995) of an association between elevated CRP and outcome,
several studies have found an independent association between CRP levels and both
all cause and cardiovascular mortality in CKD (Menon et al., 2005) as well as ESRD
patients treated with haemodialysis (Ikizler et al., 1999; and Yeun et al., 2000) or
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peritoneal dialysis (Noh et al., 1998; and Ducloux et al., 2002). Zimmerman and
colleagues (1999) monitored mortality in 280 stable haemodialysis patients over a 2
year observational period and found that all cause and cardiovascular mortality rate
have been increased with increasing quartiles of CRP. Patients with CRP levels in
the highest quartile >15.7 mg/dl experienced almost a 5-fold increase in all cause and
cardiovascular mortality compared with patients who had CRP levels less than
3.3mg/dl. This effect was independent of several other known mortality predictors.
This study strongly agrees with Iseki and coworkers (1999) study which included
163 haemodialysis patients and again showed that high CRP levels are a strong
predictor of death in chronic dialysis patients. Recent experimental work showed
therapeutic inhibition of CRP is a promising new approach to cardio-protection in
acute myocardial infarction. Pepys and colleagues (2006) found that administration
of CRP binding inhibitor [l,6-bis(phosphocholine)-hexane] to rats undergoing acute
myocardial infarction stopped the increase in infarct size and cardiac dysfunction
produced by injection of human CRP (Pepys et al., 2006).
1.3.1.9.2 Inflammation and malnutrition
The association between malnutrition and inflammation in ESRD patients could be
an explanation for malnutrition associated mortality (Kalantar-Zadeh et al., 2001;
Kaysen et al., 2002; and Qureshi et al., 2002). Many studies suggested that
malnutrition is a consequence of chronic inflammation in patients with renal
insufficiency (Kaizu et al., 1998; Yeun et al., 1998; and Stenvinkel et al., 2002). The
malnutrition secondary to inflammation could be developed due to elevated levels of
pro-inflammatory cytokines that could increase protein degradation, suppress protein
synthesis and induce anorexia by suppression of appetite through the anorexic
hormone leptin, which at least in animal experiments has been shown to be up-
regulated by pro-inflammatory cytokines (Flores et al., 1989; Espat et al., 1994;
Grunfeld et al., 1996; and McCarthy et al., 2000). Also the synthesis and serum
concentrations of nutritional markers (serum albumin, prealbumin, serum cholesterol
and transferrin) decrease during inflammation entirely independently of nutritional
state (Ritchie et al., 1999; Lowrie 1998; and Moshage et al., 1987). Stenvinkel and
colleagues (1999) established that patients with pre-ESRD who were judged to be
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malnourished by measurement of subjective global assessment also had markers
consistent with the presence of inflammation. CRP was significantly greater in
malnourished patients.
1.3.1.9.3 Malnutrition inflammation and cardiovascular disease
Although malnutrition and inflammation have been reported to be strong predictors
of cardiovascular mortality in dialysis patients (Acchiardo et al., 1983; and Owen et
al., 1998), they do not appear to be the direct causes of mortality in most patients.
Instead, CVD is the most common cause of mortality in this population (Foley et al.,
1998), whereas malnutrition may be a direct cause of less than 5% of deaths (ERA-
EDTA 1986). A study by Qureshi and colleagues (2002) to assess the importance of
nutritional status, inflammation and comorbidity as predictors of mortality in 128
haemodialysis patients showed that malnutrition, inflammation and CVD were all
significant independent risk factors for mortality and they suggested that
inflammation, malnutrition, and CVD could be interrelated. Moreover, malnutrition
and inflammation are associated with a higher cardiovascular mortality in
haemodialysis patients (Keane et al., 1994; and Zimmerman et al., 1999).
1.3.1.9.4 Reverse epidemiology
Traditional risk factors (hypertension, obesity and hypercholesterolemia) are
predictors of cardiovascular disease in the general population, whereas the reverse is
observed in chronic haemodialysis patients. In these individuals, high blood pressure,
obesity, and high levels of serum cholesterol levels appear to be associated with a
survival advantages (Fleischmann et al., 1999; Zager et al., 1998; and Iseki et al.,
2002). Interestingly, reversal back to traditional epidemiology has been described
after successful renal transplantation (Kasiske 2000). These contradictory
observations, which are in contrast to the well known association between
hypercholesterolemia, hypertension, obesity, and poor outcome in the general
population, have been referred to as reverse epidemiology (Kalantar-Zadeh et al.,
2003b). The aetiology of the switch to the opposite direction in chronic
haemodialysis patients is not clear. The reverse epidemiology phenomenon may be
related to the presence of malnutrition inflammation and atherosclerosis complex and
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its strong impact on outcome in this group of patients. Based on 10 years follow up
of 1167 haemodialysis patients, Iseki and his group (2002) reported that patients with
hypocholesterolemia had a higher prevalence of elevated CRP and a lower survival.
The confounding effect of malnutrition inflammation atherosclerosis syndrome on
the association between CVD risk and risk factors, such as hypercholesterolemia and
obesity as indicated by high BMI, is apparently able to reverse the associations
observed in the general population. The reverse epidemiology phenomenon could be
also due to survival bias as patients with CKD who are not on dialysis have a high
mortality and small number of these patients reaches ESRD. Therefore, it is possible
that selection of survivors leads to a different epidemiology. A study of the natural
history of chronic kidney failure which included 28,000 patients (GFR
<90ml/min/1.73m ) showed that the prevalence of hypertension and hyperlipidemia
was lower in patients who died before advancing to ESRD than in survivors (Keith et
al., 2004).
1.3.1.10 Malnutrition
Malnutrition is common in patients with CKD, with prevalence ranging from 28% to
48% in predialysis patients (Heimburger et al., 2000; and Lawson et ah, 2001) and 9
to 72% in dialysis patients (Kopple 1997a; and Stratton et al., 2003). The nutritional
status in dialyzed patients is affected mainly by presence of comorbid conditions
(CANUSA, 1996).
According to Stenvinkel and colleagues (2000), there are 2 forms of protein energy
malnutrition (PEM) in dialysis patients: type 1, a more benign form, in which
inadequate nutritional intake is the predominant cause, can be effectively treated by
increased nutritional intake and with little or no important consequences for clinical
outcome. In contrast, type 2, a malignant form essentially caused by inflammation
and associated with poor clinical outcome. Table 1.4 lists the major groups of
measurements (dietary intake, body compositions, scoring system, and laboratory
tests) that have been used to assess nutritional status in dialysis patients (Kalantar-
Zadeh et ah, 2003a). However there is no one agreed measurement that functions
well for assessing nutritional status in dialysis patients.
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Malnutrition is a common risk factor of poor quality of life and increased morbidity
and mortality, including cardiovascular death in maintenance dialysis patients
(Kopple 1997b and; Kopple et al., 1999). Malnutrition may be a direct cause of less
than 5% of deaths (ERA-EDTA 1986), but the significant relationship between
malnutrition and CVD morbidity and mortality in haemodialysis patients has been
demonstrated in many studies (Bergstrom et al., 1998; Foley et al., 1996a;
Zimmermann et al., 1999; and Kaysen et al., 2001). Moreover, under-nutrition state
of maintenance dialysis patients may predispose to infection or other inflammatory
processes that may be responsible about association between malnutrition and
adverse outcome (Kalantar-Zadeh et al., 2001; and Kaysen et al., 2002).
Furthermore, the malnutrition, inflammation and atherosclerosis relationship which




• Direct: Diet recalls and diaries, food-frequency questionnaires.
• Indirect: based on urea nitrogen appearance: normalized protein nitrogen
appearance (nPNA) = normalized protein catabolic rate (nPCR)
2. Body composition
• Weight based measures: BMI, weight for height, oedema-free fat-free weight
• Skin and muscle anthropometry by calliper: skin-folds, extremity muscle mass
• Total body elements: total body potassium
• Energy-beam-based methods: Dual Energy X-ray Absorptiometry, (DEXA),
Bioelectrical Impedance analysis, (BIA), Near-Infra Red interactance (NIR)
• Other energy-beam- related methods: total body nitrogen
3. Scoring System
• Conventional Subjective Global Assessment (SGA), and it is modifications (e.g.
Dialysis Malnutrition Score), Malnutrition-Inflammation Score (MIS))
• Other scores: Haemodialysis Prognostic Nutritional Index, e.g. (Harty et al, 1994;
Merkus et al, 2000)
4. Laboratory values
• Serum proteins; Albumin, Prealbumin
• Serum creatinine, semm urea nitrogen
• Growth factor: IGF-1, leptin
Table. 1.4; Assessment tools for evaluation of malnutrition in maintenance dialysis patients (Kalantar-
Zadeh et al., 2003a)
1.3.1.11. Malnutrition markers and mortality
The malnutrition and adverse outcome relationship has been demonstrated by several
studies where the malnutrition status has been assessed by the following nutritional
markers :-
1.3.1.11.1. Serum Albumin
Serum albumin is probably still the most commonly used nutritional marker in ESRD
patients. Lowrie and Lew (1990) found a strong inverse relationship between serum
albumin and all-cause mortality in a retrospective analysis of more than 12,000
prevalent dialysis patients. The relative risk of death for patients with a serum
albumin < 2.5 g/dl was about 20 fold greater compared to patients with a serum
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albumin of 4.0-4.5g/dl. The HEMO study group analysis to determine if indicators of
nutritional status were associated with subsequent mortality in haemodialysis patients
found that elevated serum albumin as independently associated with decreased
mortality, especially during early follow up as subjects with low serum albumin
values (<3.6 g/dL) had elevated relative risks of mortality compared to the reference
(M.O g/dL) (Dwyer et al 2005). Also data analysis from USRDS which included
3607 haemodialysis patients found increased mortality among those with low serum
albumin and low body mass index (BMI) (Leavey et al., 1998).
However, serum albumin value has been questioned because a low serum albumin
levels may reflect not only poor nutrition, but also albumin losses in urine and/or
dialysate, the presence of an inflammatory reaction, systemic diseases, and old age
(Heimburger et al., 1994).
1.3.1.11.2. Serum Creatinine
Serum creatinine is useful marker of nutritional status in dialysis patients (K/DOQI,
2000). Low levels of serum creatinine in maintenance dialysis patients with
negligible renal function suggest decreased skeletal muscle mass and/or possible a
reduced dietary protein intake and may be associated with increased mortality in
dialysis patients. A study of 250 haemodialysis and 140 peritoneal dialysis patients
showed that a low level of serum creatinine was an independent predictor of
mortality (Avram et al., 1995). The DOPPS study also found higher mortality risk for
lower baseline serum creatinine (Pifer et al., 2002). Serum creatinine as nutritional
marker was found to be a good predictor of mortality in the HEMO Study (average
mortality reduction of 13% per 1 mg/dl elevation in baseline serum creatinine value).
Subjects with low serum creatinine (those <12 mg/dl) had elevated relative risk
compared to a group defined as having normal serum creatinine of 12 mg/dl or
greater (Dwyer et al., 2005).
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1.3.1.11.3. Body mass index and obesity
Body mass index (BMI) is the ratio of weight (kilogram) to height (meter) squared.
Obesity is defined as a BMI > 30kg/m2. In the general population obesity is mainly
associated with comorbid conditions such as diabetes and hypertension that will
increase the cardiovascular mortality (Henegar et ah, 2001) and many epidemiologic
studies have shown a strong association between obesity and decreased survival
especially that due to an increased risk of cardiovascular disease (Lew et al., 1979;
Byers 1995).
Haemodialysis patients appear to have a lower BMI than age and sex matched
control subjects from the general population (Kopple et al., 1997b; USRDS, 2003).
Obesity has generally been associated with improved survival among chronic
haemodialysis patients. Many observational studies have shown the inverse
association between BMI and mortality in maintenance haemodialysis patients.
Among these studies; the Diaphane collaborative study group in France which
included over 1500 haemodialysis patients, was one of the first to report on the
contradictory observation of reduced mortality with high BMI in dialysis patient
(Degoulet et al., 1982). The DOPPS study provided baseline demographic,
comorbidity and BMI data on 9714 haemodialysis patients in the US and Europe
from 1996 to 2000 and showed a decreased mortality risk with increasing BMI
(Leavey et al., 2001). Johansen and colleagues (2004) analyzed retrospective data
from 418055 maintenance dialysis patients, who were observed over an average of 2
years follow-up time, and found that high BMI was also associated with a reduced
risk of hospitalization and a lower rate of mortality. Kalantar-Zadeh and associates
(2004a) found that obesity, including morbid obesity (BMI>35), in 54535
haemodialysis patients was associated with survival advantage. The same inverse
weight mortality relation in haemodialysis patients was reported in peritoneal
dialysis patients. The Canada and United States of America (CANUSA) study
included 680 peritoneal dialysis patients, and showed that a 1% reduction in
percentage of lean body mass was associated with a 3% change in the relative risk
(RR) of death (CANUSA 1996). Johnson and co-workers (2000) studied BMI in 43
peritoneal patients and found that obesity confers a significant survival advantages.
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Chung and colleagues (2000) found a similar association between low BMI and
increased mortality in 91 peritoneal dialysis patients.
It has been suggested that BMI confers survival advantages in dialysis patients in
presence of inflammation or other severe comorbid illnesses. Others have suggested
that it is due to survival bias as CKD patients who survive to reach dialysis are those
who have higher BMI, cholesterol levels and systolic blood pressure (see section
1.3.1.9.4)
1.3.1.11.4. Serum Cholesterol
Serum cholesterol was discussed in 1.3.1.8.1.1.3.
1.3.1.11.5 Subjective Global Assessment
The CANUSA study included 680 peritoneal dialysis patients in 14 centers in
Canada and the United States to evaluate the association of nutritional status with
mortality and hospitalisation. It showed that lower scores of SGA (which indicate
poor nutritional status) were associated with poorer outcomes. A 1 unit change in the
7 point SGA scale was associated with 25% increase in the relative risk of death
(CANUSA 1996). Based on the results of the CANUSA study the DOQI guidelines
recommended that SGA should be performed to measure and monitor nutritional
status periodically in dialysis patients (K/DOQI 1997b). Pifer and collaborates
showed that lower scores of SGA together with lower values of other nutritional
parameters (serum albumin, serum creatinine, and BMI) were associated with
increased mortality in study sample consisted of 7719 haemodialysis patients from
U.S faculties enrolled in DOPPS study (Pifer et al., 2002). A cross sectional study
which involved 158 haemodialysis patients to evaluate the predictive value of
nutritional markers showed that SGA was a significant predictor of mortality (Hung
et al., 2005).
1.3.1.12 Late Referral to Nephrologist
One of factors that may significantly affect morbidity and mortality in dialysis
patients is the timing and the quality of care before the start of dialysis. Previous
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studies had defined late referral as a patient being seen by nephrologists less than one
month (Campbell et al., 1998), four months (Kinchen et al., 2002), or six months
(Jungers et al., 2001), before the initiation of dialysis. Late referral can be associated
with many adverse effects that may increase patients morbidity and mortality;
including hypoalbuminaemia and renal bone disease (Arora et al., 1999; Ifudu et al.,
1996), higher rates of emergency dialysis with use of temporary access that is
associated with high risk of infection (Schmidt et al., 1998; Ifudu et al 1998),
reduced chances of receiving a kidney transplant (Schmidt et al., 1998), increased
health care costs (Campbell et al., 1998), and longer hospitalisation (Jungers et al.,
1993).
An increasing number of studies, although all observational and retrospective,
suggest that patients referred late to a nephrologists for predialysis medical care,
compared with those referred early in the disease course, have an enhanced mortality
risk once dialysis is initiated. Ratcliffe and coworkers (1984) highlighted the need to
refer patients earlier and demonstrated the adverse effect of late referral as they
found an association between the length of regular nephrological review and survival
after starting RRT. Innes and colleagues (1992) found that early death of patients
receiving RRT was associated with late referral to a nephrologist. In this study, the
patients who died were first seen by a nephrologist later (a medium of 36 days before
starting dialysis) than the age and sex matched subjects who survived (median 30
months) (Innes et al., 1992). Chandna and collaborators (1999) by looking at factors
affecting survival and morbidity in 292 dialysis patients showed that late referral for
dialysis was a major determinant of poor survival (Chandna et al., 1999). A
retrospective national cohort study, using data from the Australia and New Zealand
Dialysis and Transplant Registry database (ANZDATA), which included 4243 who
patients started dialysis between 1995 and 1998, found that 1141 patients were
referred late (27%) (those who needed to commence dialysis within three months of
referral to a nephrologist). The median age for both referred early and referred late
patients was 56 years with 60% male. Glomerulonephritis constitutes about 30% vs.
34% of patients who were referred early or late, respectively. The percentage of
patients with no comorbid condition was 40% vs. 35% and diabetes presented in
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28% vs. 35% of those referred early and late, respectively. This study found that late
referral is associated with increased mortality, and the authors suggested that early
referral to improve predialysis care might improve long term survival. The high
incidence of late referral could be related to inadequate communication of primary
care doctors with nephrologists (Cass et al., 2002).
1.3.1.13 Health Related Quality of Life
Health related quality of life (HRQoL) refers to the measurement of patient
functional wellbeing and general health perception in each of 3 domains: physical,
mental, and social. HRQoL may be affected by the clinical manifestation of diseases,
the side effects of treatments, and the quality of the relationships of the patients with
family members (Valderrabano et al., 2001).
Analysis of data from the DOPPS study showed that lower scores of the 3
components of the health related quality of life short form (physical, mental and
kidney disease) were strongly associated with higher risk of death and hospitalization
in haemodialysis patients (Mapes et al., 2003). A study of 1000 haemodialysis
patients also reported an association between lower scores in physical component
summary of quality of life and higher risk of death and hospitalisation (DeOreo,
1997). Lopes and colleagues (2002) showed that mental component summary of
quality of life was a significant predictor of death and hospitalisation.
The assessment of HRQoL has become a vital tool in the monitoring of treatment
outcomes in patients on various modalities of renal replacement therapy and the
influence on morbidity and mortality (Knight et al., 2003; Rosas et al., 2003; and
Mapes et al., 2003). Both Karnofsky Performance Status Scale (KPSS) and Short
Form-36 Health Survey (SF-36) instruments have been used in assessment of
HRQoL in chronic renal failure patients on various treatment modalities, each with it
is specific advantages and disadvantages but with generally good correlation (Gokal
et al., 1999).
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The Karnofsky Performance Status Scale (KPSS) is a physician rating scale designed
in 1948 by David Karnofsky, evaluating the performance status of cancer patients. It
utilises a single numerical scale that guarantees an objective assessment of the
patient's clinical state (Karnofsky et al., 1949). KPSS is perhaps the most commonly
used HRQoL instrument. KPSS ranges from 0 (at death) to 100 (that implies full
functional capability to carry out normal daily activities without clinical evidence of
disease) (Karnofsky et al., 1949; and Evans et al., 1985). KPSS rating is based on
observations of a patient's ability to perform common tasks. It is often used in
clinical research to monitor and record the health of patients. So Karnofsky score is a
method which measures patient performance of activities of daily living.
100 Normal, no complaints or evidence of disease
90 Able to perform normal activity; minor signs and symptoms of disease
80 Able to perform normal activity with effort: some signs and symptoms of
disease
70 Cares for self, unable to perform normal activity or to do active work
60 Requires occasional assistance but is able to care for most of own needs
50 Requires considerable assistance and frequent medical care
40 Requires special care and assistance; disabled
30 Hospitalization indicated, although death not imminent; severely disabled
20 Hospitalization necessary; active supportive treatment required, very sick
10 Fatal processes progressing rapidly; moribund
0 Dead
Table. 1.5; Karnofsky Functional score
KPSS illustrated in the table above can categorize the patient into 3 groups
1. Patients with < 40 are dependent or requiring institutional or hospital care
2. Patients with 50-70 score require assistance
3. Patients with>80 are able to carry out normal activity
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The short form 36 health survey (SF-36) looks at quality of life as a
multidimensional model assessing eight different perspective of HRQoL namely
physical functioning; role of limitations due to physical health problems; bodily pain;
general health; vitality (energy fatigue); social functioning; role of limitations due to
emotional problems; and mental health, which implies psychological distress and
psychological well-being (Ware et al., 1993). It unitizes a 36-item questionnaire,
which was constructed as an improvement on the older SF-8 and SF-20 scales (Evans
et ah, 1985). The SF-36 rating is dependent on the patient's assessment perception of
their health status, it is high comprehensiveness and conciseness, and it is validity
have been variously demonstrated even in different languages (Rebollo et ah, 2000;
and Kusztal et ah, 2003).
1.3.2 Risk factors related to dialysis procedure
1.3.2.1 Dialysis adequacy
The dose of haemodialysis is usually measured in terms of Kt/V for urea or urea
reduction ratio (URR). These two measures are calculated from the fractional
reduction of blood urea nitrogen concentration during a single haemodialysis
treatment (K/DOQI 1997c) and they are practically and mathematically similar
(Lowrie et ah, 1991). The DOQI Clinical Practice Guidelines (2001) recommended a
minimum delivered dose per session be a Kt/V of 1.2 or a URR of 65% for thrice
weekly haemodialysis. To achieve these targets, it was further recommended that the
prescribed dialysis dose be a Kt/V of 1.3 or a URR of 70%. The recommendation of
the DOQI guidelines was based on retrospective studies of mortality outcome for
ESRD patients suggested that death progressively increases when URR fall below
60-65% (Hakim et ah, 1992; Owen et ah, 1993; Held et ah, 1996; Lowrie, 1996). The
European Best Practice (2002) recommended a higher value than DOQI with Kt/V of
1.4. The UK Renal Association recommended the same dose as the DOQI
guidelines.
Low urea clearance on haemodialysis is strongly associated with lower overall
survival. The National Cooperative Dialysis study (NCDS) (1983) was the first
multicenter randomized control trial to investigate the impact of dialysis dose on
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patient outcome and used the concentration of urea in the blood (BUN) as a measure
of dialysis dose with lower average BUN indicating a higher dialysis dose. The study
included 160 patients using low permeability dialysis membrane who were
randomized to different treatment times (2.5-3.5 versus 4.5-5h) and different urea
time averaged concentration (TAC) (100 versus 50mg/dl) with a follow up period of
more than 6 months. It concluded that patient morbidity and treatment failure are
related to the dialysis dose. In a secondary analysis of NCDS data by Gotch and
Sargent (1985) were first to propose a quantification of dialysis dose using Kt/V, and
showed no further benefits for Kt/V>0.9 with average treatment consisting of
dialysis for 4 hours with dialyzer efficiency about one half to one third of modern
dialyzers. Another analysis of NCDS by Keshaviah (1993) showed a progressive
benefit as Kt/V increased beyond 0.9.
A number of observations are compatible with the hypothesis that more intensive
dialysis leads to improved survival. In many reports Kt/V values have increased over
the last decade because of concerns about underdialysis and the outcomes compared
to those observed previously. Increasing the mean Kt/V from 0.82 (pre-1988) to 1.33
reduced the gross mortality rate from 22.8 down to 9.1% per year (Collins et al.,
1994). This was associated with increases in protein catabolic rate from 0.83 to 1.0
and plasma albumin concentration from 35 to 39 g/1. Thus, enhanced nutrition
probably contributed to the improvement in survival. In another report, increasing the
mean Kt/V from 1.18 to 1.46 (and the URR from 61 to 70%) was associated with
reduction in the gross mortality rate from 22.5 to 18.1% per year (Parker et al.,
1994). This improvement was achieved with standard cellulose biocompatible
membranes. Held and coworkers (1996) analyzed 2311 patients from 374 dialysis
centers in the US and showed the risk of mortality was 7% lower with 0.1% increase
in Kt/V. The DOPPS study observed that mortality and morbidity decrease with
increasing Kt/V to at least 1.4 (McCullough et al., 2000). Port and colleagues (2002)
included 45967 haemodialysis patients and found that a higher dialysis dose
substantially above the DOQI guidelines was a strong predictor of lower patient
mortality for patients of all body sizes. All of the above studies were, however,
observational in nature.
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However, in the HEMO study, a large prospective clinical trial, 1846 patients were
randomly assigned to a standard or high dose of dialysis and a low or high flux
dialyzer, and produced surprising and disappointing results to those who believe in
improving the patient outcomes with higher dialysis dose than those recommended
by guidelines (Eknoyan et al., 2002). The standard dose goal was an equilibrated
Kt/V of 1.05, which is equivalent to a single pool Kt/V of 1.25 or URR of 65%. The
high dose goal was an equilibrated Kt/V of 1.45, equivalent to a single pool Kt/V
1.65 or a URR 75%. the primary outcome was death from any cause, while the main
secondary outcomes were rate of all hospitalisations (but excluding those related to
access), and the composite outcomes of the first hospitalisation for cardiac problem
or death from any cause, the first hospitalisation for an infectious cause or death, and
the first decline of greater than 15% of the serum albumin from baseline value or
death. The following results concerning dialysis dose were reported at a mean follow
up of 4.5 years:
• The primary outcomes for the HEMO study demonstrated no significant
differences in all cause mortality between patients treated in the standard dose
versus high dose groups, between the low flux and high flux dialyzer groups.
• The risk of the main secondary outcomes was also the same for both dialysis
doses. However, there was a 20% reduction in cardiac deaths in the high flux
group (but not all cause mortality).
The HEMO study has drawn a line under the adequacy debate as it confirmed that 3
times/week therapy will remain the standard treatment for the majority. The results
of the HEMO study were disappointing, to many nephrologists who believed that an
increase in the dose of haemodialysis, and the use of high flux membranes, could




Several studies have documented a relationship between shorter dialysis time and
poorer outcome (Held et al., 1991; and Woods et al., 1996). Patients dialyzed fewer
than 3.5 hours three times per week have approximately twice the mortality risk
compared to patients dialyzed 4 or more hours three times per week (Held et al.,
1991). A study from the Tassin group from France, which included 445
haemodialysis patients, has reported one of the best dialysis survival estimates of any
program. They have shown that patients receiving large dose of dialysis with Kt/V of
1.67 (8 hours per session, 3 times/week), had survival rate of (87% at 5 years, 65% at
15 years and 43% at 20 years). Ninety eight percent of these patients achieved
normotension without the need for antihypertensive medications (Charra et al., 1992;
and 2004).
Short daily haemodialysis is an emerging and promising therapy that may prove not
only to improve patient outcomes, but to provide a cost-effective alternative to
conventional in-centre haemodialysis. Several observational studies have evaluated
the potential benefits and risks of daily haemodialysis, compared with intermittent
haemodialysis. Short daily haemodialysis is associated with improved patients
survival, nutritional status, quality of life and blood pressure control, reduced left
ventricular hypertrophy, and reduction in cardiovascular risk (Wood et al., 1999;
Maduell et al., 2003; Chan et al., 2003). These effects seem to be related to an
optimization of body volume status. Future studies in this area will hopefully help
established a role for daily haemodialysis in the next decade. Unfortunately these
observational studies suffer from several methodological limitations, including small
sample size, use of non ideal control groups and selection bias (Suri et al., 2006).
More explanation about effect of dialysis time will hopefully come up from a
randomized control trial currently started in Canada. It will examine the impact of
nocturnal haemodialysis compared to conventional haemodialysis on the clinical
outcomes for a six months period. The primary outcome is change in left ventricular
mass. The secondary outcomes include blood pressure control, mineral metabolism,
anaemia, HRQoL and costs) (Walsh et al., 2006).
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1.3.2.3. Haemodialysis membrane
Survival, dialysis adequacy and the biocompatibility of haemodialysis membrane
may all be closely interrelated. A report from the USRDS case mix adequacy study
enrolled 2410 haemodialysis patients. The types of dialysis membranes used were
broadly classified into three categories: un-substituted cellulose, modified cellulose
(generally cellulose membranes that have been modified by substitutions of some or
most of their hydroxyl moieties) and synthetic membranes that are not cellulose
based. The results showed that the relative risk of mortality of patients dialyzed with
modified cellulose or synthetic membranes was at least 20% less than that of patients
treated with un-substituted cellulose membranes, this study suggest that the dialysis
membrane plays an important role in the outcome of haemodialysis patients (Hakim
et al., 1996). One possible contributing factor to this difference other than
biocompatibility was that either modified cellulose or synthetic membranes typically
have higher surface areas and higher urea clearances than un-substituted cellulose
membranes and patients dialyzed with modified or synthetic membranes received
significantly more intensive dialysis than those dialyzed with cellulose membranes
(Kt/V of 1.14 versus 1.07).
Further information regarding the effect of dialysis membrane on survival came from
the HEMO study that failed to show any survival advantages of increasing neither
dialysis dose nor the type of dialysis membrane. There was no significant difference
in the all cause of death between high and low flux groups (RR of 0.92). But in the
high flux group, there was a significant reduction in the risk of first hospitalisation
and death from a cardiac cause (but not all cause mortality) compared with low flux
group (Eknoyan et al., 2002). Further clarification about importance of membrane
flux will hopefully arise from the Membrane Permeability Outcome (MPO) study
currently underway in Europe. This randomized control trial, which included only
incident patients, will examine the influence of high flux membranes on clinical
outcomes (including mortality, morbidity, vascular access survival and nutritional
status) (Locatelli et al 2005).
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1.3.2.4. Vascular Access
There are three types of vascular access (native arteriovenous fistula (AVF)
constructed by anastomosis of native artery with a native vein, synthetic
Arteriovenous fistula/graft (AVG), and central venous catheter (CVC) (cuffed,
tunnelled internal jugular dialysis catheter). The difference between these types has
been demonstrated by DOPPS study which showed that AVF is the most desirable
vascular access for haemodialysis because AVF produces the highest flows,
minimizes infection and has the greatest longevity (Rayner et al., 2003). New AVF
should be allowed to mature for at least 1 month, and ideally for 3 to 4 months, prior
to an anticipated need for haemodialysis (K/DOQI 1997d). This avoids the need for
emergency insertion of central venous catheter, which is associated with morbidity
due to major vessel thrombosis and infection (Dhingra et al., 2001).
Haemodialysis access failure remains a major source of morbidity and hospitalisation
for ESRD patients. Access failure is second only to cardiovascular disease as a cause
of hospitalisation (Eggers 2004). Infection is the second leading cause of death in
dialysis patients and vascular access especially venous catheters are associated with
increased risk of infection related mortality among haemodialysis patients.
Moreover, the venous catheter for haemodialysis is associated with increased risk of
thrombosis, central venous stenosis, short access survival and inadequate dialysis
(Feldman et al., 1996; Nassar et al., 2001). The USRDS (1996) reported that cardiac
deaths accounted for 45% of total deaths and also showed the associated risk of death
due to cardiac cause was higher among patients dialyzed with CVC when compared
with AVG and AVF. The risk of septicaemia associated with venous catheters is
elevated in haemodialysis patients. Avoiding temporary vascular access may
decrease the incidence of septicaemia and mortality associated with haemodialysis
(Powe et al., 1999).
1.3.2.5 Modality of dialysis
Comparison between modalities is difficult because mortality difference between
haemodialysis and peritoneal dialysis may be due to the difference in patient
selection and characteristics between prevalent and incident ESRD patients
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(Friedman 2000). For instance, the patients selected to peritoneal dialysis tend to be
younger and less likely to have CVD and other comorbid conditions compared with
haemodialysis patients (Thamer et al., 2000; Stack 2002).
An observational study of 822 Canadian dialysis patients comparing the mortality
differences between haemodialysis and peritoneal dialysis found that both modalities
are associated with similar overall survival rates when comorbidity was taken in
account because haemodialysis patients had higher burden of comorbid illness and
acute onset of renal failure compared with peritoneal dialysis patients (Murphy et al.,
2000). Studies in mortality comparison of peritoneal dialysis and haemodialysis
among new ESRD patients has suggested that survival on peritoneal dialysis is at
least similar to that of haemodialysis, if not better within the first 2 years of therapy
(Gokal et al., 1999; Collins et al., 1999; Tanna et al., 2000). Efforts should be made
to start and complete adequately powered randomized control trials to compare
peritoneal dialysis and haemodialysis modalities which would ensure that any
differences in outcomes seen on follow up would be solely due to one modality
treatment or the other.
1.3.2.6 Vintage
Vintage is length of time on dialysis. Prolonged dialysis is a significant predictor of
death in chronic haemodialysis patients (Iseki et al 2003). Chertow and associates
(2000) found that the mortality risk increases by 6% with each year on dialysis
therapy. UKRR and USRDS demonstrated a rising hazard of death with increasing
length of time on RRT. Vintage is important also for patients undergoing kidney
transplant, as Cosio and colleagues (1998) showed that pre-transplant dialysis has a
significant effect on patient survival after transplantation. Increased time on dialysis
prior to renal transplantation was associated with decreased patient survival. They
explained this by the development of heart disease in long term dialysis patients.
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1.4. Aim of the Study
The studies described in this thesis were devised with the following aims:
• To evaluate the importance of using subjective global assessment (SGA)
alone in predicting the survival and whether it is valuable to have SGA
assessed to improve prediction of haemodialysis patients' outcome.
• To assess the impact of comorbid illness and nutritional status upon dialysis
patient survival.
• To investigate the factors that predicting the survival of all patients starting
RRT in Southeast Scotland in 2003 and 2004.
• To compare the data of this study with the data of the study previously






This study was conducted in the renal unit of Edinburgh Royal Infirmary (RIE) that
provides a renal service for the population of the Lothian and Borders region, about
850000 people. In 2003 the renal unit moved to the new Royal infirmary site at little
France. The UKRR ninth annual report 2006 showed that Edinburgh renal unit cared
for 273 haemodialysis patients, 61 peritoneal dialysis patients and 372 transplant
patients.
In this chapter I will describe the methods used in an incident cohort Edinburgh
study that included patients who started RRT in 2003 and 2004 and a cross-sectional
study of prevalent patients which examined the additional predictive value of
subjective global assessment (SGA) on survival of dialysis patients.
2.2. Patients
2.2.1. Incident Cohort Edinburgh Study
Patients starting RRT for end stage renal disease (ESRD) at the RIE renal unit
between 01/01/2003 and 31/12/2004 were included. Patients with acute renal failure
were excluded. Data collection for 183 patients (85 patients started RRT in 2003 and
98 patients in 2004) enrolled in this study was started at 11/10/2005. 156 patients
started on haemodialysis, 25 patients started on peritoneal dialysis and only 2
patients started as pre-emptive kidney transplant. 13 patients died within the first 90
days of their treatment. This study was a continuation of auditing thus ethical
approval was not required.
2.2.2. Prevalent Cross-Sectional Study
This study was initiated by a team of dieticians in the renal unit aiming to find a
malnutrition screening tool for dialysis patients that could save dietician, nursing and
medical staff time. This study included 122 prevalent dialysis out-patients at the RIE
(13 peritoneal dialysis and 109 haemodialysis). The subjective global assessment
[will be described later in this chapter] was measured by dieticians in the renal unit
for all patients by taking the history and measuring body weight needed to provide
the score from 1 to 7 (Appendix 4). Follow up of the dietician study was started in
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11/4/2005 and continued until 12/4/2007 (period of 2 years). The ethical approval
was granted for the study to the dietician team.
2.3. Data collection
2.3.1. Incident cohort study
The data were collected by one observer (FL) throughout, to avoid inter observer
errors in scoring of patients. At the beginning the data was collected from computer
based information (Proton) and then by interrogation of patients' clinical notes to
extract information on comorbidity and complete the data that was uncertain or
missing from the Proton database.
Survival data was obtained at January 2007 and analyzed in 2 different ways:-
I. In the continual survival study (chapter 5) patients were followed until
1/1/2007 a period of minimum 2 years for who started RRT in December
2004 and maximum 4 years for those who started RRT in January 2003 or
until death if sooner.
II. In the comparison survival study (chapter 6) all patients were followed for a
period of exactly 2 years (minimum 7 days and maximum 730 days) unless
the patients died.
The hospitalisation data was collected by using the patients' admission system (PAS)
to determine the total period of hospital admission for all patients within exact 2
years since they started their RRT.
2.3.2. Prevalent cross section study
The dietician team collected the following data age, gender, laboratory (urea,
albumin, CRP, Cholesterol), nutritional measurements [(body mass index (BMI), mid
arm circumference (MAMC), and triceps skin fold (TSF)], and total SGA score). The
study was supplemented by collecting comorbidity from the patients' notes, and
primary renal diagnosis and cause of death based on ERA-EDTA codes. Survival
data was obtained at April 2007 (for a period of exact 2 years). Hospitalization was
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studied by assessing the frequency of hospitalisation and its total duration in days
over the 2 years of the study.
2.4. The data set
The main reason of choosing these data sets was to define a minimum data set
providing maximal information that will help in evaluating patient survival.
1. Data which give a very clear description of the Lothian and Borders dialysis
population in terms of demography; primary renal disease; and the burden of
comorbid disease.
2. Data which could describe how patients' initial therapy was conducted, and
how long they had been known to the renal unit before starting dialysis in 2
different periods 3 and 6 months.
3. Data which would be most useful in predicting patient survival.
4. Data which provides information about the nutritional status.
2.5. Baseline data
2.5.1. Incident cohort study
• Date- of birth, of start of the study, of end of the study, of starting of treatment,
of death. Demographic (age, and gender), according to UKRR patients were
grouped into 2 age groups (young <65, and old >65 years) to determine the
effect of age on patients survival.
• Clinical (the first mode of RRT, access for first RRT, primary renal diagnosis,
causes of death and comorbid conditions). Permanent access is used to describe
an arterio-venous fistula/graft for haemodialysis patients and Tenckhoff
catheter for peritoneal dialysis patients. Comorbid conditions were scored using
3 different comorbidity scores (Charlson, Khan, and Davies)
• Biochemical [serum- albumin (g/1), creatinine (pmol/l), urea (mmol/1),
haemoglobin (g/1), cholesterol (mmol/1), CRP (mg/1), and also estimated GFR
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(ml/min)] all these laboratory data were collected at zero time or when patient
started RRT.
• Referral to nephrology care unit or the length of follow-up by a nephrologist
prior to commencing RRT was determined by calculating the difference
between the date of the first biochemical investigations recorded on Proton and
the date of the first RRT session. Referral times of 90 days or more from start
of RRT were considered as early referral. Referral times less than 90 days from
start of RRT were defined as late referral. Another consideration in the same
way was done for a period of 6 month
2.5.2. Prevalent cross section study
• Date- of birth, Start of the study, end of the study in, starting of treatment, of
death. Demographic (age, and gender).
• Clinical (mode of RRT at start of the study, duration of treatment since the
patients started RRT, primary renal diagnosis, comorbid conditions, statin
therapy, and causes of death). Comorbid conditions were scored using Khan
score.
• Biochemical [serum- albumin (g/1), urea (mmol/1), cholesterol (fxmol/1), and
CRP (mg/1)] all these laboratory data were collected at time of the study started.
• Nutritional measurements (body mass index (BMI), mid arm muscle
circumference (MAMC), triceps skin fold (TSF), and subjective global




Vintage is the time spent on RRT which was calculated differently in both studies as
explained below.
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• In the incident cohort study duration of treatment has been calculated in days
as the time difference between date of starting dialysis and either the date of
end of study follow-up or date of death.
I. In the continual survival study (chapter 5) the period calculated of
minimum 2 years for who started RRT in December 2004 and
maximum 4 years for who started RRT in January 2003 unless the
patients died. The median time of treatment (median time of follow
up) was 817 days (minimum 7 days and maximum 1440 days).
II. In the comparison study (chapter 6) the calculated period of exactly 2
years (minimum 7 days and maximum 730 days) unless the patients
died.
• In the prevalent cross sectional study the time spent on treatment has been
calculated in days as the time difference between date of starting the study and
either the date of end of study follow-up or date of death.
2.6.2. Hospitalisation
Hospitalisation is the percentage of patients live time spent in hospital.
Hospitalisation was defined as any hospital admission that included at least one
overnight stay in the hospital. The admission day was counted as one full
hospitalisation day but the discharge day was not. Therefore, the minimum duration
of hospitalisation per admission was 1 day. Percentage of hospitalisation was the sum
of all hospital admissions as a percentage of the sum of total duration of treatment.
• In the incident study the data on hospital admission were collected for exactly 2
years from the date of starting RRT or until the patient died.
• In the prevalent study the data on hospital admission were collected for exactly




The date of death was recorded to calculate the duration of survival for those who
died in the study. Causes of death were coded according to ERA-EDTA as shown in
section 2.10. The data for cause of death was extracted from Proton database.
2.7. Instruments of data collection, coding and grouping
I. Primary renal diagnosis codes and grouping based on ERA-EDTA
classification was used in all studies
II. Cause of death codes and grouping according to ERA-EDTA
classification was used in all studies
III. Comorbidity
□. In the incident cohort continual study Charlson index, Khan score
and Davies score were all used in the analysis
□. In the incident comparison study; patients were stratified into three
risk groups according to age and number of comorbid condition which
is similar to Khan's method but with fewer comorbid conditions
(CCF, CPD, Liver disease)
□ . In the prevalent cross section study only the Khan score used.
IV. SGA classification was used only in prevalent cross section study
2.8. Comorbid diseases
20 different comorbid diseases listed below have been collected which allow any
kind of comorbidity score to be used to assess the comorbidity burden. In the
incident study the comorbid diseases were assessed at the time when patients started
RRT, but in the prevalent cross sectional study comorbid illnesses were collected at
the start of the study. All the detailed information about comorbidity was audited
from the patients clinical notes and assessed by using 3 different scores:-
(I) The Charlson index (CCI) that includes more conditions than Khan and Davies
scores. Angina was considered as single comorbid illness (Appendix 1.1). Charlson
scores ranges from 0 to 35 and according to total score patients were assigned into
one of following 4 groups which roughly represented quartiles.
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• Group 0 = patients with no comorbid conditions (CCI = 0)
• Group 1 = patients with one comorbid condition (CCI = 1)
• Group 2 = patients with two comorbid conditions (CCI = 2)
• Group 3 = patients with more than two comorbid conditions (CCI > 2)
(II) The Khan score includes age and total comorbid conditions to form classify
patients into 3 risk groups (low, moderate and high) (Appendix 1.2).
(III) The Davies score consists of seven comorbid conditions and age is not included
(Appendix 1.3). Similar to Charlson scores the Davies scores were separated into 4
groups which roughly represented quartiles.
• Group 0 = patients with no comorbid conditions (Davies = 0)
• Group 1 = patients with one comorbid condition (Davies =1)
• Group 2 = patients with two comorbid conditions (Davies = 2)
• Group 3 = patients with more than two comorbid conditions (Davies > 2)
The 3 scores had calculated their total score from the following comorbid
conditions:-
1. Myocardial infarction (MI) (raised cardiac enzymes, ECG changes,
PTCA/CABG)
2. Angina (chest pain relieved by nitroglycerine, or positive exercise test)
3. Cerebrovascular (CeVD) [(transit ischaemic attack (TLA), cerebrovascular
accident (CVA)].
4. Congestive cardiac failure (CCF) was difficult to assess. Therefore, we used
the Scottish Renal Registry criteria in defining CCF (Appendix 5)
5. Peripheral vascular disease (PVD) (intermittent claudication, amputation, PV
bypass)
6. Chronic pulmonary disease (CPD) (chronic obstructive airway disease
(COAD), Asthma, pulmonary fibrosis)
7. Connective tissue disease (Rheumatoid arthritis, SLE, Systemic sclerosis)
8. Mild liver diseases (hepatitis or elevated liver enzymes).
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9. Severe liver disease (liver cirrhosis or portal hypertension) which scores
higher in CCI
10. Diabetes mellitus (DM)
11. Diabetes mellitus with end organ damage such as peripheral neuropathy,
retinopathy and autonomic complications scored higher in CCI
12. Peptic ulcer disease
13. Dementia
14. Hemiplegia





20. Metastatic solid Tumour, CCI (skin tumours not included) has the highest
score in CCI.
2.9. Primary renal diagnosis
The primary renal diagnosis codes were chosen from the list issued by European
Renal Association-European Dialysis and Transplant Association (ERA-EDTA)







2.10. Causes of death
The death cause codes were chosen from the list issued by ERA-EDTA (Appendix






(5) Other known causes
2.11. Subjective Global Assessment
Subjective global assessment (SGA) is a malnutrition screening tool that identifies
abnormal nutritional status in dialysis patients based on these following 4 items:
1. Weight changes over the past 6 months. A loss of >10% is severe and 5% to
10% is moderate, while 0-5% is mild.
2. Dietary intake assessed by comparison of the patient's usual and
recommended intake to current intake. Duration and frequency of
gastrointestinal (GIT) symptoms (anorexia, nausea, vomiting and diarrhoea)
are also assessed.
3. Loss of subcutaneous fat by examining the fat pads directly below the eyes
and by gently pinching the skin above the triceps and biceps. The fat pads
should appear as a slight bulge in a normally nourished person but are
"hollow" in a malnourished person.
4. Muscle wasting or presence of ankle, sacral oedema and ascites. Muscle
wasting can be assessed by examining the temporalis muscle, the prominence
of the clavicles, the contour of the shoulders (rounded indicates well-
nourished; squared indicates malnutrition).
For each above item a score on a 7 point scale is recorded with higher score
indicating better nutritional status. The score from each of the 4 items are averaged to
give the SGA rating which ranges from l=severely malnourished to 7= normal
nutrition. Patients are categorized into 3 distinct classes of nutritional status, well
nourished (SGA A), moderately malnourished (SGA B), and severely malnourished
(SGA C) (Table 2.1).
The SGA, being a subjective method, relies on the observer's ability to collect and
interpret information, and as a result, is likely to suffer from observer bias. This bias,
however, was minimized by restricting the use of the SGA to well-trained dieticians
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with an expertise in the use of this clinical instrument and they work together to
ensure consistency. Also the measured data (MAMC, TSF and body weight) were
carried 3 times and the average was recorded as the value for these parameters.
SGA Classification
severe moderate mild normal
1 2 3 4 5 6 7
C B A
Table 2.1; Classification of subjective global assessment
2.12. Statistical analysis
Data management, computations and graphical representations were performed using
the standard Statistical Package for Social Sciences software (SPSS for Windows,
Version 14.0, SPSS Inc., Chicago, IL, USA), and Microsoft Excel. Data were tested
for the symmetry of its distribution, when the skewness value was less than one, the
variable was considered normally distributed.
When the variables were normally distributed, continuous variables were expressed
as mean ± standard deviation (SD) and compared with parametric tests (independent
sample t-test when comparisons between groups were made). When the variables
were skewed, continuous variables were expressed as median and interquartile range
(IQR) and/or minimum and maximum values and compared with nonparametric tests
(Mann-Whitney U test when comparison between groups were made). Categorical
variables were expressed as proportions and compared with the Chi-square test (x
test).
The overall median percentage of live time spent in hospital and median percentage
between different groups was estimated using nonparametric Kruskal Wallis test.
The associations between the different continuous variables were performed using
Pearson's rank correlation coefficient.
52
The P values for comparison of survival curves were determined by the log-rank test
by using Kaplan-Meier model. A multivariate time-to-death adjusted Cox regression
model was used to identify time-independent predictors of cumulative risk of death.
A forwards likelihood-ratio selection procedure was applied (inclusion criterion
P<0.05, exclusion criterion P>0.055) to test for their independent contribution to
predict survival within the model, the relative risk (RR) and their 95% confidence
intervals (95% CI) were calculated. Survival time was measured in terms of number
of days until death or censorship exactly 730 days in the prevalent cross section
study and the incident comparison study but minimum 7 days and maximum 1440






Comorbid conditions are difficult to collect from clinical note as it is time
consuming. However, relying on computer based information may not be enough to
provide comprehensive details of comorbid conditions.
3.2. Aim
To find whether collecting information about comorbidity from the computer based
data system (Proton) was adequate or it would be necessary to collect the information
about comorbidity from the clinical notes.
3.3. Method
30 patients randomly selected out of all incident patients started dialysis in 2003. The
20 comorbid illnesses considered for this study as listed in chapter 2 were recorded
from both the computer based data system (Proton) and from the clinical notes of the
same patients. The comorbid conditions information from computer and clinical note
were compared to see whether both sources were equivalent or not in providing
information on comorbidity.
3.4. Results
Table 3.1 shows several comorbid conditions were not recorded on computer based
system, following the criteria explained in chapter 2 and appendix 5 in definition of
comorbid condition. Congestive cardiac failure was the most difficult comorbidity to
assess and it was rarely clearly mentioned on Proton. In addition, the label ischaemic
heart disease was often used on Proton. However, angina and myocardial infarction
are different comorbid illnesses according to Charlson, Khan and Davies comorbidity
scores.
Furthermore, the Charlson index (explained in chapter 2) was used to classify the
patients into 4 risk groups according to the total Charlson comorbidity Index (CCI),
the patients who scored from 3 to 7 on the total Charlson index were gathered into a
CCI>2 group, whereas the other groups were given a score equivalent to the total
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CCI score. The risk groups produced from the information collected from Proton
were compared with risk groups of clinical notes. The percentage of patient with no
comorbid conditions on Proton dropped after auditing the clinical notes (36.7% vs.
23.3%). On the other hand the number of patients with 2 and >2 comorbid conditions
increased when the comorbid conditions were collected from the clinical notes
(Table 3.1).
Groups of Charlson score Proton Clinical notes
no % no %
olluu 11 36.7 7 23.3
CCI= 1 6 20 4 13.3
CCI = 2 4 13.3 8 26.7
CCI >2 9 30 11 36.7
Total number of patients 30 100 30 100
Table 3.1: Comorbidity differences between Proton and clinical notes
3.5. Conclusion
The study showed that computer based data did not include all the information
needed for this work and it is better to extract the comorbid information from the
clinical note. A clear definition for congestive cardiac failure and ischaemic heart
disease should be considered in recording comorbid diseases on proton.
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Chapter 4





Subjective global assessment (SGA), which assesses nutritional status based on
features of the history and physical examination, can be used to estimate malnutrition
in dialysis patients, and has been shown to be predictive of poor outcomes.
Aims
A prospective study of 122 prevalent dialysis patients was originally designed to
determine whether the SGA provided added value on top of more simply collected
numerical and diagnostic data.
Method
SGA was performed by an observer unaware of the results of the objective
measurements at the beginning of the study. Numerical data including serum
albumin, urea, body mass index (BMI), mid arm muscle circumference (MAMC),
serum cholesterol, and C-reactive protein (CRP) were extracted from the renal IT
system, and comorbidity was determined from case records and scored using the
Khan method. Univariate and multivariate Cox regression was used to identify
independent predictors of survival.
Results
At 24 months 87 patients (71.3%) were alive. Cardiovascular disease was the leading
cause of death (57.1%). A univariate analysis showed that SGA was strong predictor
of patients outcome (p=0.001), the most severely malnourished patients having 25%
survival versus 80.6% for the best scores. The Cox regression model of multivariate
analysis showed that patient survival was significantly associated with age, with
SGA, CRP, and the presence of comorbid diseases at start of dialysis.
Conclusion
Significant additional information is provided by measuring SGA.
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4.2. Introduction
Malnutrition is a common risk factor in dialysis patients and there is no ideal method
that can be used to assess malnutrition in these patients. A dietician team initiated a
study aiming to find a nutritional screening tool that reduced of dietetic, nursing or
medical staff time, with the hypothesis that a computer based malnutrition screening
tool could identify dialysis patients at risk of malnutrition as accurately as subjective
global assessment (SGA). They had found that SGA, which relies on an experienced
dietician carrying out the assessment, was time consuming, meaning that they could
not use this method to assess the nutritional status of dialysis patients every 4 months
as recommendation by the international guidelines (DOQI 1997). In this study I
extended the dieticians original nutritional study by adding the different comorbid
conditions at start of the study aiming to evaluate whether there was added value in
using SGA to predict patient's survival.
4.3. Methods
This cross section study included 122 prevalent patients receiving dialysis treatment
at the renal unit in the RIE, selected by the dieticians in the renal unit according to
the following criteria
1. the study involved out-patient dialysis patients only
2. Patients who had been on dialysis for more than 90 days
3. Patients were able to communicate and answer simple questions required for
SGA.
SGA assessments includes, patient history of weight loss, incidence of anorexia, and
incidence of vomiting, and the physician's grading of muscle wasting, presence of
oedema, and loss of subcutaneous fat. On the basis of these assessments, each patient
was given a score that reflect the nutritional status (Chapter 2).Other nutritional
parameters were measured; BMI, TSF, MAMC, serum albumin, serum urea, and
serum cholesterol in addition to age, sex, modality of treatment, primary renal
diagnosis (based on ERA-EDTA codes for renal disease), and CRP at the time of
start of the study (11/4/2005). Comorbid diseases were collected by one observer
(FL). Patients were followed until 12/4/2007 (2 years).
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4.4. Patient mortality and causes of death
Figure 4.1 shows the cumulative survival curve in this study and after 2 years of
follow up 35 patients (28.7%) had died. Cardiovascular disease accounts for over
half of all deaths, while infections account for more than one quarter (Table 4.1).
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Figure 4.1; Survival curve of prevalent patients
Cause of death n %




Table 4.1; Causes of death
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ERA-EDTA Cause of Death Code no (%)
Cardiovascular/vascular causes
Cardiac arrest Unknown cause 15 14 (40%)
Myocardial ischemia and infarction 11 4 (11.4%)
Cerebrovascular accident 22 2 (5.7%)
Infection
Pulmonary infection 31 4 (11.4%)
Septicaemia 35 6 (17.2%)
Malignancy 67 2 (5.7%)
Others
ESRF treatment withdrawn for medical reasons 54 3 (8.6%)
Table 4.2; List of all causes of death
4.5. Demographic data
The main clinical and demographic characteristics with summary statistics for all 122
prevalent patients are shown in table 4.3 and 4.4 below. Data are presented as mean
± SD, median (range) and number (%). The minimal dialysis time was 282 days as
the patients involved in this study were those who survived more than 6 months.
Variables No %
Age groups
< 65 years 68 55.7










Table 4.3; Basic clinical and demographic characteristics of study
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Variables Median (min-max) Mean ± SD
Age (years) 60.5 (17-88)
CRP (mg/1) 8 (3-22)






Serum albumin (g/1) 37.8 ±5.2
Serum urea (mmol/1) 18.7 ±4.3
Serum cholesterol (mmol/1) 4.2 ± 1.0
MAMC (cm) 24.5 ± 3.4
TSF (mm) 14.9 ±7.2
Table 4.4; Summary statistics of the study population at entry to the study
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4.6. Patient characteristics and univariate analysis
Univariate analysis of the patients showed that age, comorbidity, nutritional status
based on SGA classification, primary renal diagnosis, serum urea, serum albumin,
serum cholesterol, CRP, and time spent on dialysis prior to the study, were all
significantly associated with death. Patients' sex did not significantly influence
survival, nor did BMI, MAMC, or modality of treatment (Table 4.5).
Cohort Survivors Dead p-value &
n=122 n=87 (71.3%) n=35 (28.7%) statistic test
Median age (years) (IQR) 60.5 (46-72) 57 (43-68) 72 (58-76) P=0.0001 M W
Age> 65 years 54 (44.3) 31 (35.6) 23 (65.7%) p=0.002
Gender p=0.542 x2
Male 75 (61.5) 52 (59.8) 23 (65.7)
Female 47 (38.5) 35 (40.2) 12 (34.3)
Modality p=0.636 x2
Haemodialysis 109 (89.3) 77 (88.5) 32 (91.4)
Peritoneal dialysis 13 (10.7) 10(11.5) 3 (8.6)
Statin Therapy p=0.149 x2
Yes 48 (39.3) 30 (34.5) 18(51.4)
No 71 (58.2) 45 (62.1) 17 (48.6)
Diagnosis p=0.001 x2
glomerulonephritis 32 (26.2) 24 (27.6) 8 (22.9)
Interstitial Nephritis 29 (23.8) 27 (31) 2 (5.7)
Multisystem disease 25 (20.5) 10(11.5) 15 (42.9)
Diabetic nephropathy 7 (5.7) 5 (5.7) 2 (5.7)
Unknown 29 (23.8) 21(24.1) 8 (22.9)
SGA p=0.005 x2
Severe 4 (3.3) 1 (1-1) 3 (8.6)
Moderate 41 (33.6) 24 (27.6) 17 (48.6)
Normal 77 (63.1) 62 (71.3) 15 (42.9)
Khan score p=0.0001 x2
Low 43 (35.2) 41 (47.1) 2 (5.7)
Medium 29 (23.8) 23 (26.4) 6(17.1)
High 50 (41) 23 (26.4) 27 (77.1)
Ischaemic heart disease 42 (34.4) 19(21.8) 23 (65.7) p=0.0001 X2
Congestive cardiac failure 18 (14.8) 6 (6.9) 12 (34.3) p=0.0001 X2
Peripheral vascular disease 22(18) 7(8) 15 (42.9) p=0.0001 X2
Cerebrovascular disease 24 (19.4) 8 (9.2) 16(45.7) p=0.0001 X2
Diabetes 21 (17.2) 11 (12.6) 10(28.6) p=0.035 x2
Peptic ulcer disease 8 (6.6) 3 (3.4) 5 (14.3) p=0.029 x2
Chronic pulmonary disease 18 (14.8) 11 (12.6) 7 (20) p=0.300 x2
Malignancy 11(9) 7(8) 4(11.4) p=0.555 x2
Mean Albumin (g/1) 37.8 SD 5.2 38.6 SD 4.1 35.9 SD 4.1 p=0.001 T-test
Mean Urea (mmol/1) 18.7 SD 4.3 19.2 SD 4.3 17.3 SD 4.1 p=0.023 T test
Mean Cholesterol (mmol/1) 4.2 SD 1.0 4.3 SD 1 3.9 SD 0.9 p=0.049 T test
CRP (mg/1) (IQR) 8 (5-21) 6(5-15) 18(8-31) p=0.0001 M-W
Median Time on dialysis 1491 (1020-3222) 1753(1142-3370) 4.8 1234 (698-2190) p=0.008 M-W
(days) & (years) (IQR) 4.1 (2.7-8.8) (3.1-9.2) 3.3(1.9-6)
Median BMI (kg/m2) (IQR) 25.2 (21.5-28.6) 25.5 (21.6-28.7) 24.2 (20.9-25.9) p=0.094 M-W
Mean MAMC (cm) 24.5 SD 3.4 24.9 SD 3.4 23.6 SD 3.2 p=0.054 T teat
Table 4.5; Patient characteristics and univariate analysis, x2=Chi square test, M.W= Mann Whitney test
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4.7. Comparison between the groups, according to survival
4.7.1. Age
In this study the median age of 122 patients was 60.5 years (IQR= 46-72). When
these patients were distributed according to age in 10 year periods, 46% were older
than 60 years (Figure 4.2).
Figure 4.2; Age distribution in 10 years period
4.7.1.1. Comparison between age groups according to survival
The patients were grouped according to age: young patients (less than 65 years) and
old patients (65 years or more) according to UKRR reports. A log rank test showed
that survival of the two groups differed significantly (p=0.001) (Figure 4.3). The
mortality rate was more than 2 times higher in old patients compared with young
patients (42.5% vs. 17.6% Table 4.6.
Age groups Number of patients Number dead in 2 years % dead in 2 years Log rank
p-value
<65 years 68 12 17.6 0.001
>65 years 54 23 42.5
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Figure 4.3; Survival difference between age groups (p=0.001)
4.7.2. Primary renal diagnosis
The distribution of patients according to primary renal diagnosis with median age is
shown in Table 4.7 and Figure 4.4. The most frequent group is glomerulonephritis
26.2% with median age 63 years. Multisystem disease has the oldest median age at
71 years. Only 7 patients included in this study were known to be diagnosed as
diabetic nephropathy. List of primary renal diagnosis with ERA-EDTA code, number
of patients and percentage in each diagnosis are shown in Table 4.8.
PRD groups NO % Median age (IQR)
Glomerulonephritis 32 26.2 63 (46-74)
Interstitial Nephritis 29 23.8 53 (43-64)
Multisystem disease 25 20.5 71 (57-75)
Diabetic Nephropathy 7 5.7 66 (57-75)
Unknown and Others 29 23.8 58 (42-73)
Table 4.7; Distribution of primary renal diagnosis into 5 main groups
Age Groups
J1 *-65 years
_TI > 65 years







Figure 4.4; Percentage of primary renal disease
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ERA-EDTA Primary Renal Diagnosis Code No %
Aetiology unknown 0 25 20.5
Polycystic kidneys, adult (dominant) 41 12 9.9
Renal vascular disease due to hypertension 72 8 6.7
Ischaemic renal disease/cholesterol embolism 75 8 6.7
IgA nephropathy 12 7 5.7
glomerulonephritis; histologically examined, not given above 19 7 5.7
Diabetic glomerulosclerosis or diabetic nephropathy 81 7 5.7
Membranous nephropathy 14 5 4.1
glomerulonephritis; histologically not examined 10 4 3.3
FSGS with nephrotic syndrome 17 4 3.3
Pyelonephritis due to vesico-ureteric reflux without 24 4 3.3
obstruction
Renovascular disease 70 4 3.3
Pyelonephritis due to congenital obstructive uropathy +/- vesico- 22 3 2.5
ureteric reflux
Renal hypoplasia (congenital) 60 3 2.5
Interstitial nephritis 30 2 1.6
Hereditary nephritis with nerve deafness (Alport's syndrome) 51 2 1.6
Renal vascular disease due to malignant hypertension 71 2 1.6
Goodpastures syndrome 86 2 1.6
Pyelonephritis - cause not specified 20 1 0.8
Pyelonephritis associated with neurogenic bladder 21 1 0.8
Pyelonephritis due to acquired obstructive uropathy 23 1 0.8
Pyelonephritis due to urolithiasis 25 1 0.8
Interstitial nephropathy due to analgesic drugs 31 1 0.8
Medullary disease including nephronophthisis 43 1 0.8
Renal vascular disease due to polyarthritis 73 1 0.8
Wegener's granulomatosis 74 1 0.8
Myelomatosis/light chain deposit disease 82 1 0.8
Lupus erythematosus 84 1 0.8
Tubular necrosis (irreversible) or cortical necrosis 90 1 0.8
Traumatic or surgical loss of kidney 96 1 0.8
Interstitial nephritis 99 1 0.8
Table 4.8; List of primary renal diagnosis of 122 patients
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4.7.2.1. Comparison between the primary renal diagnosis groups according to
outcome
The log rank test for primary renal diagnosis was significant (p=0.0001) (Figure
4.5). The highest mortality rate was among those with a diagnosis of multisystem
disease 60% were dead at the end of the study with median survival 1.8 year. The
interstitial nephritis group had the lowest mortality rate 6.8% (median survival not
recorded during study) (Table 4.9).
PRD Number Number % dead Median 95% CI for Log rank
groups of dead in 2 in 2 years survival median survival p-value




GN 32 8 25
rN 29 2 6.8
MS 25 15 60 1.8 1.1 2.4
DN 7 2 28.5
Unknow 29 8 27.5 >2





















Figure 4.5; Survival curve for primary renal diagnosis (p=0.0001)
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4.7.3. Subjective global assessment
According to total SGA score patients were classified into 3 groups (Figure 4.6).
Group A or severely malnourished patients (score 1 to 2) included only 4 patients
(3.3%) with median age 62 years. Group B or moderately malnourished patients
(score 3 to 5) included 41 patients with median age of 59 years. Group C or well
nourished patients (score 6 to 7) was the most frequent group, 77 patients (63.1%),
with the higher median age 71 years (Table 4.10).
variables NO % Median age (IQR)
Severe malnutrition 4 3.3 62 (46-77)
Moderate malnutrition 41 33.6 59 (43-75)
Normal 77 63.1 71 (57-75)
Table 4.10; SGA groups and median age
63.1%
□ Severe ■ Moderate ■ Normal
Figure 4.6; Percentage of SGA groups
4.7.3.1. SGA Correlations
The relationship between SGA total score and other continuous data was investigated
using Pearson product-moment correlation coefficient (Table 4.11). A strong
positive correlation was found between SGA and nutritional indices (serum albumin,
BMI, MAMC and TSF), a higher score of SGA was associated with a higher level of
serum urea, serum albumin, and higher measurements of BMI, MAMC, and TSF
(Figures 4.7,8,9,10,11). There was no significant correlation between SGA and
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either age or serum cholesterol. There was strong negative correlation between SGA
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Figure 4.7; Scatter-plot of SGA vs. Albumin Figure 4.8; Scatter-plot of SGA vs. Urea
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Figure 4.9; Scatter-plot of SGA vs. BMI
ooonmo od o











OOO CD O O
o aocmj aoancoo oco oooooooo
COO <35 OD CO O










50 100 150 200
CRP
Figure 4.11; Scatter-plot of SGA vs. TSF Figure 4.12; Scatter-plot of SGA vs. CRP
4.7.3.2. Univariate analysis and characteristic of malnourished and well
nourished patients
4.7.3.2.1. Univariate analysis ofmalnourished patients
Due to the small number of severely malnourished patients, I have combined both
severely and moderately malnourished patients into one "malnourished group" which
included 45 patients according to SGA classification. The analysis showed that
mortality at two years was 44.4% and the main cause of death was cardiovascular
disease (55%) followed by infection (35%) (Table 4.12). The analysis also showed
that age, comorbidity, serum cholesterol, primary renal diagnosis, and time spent on
dialysis prior to the start of the study were all significantly associated with death in
malnourished patients. The mortality of malnourished patients was associated with
the presence of ischaemic heart disease, peripheral vascular disease and
cerebrovascular disease (Table 4.13).
4.7.3.2.2. Univariate analysis of well nourished patients
Univariate analysis of well nourished patients showed that the mortality at two years
was 19.4%. Cardiovascular disease was the leading cause of death (60%) followed
by infection (20%) (Table 4.12). The analysis revealed that age, comorbidity,
modality, serum albumin serum urea, MAMC, were all associated with death among
well nourished patients. Moreover presence of congestive cardiac failure, ischaemic
heart disease, peripheral vascular disease, cerebrovascular disease and diabetes all
significantly influenced the survival of the well nourished group of patients (Table
4.14).
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Cause of death Malnourished Well nourished
no % no %
Cardiovascular disease 11 55 9 60
Infection 7 35 3 20
Malignancy 0 0 2 13.3
Others 2 10 1 6.7
Table 4.12; Causes of death in well nourished and malnourished patients
Cohort survivors Dead by p value &
n=45 n=25 n=20 statistic test
Median age (years) (IQR) 59 (44-75) 46 (39-60) 75 (62-79.5) p=0.0001 M-W
Age>65 years 17 (37.8) 4(16) 13 (65) p=0.001 x2
Gender p=0.428 x2
Male 31 (68.9) 16(64) 15 (75)
Female 14(31.1) 9(36) 5(25)
Mode of RRT p=0.815x2
Haemodialysis 41 (91.1) 23 (92) 18 (90)
Peritoneal dialysis 4 (8.9) 2(8) 2(10)
Mean Albumin (g/1) 36.5 SD 4.6 37.4 SD 4.2 35.3 SD 5 p=0.13 T-test
Mean Cholesterol (mmol/1) 4.2 SD 1.1 4.5 SD 1.1 3.8 SD 0.9 p=0.034 T-test
Median CRP (mg/1) (IQR) 13 (5-31) 7 (5-35) 19.5 (10-30) p= 0.11 M-W
Mean Urea (mmol/1) 17.5 SD 5.1 17.8 SD 5.3 17.2 SD 5 p=0.589 T-test
BMI (kg/m2) 23 (19.5-25.8) 21.9(19.1-26.7) 24.3 (19.9-25.7) p= 0.936 M-W
Mean MAMC (cm) 23.3 SD 3.2 23 SD 3.2 23.6 SD 3.2 p=0.579 T-test
Time on dialysis (years) 3.3 (2.2-7.6) 4 (2.5-9.8) 2.3(1.6-4.9) p= 0.010 M-W
PRD p=0.020 x2
Glomerulonephritis 11 (24.4) 6(24) 5(25)
Interstitial Nephritis 9(20) 9(36) 0
Multisystem diseases 13 (28.9) 4(16) 9(45)
Diabetic nephropathy 1 (2.2) 0 1 (5)
Unknown 11 (24.4) 6(24) 5(25)
Comorbid Conditions
Ischaemic heart disease 18 (40) 6 (33.3) 12(60) p=0.014x2
Congestive cardiac failure 8(17.8) 2(8) 6(30) p=0.055 x2
Peripheral vascular disease 9(20) 2(8) 7(35) p=0.024 x2
Cerebrovascular disease 11 (24.4) 3(12) 8(40) p=0.030 x2
Diabetes 5(11.1) 1 (4) 4(20) p=0.090 x2
Khan Score p=0.0001 x2
Low 15 (33.3) 15(60) 0
Medium 9(20) 4(16) 5(25)
High 21 (46.7) 6(24) 15 (75)
Table 4.12; Characteristics and univariate analysis of malnourished patients x2=Chi square test, M.W=Mann
Whitney test
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Cohort survivors Dead by p value &
n=77 n=62 n=15
statistic test
Median age (years) (IQR) 63 (46-71) 58 (44-70) 70 (57-75) p=0.024 M-W
Age>65 years 37 (48.1) 27 (43.5) 10(66.7) p=0.108 x2
Gender p=0.740 x2
Male 44 (57.1) 36 (58.1) 8 (53.3)
Female 33 (42.9) 26(41.9) 7 (46.7)
Mode of RRT p=0.006 x2
Haemodialysis 68 (86.2) 54 (87.1) 14 (93.3)
Peritoneal dialysis 9(11.7) 8 (12.9) 1 (6.7)
Mean Albumin (g/1) 38.6 SD 3.1 39.1 SD 3.1 36.8 SD 2.5 p=0.005 T-test
Mean Cholesterol (mmol/1) 4.2 SD 0.9 4.2 SD 0.9 4.1 SD 0.9 p=0.568 T-test
Median CRP (mg/1) (IQR) 6(5-18) 5(5-12) 16(7-32) p= 0.004 M-W
Mean Urea (mmol/1) 19.4 SD 3.6 19.8 SD 3.7 17.4 SD 2.3 p=0.021 T-test
BMI (kg/m2) 26.1 (23.7-29.2) 26.6 (24.1-29) 24.2 (23.1-29.6) p= 0.410 M-W
Mean MAMC (cm) 25.2 SD 3.3 25.6 SD 3.2 23.5 SD 3.3 p=0.039 T-test
Time on dialysis (years) 4.7 (3.2-9.2) 4.8 (3.2-9.2) 3.5 (3-11.2) p= 0.563 M-W
PRD p=0.068x2
Glomerulonephritis 21 (27.3) 18 (29) 3 (20)
Interstitial Nephritis 20 (26) 18(29) 2(13.3)
Multisystem diseases 12(15.6) 6 (9.7) 6(40)
Diabetic nephropathy 6 (7.8) 5(8.1) 1 (6.7)
Unknown 18 (23.4) 15 (24.2) 3(20)
Comorbid Conditions
Ischaemic heart disease 24 (31.2) 13 (21) 11 (73.3) p=0.0001 x2
Congestive cardiac failure 10(13) 4 (6.5) 6(40) p=0.001 x2
Peripheral vascular disease 13 (16.9) 5(8.1) 8 (53.3) p=0.0001 x2
Cerebrovascular disease 13 (16.9) 5(8.1) 8 (53.3) p=0.001 x2
Diabetes 16(20.8) 10(16.1) 6(40) p=0.041 x2
Khan Score p=0.001 x2
Low 28 (36.3) 26(41.9) 2(13.3)
Medium 20 (26) 19(30.6) 1 (6.7)
High 29 (37.7) 17 (27.4) 12 (80)
Table 4.14; Characteristics and univariate analysis of well nourished patients x2=Chi square test, M.w=
Mann Whitney test
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4.7.3.3. Comparison between SGA groups according to survival
Figure 4.13 shows the significant influence of SGA groups on survival (p=0.001).
Patients classified as well nourished (total SGA score = 6 to 7) had the lowest
mortality rates with 19.4% and median survival >2 years. On the other hand the
severely malnourished group had the highest mortality rate 75% with median
survival of 1.3 years. The mortality rate of moderate malnourished group was 41.4%
with median survival >2 years (Table 4.15).
When the same analysis was carried out but this time comparing well nourished
patients with malnourished patients (severe and moderate malnourished groups) the
mortality rate among the malnourished group was 2 times greater than well
nourished group (44.4% vs. 19.4%) (Figure 4.14).
SGA Number Number % dead Median 95% CI for
of dead in 2 in 2 survival median survival
patients years years (years) (years)
lower upper
Severe 4 3 75 1.3 0.4 2.2
Moderate 41 17 41.4 >2






malnourished 45 20 44.4
Normal 77 15 194
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Figure 4.14; Survival curve for 2 groups of SGA (p=0.001)
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4.7.4. Comorbidity
4.7.4.1. Frequency of comorbid disease
Ischaemic heart disease (angina and myocardial infarction) was the most frequent
comorbidity, found in 42 patients (34.4%). Cerebrovascular disease, which was
found in 24 patients (19.6%), was the second most common comorbidity. 21 (17.2%)
patients had diabetes, but only 7 patients (5.7%) were diagnosed with diabetic
nephropathy (Figure 4.15)
Figure 4.15; Distributions of comorbid illnesses
The frequency of comorbidity in males was higher than females except for diabetes
mellitus, which was slightly higher in females (11 vs. 10). The frequency of
cerebrovascular disease was equal in both sexes (12 vs. 12), CT disease was equally
common in both sexes but the number of patients involved was very small (3 vs.3)
(Figure 4.16).
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Figure 4.16; Distribution of comorbid illnesses in both sexes
The frequency of comorbid conditions was higher in the older age group (> 65 years)
than in younger patients except for peptic ulcer disease for which the frequency was
equal, although the number of patients involved was very small (4 vs. 4). In the case
of liver disease the frequency was higher in the younger age group but the number of
patients was small (6 vs. 2 for liver disease) (Figure 3.17).
Figure 4.17; Frequency of comorbidity and age group difference
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4.7.4.2. Outcome according to comorbid conditions
The influence of comorbid illnesses on survival is illustrated in (Table 4.16).
Ischaemic heart disease showed a significant difference (p=0.0001) in survival
between the 2 groups of patients, those with ischaemic heart disease had mortality
rate of 57.7% with median survival 1.8 year (p=0.0001) (Figure 4.18). Patients with





















Figure 4.18 Survival curve for
Ischaemic heart disease (IHD) (p=0.0001)
600 800
Survival in Days
Figure 4.19; survival curve for
Congestive cardiac failure (CCF) (p=0.0001)
Figure 4.20 shows a significant difference (p=0.029) in survival between diabetic and
non diabetic patients (mortality rates 47.6% compared with 24.7%). Also a
significant survival difference in patients with peripheral vascular disease, and
cerebrovascular disease from those who were without these comorbid conditions
(Figure 4. 21, 22).
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Figure 4.20; Survival curve for
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Figure 4.21; Survival curve for
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Figure 4.22; Survival curve for cerebrovascular disease (CeVD) (p=0.0001)
Malignancy, chronic pulmonary disease and connective tissue diseases did not show
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Figure 4.24; Survival curve for
Chronic pulmonary disease (CPD) (p=0.508)
Survival in Days
Figure 4.25; Survival curve for
Connective tissue disease (p=0.558)
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Comorbid Number Number % dead Median
conditions of dead in 2 in 2 survival








































































































Table 4.16; Mortality difference in different comorbid conditions
4.7.5. Khan score
According to Khan score 50 patients (41%) were classified as high risk and they
were the oldest with median age 72 years. The proportion of low risk and medium
risk patients was 35.2% and 23.8% with median age 45 and 64 respectively (Table
4.17).
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Khan score No % Median age IQR
Low Risk 43 35.2 45 38-57
Medium Risk 29 23.8 64 51-70
High Risk 50 41 72 62-76
Table 4.17; Khan Score groups and median age
4.7.5.1. Comparison between the groups of comorbidity score according to
survival
There was a significant influence of comorbidity on survival (p=0.0001) between the
groups of Khan score (Figure 4.26). The two years mortality was 5.1% in the low
risk group, but increased by 4 and 12 fold in the medium and high risk groups
respectively (Table 4.18).
Comorbidity Number Number % dead Median 95% CI for Log rank
scores of dead in 2 in 2 years survival median survival p-value
patients years (years) (years)
lower upper
Khan 0.0001
Low 43 2 4.6
Medium 29 6 20.6
High 50 27 54.0 1.8 1.7 2
Table 4.18; Mortality difference between Khan Score risk groups
j| 0.4 ~ Khan
U High
0-2 " J] Low
Medium
0.0-
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Survival in Days
Figure 4.26; survival curve for Khan Score (p=0.0001)
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4.8. Multivariate analysis of patient mortality
The Cox regression model of survival analysis was used to identify those
independent factors associated with death. Survival analysis was performed for 122
dialysis patients. The independent variables used in the multivariate analysis were
gender, mode of RRT, serum-, albumin, urea, cholesterol, and CRP, primary renal
diagnosis, time spent on dialysis before starting the study, BMI, MAMC, SGA
(l=severe malnutrition, 2= moderate malnutrition, and 3= normal), and comorbidity
evaluated by Khan Score for classification into 3 risk groups (mild, medium and
high) as this included age, so age was not included in the analysis. The main outcome
was 2 years patient survival.
Each lmg/1 increase in serum CRP increased the chance of death by 1%. The risk of
death was significantly (p=0.011) increased by 2.4 times in moderately malnourished
(SGA score =3 to 5) compared with reference or normal group (SGA score = 6 to 7),
and was 5.1 times higher in the severely malnourished group (SGA = 1 to 2).
Comorbidity according to Khan score showed that the risk of death was significantly
(p=0.0001) increased by 4.9 times and over 17 times in the medium and high risk
groups respectively compared with the low risk group (Table 4.19).
In order to see the effect of every single comorbid diseases upon survival a separate
multivariate analysis was carried out, including the same variables that had been
described in the above analysis but entering all the comorbid diseases instead of
Khan score and adding age as independent factor. The analysis revealed the same
results from the above analysis, and in addition, patients who had cerebrovascular
and peripheral vascular diseases had increased risk of death 2.1 and 2.2 times greater
than patients who were without these diseases. Moreover, each additional year in
patient's age increased their chance of death by 5% (Table 4.20).
Other variables analysed which did not contribute significantly to multivariate model
were gender, mode of RRT, serum-albumin, serum urea, serum cholesterol, BMI,
MAMC, primary renal disease, and time on dialysis before the study had started.
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Variable significance Hazard ratio 95% CI for Hazard ratio






Moderate malnourished 2.41 1.14 5.07
Severe malnourished 5.16 1.44 18.42
Khan 0.0001 Ref
Medium risk group 4.92 0.97 24.85
High risk group 17.88 4.18 76.37
Table 4.19: Cox regression survival analysis Khan Score model
Variable significance Hazard ratio 95% CI for Hazard ratio





CRP (mg/1) 0.049 1.01 1.0 1.02
SGA .036 Ref
Moderate malnourished 2.5 1.16 5.38
Severe malnourished 3.15 0.84 11.81
Cerebrovascular disease 0.048 2.14 1.01 4.56
Peripheral vascular disease 0.043 2.27 1.02 5.03
Table 4.20; Cox regression survival analysis all comorbid conditions model
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4.9. Comparison of Survival and mean age of Edinburgh prevalent
patients and study patients of the same year
As the study in this chapter was cross sectional in design and therefore subject to the
possibility of selection bias during the initial recruitment, it is possible that only
those dialysis patients who were generally healthier agreed to participate. A
comparison of the mean age and one year survival showed that there was no
difference in the one year survival of 122 patients included in this study and overall
survival of all 298 prevalent dialysis patients in Edinburgh in the same year (87.7%
vs. 87.4%). However, the median age in this study was higher than overall prevalent
dialysis patients (Table 4.21).
Study patients Overall Edinburgh prevalent patients
Number of patients 122 298
Median age 58.5 54.9
1 year survival % 87.7 87.4
Table 4.21; Age and 1 year survival of study patients and all prevalent patients in Edinburgh
4.10. Hospitalisation
Hospitalisation rates may reflect the quality of dialysis care because patient
morbidity affects the frequency and the duration of hospital stay. Moreover hospital
stay is a common occurrence in dialysis patients.
The percentage of live time at risk spent in hospital (time from starting of the study
11/4/2005 to either death or end of study 11/4/2007) was calculated for each patient
as had been explained in chapter 2. The Kruskal Wallis test used to compare the
median percentages between the groups (p-value<0.05 was significant). The overall
median percentage of time spent in hospital was 2.4% (0.3% - 7.2%) (Mean = 5.8%).
Only 15 patients (12.3%) were not admitted to the hospital in a period of two years.
4.10.1. Correlation of hospitalisation and continuous variables
Pearson correlation showed that time spent in hospital in 2 years was associated
positively with CRP (the high levels of CRP associated with more time spent in
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hospital). Inversely serum albumin and total SGA score were negatively associated
with hospital stay. High serum albumin level associated with less time spent in
hospital also the better nutritional status measured according to SGA score associated
with less hospital admissions (Table 4.22).
CRP Serum albumin SGA
Days spent in hospital
Pearson Correlation 0.359 - 0.383 -0.295
p-value 0.0001 0.0001 0.001
Table 4.22; Pearson correlations of hospitalisation
4.10.2. Comparison between groups according to hospitalisation percentage
The median percentage of time at risk spent in hospital was highest for old patients
(1.9% under 65 years, 4% >65 years). Hospitalisation was affected by the nutritional
status according to SGA classification. Patients classified as severely malnourished
had the highest median percentage of time at risk spent in hospital 10.1% (however
this group included only 4 patients) compared with 3.6% and 1.9% for moderately
malnourished and well nourished groups respectively. The analysis showed a
significant difference in median percentage of time spent in hospital between risk
groups, where the lowest percentage was for patients with low risk (1.6%), followed
by moderate risk (2.5%) and the highest for the high risk group at 4% (Table 4.23).






<65 years 68 55.7 1.9 0.2-4.2
>65 years 54 44.3 4 0.5-11.9
SGA 0.005
Normal 77 63.1 1.9 1<No
Moderate MN 41 33.6 3.6 0.5-10.8
Severe MN 4 3.3 10.1 6.4-19.2
Khan 0.045
Low 43 35.2 1.6 0.1-3.1
Medium 29 23.8 2.5 0.2-5.2
High 50 41 4 0.6-12.3
Table 4.23; Hospitalisation according to age groups, SGA groups and Khan Score groups
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There was no significant difference in the median percentage of time at risk spent in
hospital between gender, modality and primary renal diagnosis groups (Table 4.24).
Cases Cases Median % IQR Kruskal-Wallis
no % time spent Test (p-value)
in hospital
Gender 0.505
Male 75 61.5 2.6 0.5-7.1
Female 47 38.5 1.6 0.1-7.6
Modality 0.768
Peritoneal dialysis 13 10.7 0.6 0- 13
Haemodialysis 109 89.3 2.4 0.5-5.5
Primary renal diagnosis 0.409
Glomerulonephritis 32 26.2 2.5 0.4 - 7.4
Interstitial Nephritis 29 23.8 1.6 0.2-4.6
Multisystem disease 25 20.5 3.8 0.7-10
Diabetic Nephropathy 7 5.7 0.6 0-5.3
Unknown 29 23.8 2.4 0.4-8
Table 4.24; Hospitalisation percentage according to gender, modality and primary renal diagnosis
4.11. Summary
Although this is a cross sectional study, the survival results are typical of those seen
in bigger survival studies. The one year survival rate was the same for the study
patients and all prevalent dialysis patients in the same hospital at the same year
(87.7% vs. 87.4%). The mortality of 122 prevalent patients was 28.7% at two years.
The main cause of death was cardiovascular disease (57.1%), followed by infection
(28.6%), others (8.6%), and malignancy (5.7%).
Univariate analysis revealed that age, comorbidity, primary renal diagnosis, SGA,
time on dialysis prior study started, serum-albumin, urea, cholesterol and CRP were
all associated with mortality. Of all comorbid conditions the analysis showed that
ischaemic heart disease, congestive cardiac failure, peripheral vascular disease
cerebrovascular disease, and diabetes had an influence on patient survival.
Multivariate analyses revealed that age, comorbidity, SGA, and CRP were
significantly associated with death. Cerebrovascular and peripheral vascular diseases
were contributory factors to patient survival.
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The overall median percentage of hospitalisation was 2.4%. Hospitalisation was
markedly increased in older, malnourished patients, and in patients with high
comorbidity.
All in all this study found that measuring SGA provides significant additional
information. Beyond that the main factors that influence patient survival were
comorbidity, nutritional status, and CRP.
87
Chapter 5





The morbidity and mortality of the high risk group is a general concern. The
presence of diseases such as cardiac disease, cerebrovascular disease, diabetes, and
malignancy has been recognized to play a big role in increasing the mortality risk in
dialysis patients.
Aim
To examine factors associated with survival in a detailed analysis of the cohort
commencing dialysis in south east Scotland in 2003 and 2004.
Method
183 patients started RRT in South East Scotland in 2003-2004, 156 haemodialysis,
25 peritoneal dialysis and 2 as pre-emptive transplants. Comorbidity was scored by
Charlson, Khan and Davies methods. Univariate and multivariate Cox regression was
used to identify the independent predictors of survival. The main outcomes were
overall survival and hospitalisation.
Results
The median age was 65 years. The gross mortality was 26.2% at one year 38.2% at
two years and 47.5% at the end of the study, (period of 2 - 4 years). Cardiovascular
disease accounted for 40% of all deaths. Multivariate analysis revealed that age,
comorbidity, permanent access, and initial serum cholesterol were independent
predictors of mortality. Hospitalisation percentage was higher in more elderly
patients.
Conclusion
Age, severity of comorbidity, initial access and initial serum cholesterol were
important predictors of survival of patients starting RRT in 2003 and 2004 in the
Renal Unit of the Royal Infirmary of Edinburgh.
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5.2. Introduction
Survival is the ultimate outcome measure of the success of RRT and may be used as
a tool to compare performance among different health care providers. The influence
of age, comorbidity, serum albumin and primary renal diagnosis are important to be
considered for measuring the survival in RRT patients. Early death is a useful data to
be collected to compare the survival between different centers. In particular
comparison of European data with those from the United States Renal Data System
(USRDS) excludes those dying in the first 90 days.
5.3. Methods
Patients: - This cohort study included 183 patients who started RRT in 2003 and
2004 at the RIE renal unit (85 patients started RRT in 2003 and 98 patients in 2004).
Demographic data: - age, sex, mode of first RRT, definitive access, referral to
nephrologist, primary renal diagnosis.
Laboratory measurements'. - the following parameters were measured on all patients
prior to starting dialysis treatment: serum concentrations of urea, albumin, creatinine,
haemoglobin, cholesterol and CRP. These measurements were performed in the
routine clinical laboratory of our unit.
Instruments ofdata collection, coding and grouping: - (I) the primary renal diagnosis
code was chosen from the list issued by European Renal Association-European
Dialysis and Transplant Association (ERA-EDTA). Diagnosis in ERA-EDTA list has
previously been placed into 5 categories [(1) Glomerulonephritis (2) Interstitial
nephritis (3) Multisystem diseases (4) Diabetic nephropathy (5) Unknown causes].
(II) The death causes code was chosen from the list issued by ERA-EDTA that has
been placed in main 5 groups: [(1) Cardiovascular/vascular causes (2) Infection (3)
Malignancy (4) Unknown causes (5) Other known causes].
Data on comorbid conditions: - were represented into 3 different comorbid scores.
The Charlson index does not include age, which was entered into the analysis as a
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separate variable, and angina was included within the Charlson scoring system.
Davies score is similar to Charlson using age as separate variable in the analysis but
has fewer comorbid conditions than the Charlson index. Another analysis used Khan
score, which includes age to stratify the patients into low-, medium-, and high risk
groups; therefore, age was not used in the analysis when Khan score was used as an
independent variable. In-addition, all comorbid conditions collected were included in
separate multivariate analysis to evaluate the effect of each of them on survival.
Follow-up period: - patients in this study were followed until 1/1/2007, a period of
minimum 2 years for those who started in December 2004 and maximum 4 years for
those who started in January 2003 or until death. The median time of treatment
(median time of follow up) was 817 days (27.2 months) IQR 334 to 1102 days (11.5
to 36.7months), minimum 7 days and maximum 1440 days (0 to 48 months).
Hospitalisation: - was studied by assessing the frequency of hospitalisation and its
total duration in days for exactly 2 years. Hospitalisation was defined as any hospital
admission that included at least one overnight stay in the hospital. The admission day
was counted as one full hospitalisation day but the discharge day was not. Therefore,
the minimum duration of hospitalisation per admission was 1 day. Percentage of
hospitalisation was the sum of all hospital admissions to the sum of total duration of
treatment.
5.4. Patient mortality
183 patients were studied of whom 48 (26.2%) were dead by the end of one year, 70
(38.2%) at 2 years and 87 (47.5%) by the end of the study (period of 2 - 4 years). In
order to make these figures more directly comparable with the USRDS, death
patients within the first 90 days of RRT were excluded and the mortality at the end of
one year was 35 (20.6%), 57 (33.5%) at 2 years and at by the end of the study was 74
(43.5%) (Table 5.1), survival curve of those incident patients started dialysis in 2003
and 2004 shown in Figure 5.1. All statistics presented later in this chapter refers to
overall mortality including those dying within 90 days of starting RRT unless
otherwise stated.
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n % n %
90 days 13 7.1% - -
6 month 25 13.7% 12 7.1%
1 year 48 26.2% 35 20.6%
18 months 61 33.3% 48 28.2%
2 years 70 38.2% 57 33.5%
End of study 87 47.5% 74 43.5%












Figure 5.1; Survival curve of incident patients started RRT in RIE in 2003
and 2004 from 1/1/2003 until 1/1/2007.
5.5. Causes of death
Infection was the leading cause of death in the first year 38.3%, followed by
cardiovascular 34%, other causes 21.3%, unknown cause 4.3% and malignancy
2.1%. However, the highest proportion of death at the end of the study was
cardiovascular disease 40.7%, followed by infection 29.1%, other causes 16.2%,
unknown cause 9.3%, and malignancy 4.7 % (Table 3.2). Table 3.3 list causes of
death with ERA-EDTA codes, and the number of patients and percentage in each
cause.
25d 50d 750 1000
Duration of RRT in Days
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Cause of death One year End of the study
n % n %
Cardiovascular 16 34 35 40.7
Infection 17 38.3 25 29.1
Malignancy 1 2.1 4 4.7
Unknown 2 4.3 8 9.3
Others 10 21.3 15 16.2
Table 5.2; Cause of death at one year and at end of the study
ERA-EDTA Cause of Death Code no (%)
Cardiovascular/vascular causes
Cardiac arrest Unknown cause 15 21 (24.4%)
Other causes of cardiac failure 14 4 (4.7%)
Myocardial ischemia and infarction 11 6 (7%)
Cardiovascular rupture aneurysm 26 1 (1.1%)
Cerebrovascular accident 22 3 (3.5%)
Infection
Pulmonary infection 31 10 (11.7%)
Septicaemia 35 13 (15.2%)
Infection else where 34 1 (1.1%)
Peritonitis 39 1 (1.1%)
Malignancy 67 4 (4.7%)
Cause of death uncertain/ not determined 0 8 (9.3%)
Others
Gastro-intestinal Haemorrhage 23 2 (2.4%)
Liver failure-unknown cause 46 1 (1.1%)
Bowel ischemia 99 1 (1.1%)
Perforation of colon 72 1 (1.1%)
Dementia 69 1 (1.1%)
Hyperkalemia 12 1 (1.1%)
ESRF treatment withdrawn for medical reasons 54 7 (8.4%)
Table 5.3; List of causes of death of 183 patients
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5.6. Demographic data
Main clinical and demographic characteristics with summary statistics for all 183
incident patients are shown in Table 5.4 and 5.5 below. Descriptive data are
presented as mean ± SD, median (min and max) and number (%).
Variable Number Percentage
Age groups
<65 years 86 47




Access (haemodialysis+ peritoneal dialysis)
Permanent access 89 49.2
Temporary access 92 50.8
Access haemodialysis
Permanent access 64 41
Temporary access 92 59
Modality
Haemodialysis 156 85.2
Peritoneal dialysis 25 13.7
Pre-emptive Transplant 2 1.1







Table 5.4; Basic clinical and demographic characteristic of study
Variable Median(min-max) Mean ± SD
Age (years) 65 (18-88)
CRP (mg/1) 15 (2-368)
Creatinine (umol/1) 616(174-1479)
Albumin (g/1) 33.6 ±5.5
Urea (mmol/1) 25.3 ±8.6
GFR (ml/min) 7.8 ±2.3
Haemoglobin (g/1) 9.2 ± 1.4
Cholesterol mmol/1 4.4 ± 1.2
Table 5.5; Summary statistic of the study population at initiation of RRT
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5.7. Comparisons between the groups, according to survival
5.7.1. Continuous parameters
The normally distributed parameters at start of RRT were compared by the
independent t tests and for non-parametric (not normally distributed) variables the
Mann-Whitney test was used and their results presented in Tables 5.6 and 5.7
below. The significant differences between the two groups when they started their
RRT were in age, serum albumin, serum cholesterol, serum creatinine and CRP.
variable Alive Deceased p-value
Albumin (g/1) 35.5 ±5.1 31.5 ±5.3 0.0001
Urea (mmol/1) 25.9 ±8.2 24.6 ± 8.9 0.31
eGFR (ml/min) 7.7 ±2.3 8 ±2.4 0.42
Cholesterol (mmol/1) 4.7 ± 1.2 4.1 ± 1.5 0.0001
Haemoglobin (g/1) 9.2 ± 1.5 9.1 ± 1.3 0.63
Table 5.6; Parametric comparison of baseline serum parameters (mean ± SD), by survival
Variable Alive Deceased p-value
Age (years) 55 (40-68) 72 (64-78) 0.0001
CRP (mg/1) 8(4-19) 31 (8-82) 0.0001
Creatinine (pmol/1) 669(512-811) 574 (418-692) 0.001
Table 5.7; Non-parametric comparison of baseline serum parameters (median &1QR), by survival
3.7.2. Age
The median age in this study was 65 years (IQR 50-75). The age of the patients was
distributed in 10 years periods. The highest percentage of incident patient starting
RRT was at age group 70 to 79 (28.9%) where as the lowest percentage of incident
patients starting RRT was at age group 20 to 29 (7.1%) (Figure 5.2)
60
20-29 30-39 40-49 50-59 60-69 70-79 80-89
Age Groups
Figure 5.2; Age distribution in 10 years period
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5.7.2.1. Comparison between age groups according to survival
According to the UKRR reports the patients were classified into 2 age groups young
patients (less than 65 years) and old patients (65 years or more). The two age groups
differed significantly (p=0.0001) (Figure 5.3). Mortality at end of study in old
patients (> 65 years) was 64.9% with median survival of 2 years (0.9 to 3) in contrast
the mortality rate in young patients (<65 years) was 27.9% (median survival not
recorded during study) Table 5.8.
Age Number Number % dead Median 95% CI for median Log rank
groups starting dead by by survival survival (years) p-value
RRT 1/1/2007 1/1/2007 (years)
lower upper
<65 years 86 24 27.9 0.0001
>65 years 97 63 64.9 2 0.9 3











Figure 5.3; Survival differences between young and old age groups (p=0.0001)
5.7.3. Primary renal diagnosis
Based on ERA-EDTA diagnosis code and in order to facilitate analysis of the data
the aetiology of ESRD was categorized into 5 main subgroups (chapter 2). The
distribution of all 183 patients according to these subgroups with median age of each
group is shown in (Table 5.9) and (Figure 5.4). The most frequent group is
i 1 1 1 1 1 1 r~
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multisystem diseases 28.4% with median age of 67 years that includes those who
presented with renal vascular disease, hypertensive nephropathy, kidney tumour, and
multiple myeloma. Unknown diagnosis, in which the exact cause of ESRD could not
be identified, included the most elderly patients with median age 74 years. Table
5.10 shows the list of primary renal diagnosis with ERA-EDTA code, number and
percentage of patients.
Primary Renal Diagnosis No % Median age (IQR)
Glomerulonephritis 41 22.4% 62 (41-71)
Interstitial Nephritis 34 18.6% 59 (42-70)
Multisystem Disease 52 28.4% 67 (56-79)
Diabetic Nephropathy 19 10.4% 61(45-68)
Not known and Others 37 20.2% 74 (65-80)






Figure 5.4; Percentage of primary renal diagnosis
The distribution of gender according to primary renal diagnosis is shown in Figure
5.5. Figure 5.6 shows the distributions ofprimary renal diagnosis according to age in
10 years period. Unknown cause and other multisystem disease diagnosis are more
frequent among older age groups; and interstitial nephritis is more prevalent in
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Figure 5.6; Age group differences of primary renal diagnosis
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ERA-EDTA Primary Renal Diagnosis Code No %
Chronic renal failure; aetiology uncertain/unknown/unavailable 0 36 19.7
Diabetic glomerulosclerosis or diabetic nephropathy 80 19 10.4
Ischaemic Renal Disease/ cholesterol embolism 75 15 8.2
Renal vascular disease due to hypertension 72 15 8.2
Polycystic kidneys; adult type (dominant) 41 11 6.1
IgA Nephropathy 12 9 4.9
Pyelonephritis due to vesico-ureteric reflux without obstruction 24 7 3.9
Membranous Nephropathy 14 6 3.3
Renal vascular disease-type unspecified 70 5 2.8
Myelomatosis/light chain deposit disease 82 5 2.8
Focal Segmental glomerulosclerosis with nephrotic syndrome 17 5 2.7
Goodpasture's Syndrome 86 5 2.7
Drug induced interstitial nephropathy 39 4 2.2
Renal vascular disease-due to other causes 79 4 2.2
Renal vascular disease due to malignant hypertension 71 4 2.2
Crescentic Glomerulonephritis 16 3 1.7
Pyelonephritis cause not specified 20 3 1.7
Lupus erythematosus 84 3 1.5
Glomerulonephritis histologically not examined 10 2
Glomerulonephritis, histologically examined 19 2
Pyelonephritis due to acquired obstructive uropathy 23 2
Interstitial nephritis (not Pyelonephritis) unspecified 30 2
Traumatic or surgical loss of kidney 96 2
Renal vascular disease due to polyarthritis 73 2
Wegener's Granulomatosis 74 2
Membranoproliferative glomerulonephritis type 1 15 1 0.5
Pyelonephritis due to urolithiasis 25 1 0.5
Interstitial nephritis due to cyclosporine A 33 1 0.5
Cystic kidney disease - type unspecified 40 1 0.5
Hereditary nephritis with nerve deafness (Alport's syndrome) 51 1 0.5
Nephrocalcinosis and hypercalcaemic nephropathy 93 1 0.5
Kidney tumours 95 1 0.5
Henoch-Schonlein purpura 85 1 0.5
Haemolytic uraemic syndrome (including Moschvowitz Syndrome) 88 1 0.5
Other identified renal disorders 99 1 0.5
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Table 5.10; List of primary renal diagnosis of 183 patients
5.7.3.1. Comparison between the primary renal diagnosis groups according to
outcome
In the univariate analysis survival was significantly (p=0.037) influenced by primary
renal disease (Figure 5.7). Patients with interstitial nephritis had the lowest mortality
rate 29.4% followed by diabetic nephropathy 36.8%. Patients with unknown
diagnosis had the highest mortality rate 62.2% with median survival of 2.1 years
followed by multisystem disease group 57.7% with median survival 3.2 years (Table
5.11).
PRD Number Number % dead Median 95% CI for Log
groups starting dead by by survival median survival rank P-
RRT 1/1/2007 1/1/2007 (years) (years) value
lower upper
0.037
GN 41 17 41.5 3.6 2.9 4.3
IN 3.4 10 29.4
MS 52 30 57.7 3.2 1.7 4.8
DN 19 7 36.8
Unknown 37 23 62.2 2.1 0.9 3.4
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5.7.4.1. Frequency of comorbid diseases
The most frequent comorbid disease was congestive cardiac failure which occurred
in 70 (38.2%) patients; cardiovascular disease [myocardial infarction and angina]
was found in 62 patients. The number of patients with diabetes was 44 (24%), but
only 19 (10.4%) patients were diagnosed with diabetic nephropathy (Figure 5.8).
The list of all collected comorbid conditions was shown in chapter 2.
Figure 5.8; Distribution of comorbid illnesses
The frequency of comorbid conditions was high in older age group (> 65 years)
except for peptic ulcer disease the frequency was equal although the number of
patients involved was very small (3 vs. 3). In case of liver disease the frequency was
higher in younger age group but the number of patients was small (5 vs. 3 for liver
disease) (Figure 5.9). The frequency of comorbidity according to primary renal
diagnosis is shown in Figure 5.10. Patients diagnosed with other multisystem disease
are at highest risk of serious comorbid conditions including cardiovascular
comorbidity in forms of ischaemic heart disease (angina and myocardial infarction),
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Figure 5.10; Frequency of Comorbidity according to primary renal diagnosis
Distribution of comorbid condition according to 10 years age group is shown in
(Figures 5.11). All the comorbid conditions show the same pattern of distribution in
10 years period as the graphs show the minimal comorbidity among the youngest age
group and the maximum number was among the patients between 70-79 years then
start to decline in the age group 80-89 years this decline could be due to lower
number of patients or may be those patient are die before they are considered as
candidate for dialysis treatment or that elderly patients with significant comorbidity
are not considered for RRT. The exception of distribution pattern of comorbid
conditions in relation to age groups was shown in malignancy as the maximum
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Figure 5.11; Distribution of comorbid condition in relation to 10 years age group
5.7.4.2. Outcome according to comorbid conditions
There was a significant difference in survival between those patients with and with
out congestive cardiac failure; 75.7% of those with congestive cardiac failure had
died (median survival 1 year), while for those with out congestive cardiac failure the
mortality was 30.1%. (Figure 5.12). Patients with ischaemic heart disease had a
median survival of 1.3 (0.4 to 2.2) year (Figure 5.13).
Patients with malignancy had mortality rate of 68.4% and median survival of 1.2
year (0.8 to 1.6) (Figure 5.19). Also, significant survival difference were
demonstrated between patients who started RRT with or without peripheral vascular
disease (Figure 5.14), cerebrovascular disease (Figure 5.15), chronic pulmonary
disease (Figure 5.16), and connective tissue disease (Figure 5.17) (Table 5.12).
There was no significant difference (p=0.390) in survival between patients who
started RRT with diabetes (median 2.5 years) and those who started RRT without
















































































































































Table 5.12; Mortality difference in different comorbid conditions, CCF=congestive cardiac failure,
IHD=ischemic heart disease, CeVD=cerebrovascular disease, CPD=chronic pulmonary disease, CT
diseases=connective tissue disease, DM, diabetes mellitus.
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Figure 5.12; Survival curve for
Congestive cardiac failure (p=0.0001)
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Figure 5.13; Survival curve for
Ischaemic heart disease (p=0.0001)
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Figure 5.14; Survival curve for







Figure 5.15; Survival curve for
Cerebrovascular (p=0.02)
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Figure 5.16; Survival curve for
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Figure 5.17; Survival curve for
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Figure 5.18; Survival curve for Figure 5.19; Survival curve for
Diabetes mellitus (p=0.39) Malignancy (p=0.009)
5.7.5. Comorbidity Scores
Patients were grouped by comorbidity according to 3 different comorbidity scores to
evaluate the effect of comorbid illnesses on patients' survival (chapter 2) (Khan
score, Charlson index and Davies score).
5.7.5.1. Khan score
According to Khan score about half of all incident patients were categorized as high
risk group (50.8%) with median age of 71 (64-78), the rest were assigned to low
(20.2%) and medium (29%) risk groups respectively (Table 5.13).
Khan score No % Median age IQR
Low Risk 37 202 40 27-52
Medium Risk 53 29 65 48.5-74
High Risk 93 50.8 71 64-78
Table 5.13; Khan Score and risk groups
5.7.5.2 Charlson Comorbidity Index
Charlson scores were divided into 4 groups [which roughly represented quartiles].
The patients who scored from 3 to 7 on the total Charlson score were gathered into a
CCI>2 group where as the other groups had given the same order of the total CCI
score (Table 5.14).
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CCI No % Median age IQR
CCI=0 43 2325 43 34-63
CCI=1 39 21.3 63 42-74
CCI=2 34 18.6 69 57-80
CCI>2 67 36.6 70 64-76
Table 5.14; Charlson Index groups
5.7.5.3. Davies score
Davies scores were separated into 4 groups [which roughly represented quartiles]
(Table 5.15). The group with comorbid conditions >2 included the oldest with the
highest median age 71 years (65-77), in contrast the group of patients who started
RRT with out any comorbid illness included the youngest group with median age 42
years (33-59).
Davies No % Median age IQR
0 47 25.7 42 33-59
1 48 26.2 63 51-74
2 42 23 70 57-78
>2 46 25.1 71 65-77
Table 5.15; Davies score groups
5.7.5.4. Comparison between the groups of comorbidity scores according to
survival
Figures (5.20, 21, and 22) show the influence of comorbidity on survival. There was
a significant difference in survival (p=0.0001) between the groups of all the 3
different scores. Patients with no comorbid illnesses (score zero/ low risk) had the
lowest mortality rates with 8.1% in Khan, 10.6% in Davies score, and 14% in
Charlson index. On the other hand the high risk group in Khan score and patients
who scored >2 according to Charlson and Davies scores had the highest mortality
rates 71% in Khan, 76.1% in Charlson, and 80.4% in Davies with median survival of
1.3, 1.1 and 0.9 years in Khan, Charlson and Davies score respectively (Table 5.16).
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Comorbidity Number Number % dead Median 95% CI for Log
scores starting dead by by survival median survival rank p-
RRT 1/1/2007 1/1/2007 (years) (years) value
lower upper
Khan 0.0001
Low 37 3 8.1
Medium 53 18 34
High 93 66 71 1.3 0.7 1.9
Charlson 0.0001
0 43 6 14
1 39 11 28.2
2 34 19 55.9 2.2 1 3.4
>2 67 51 76.1 1.1 0.7 1.6
Davies 0.0001
0 47 5 10.6
1 48 17 35.4 3.7 3.1 4.2
2 42 28 66.7 1.6 0.7 2.4
>2 46 37 80.4 0.9 0.6 1.2
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Figure 5.20; Survival by Charlson index groups
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Figure 5.22; Survival by for Davies score groups
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5.7.6. First RRT modality
Haemodialysis was the first modality of RRT in 85.2% of patients, peritoneal
dialysis in 13.7% and pre-emptive transplant in 1.1% (Figure 5.23).
85.2%
■ HD H PD □ Tx
Figure 5.23; Percentage of first modality of RRT
5.7.6.1. Comparison between modality according to outcomes
The mortality difference between patients who started RTT on haemodialysis or
peritoneal dialysis was significant (p=0.001) (Figure 5.24). More than half of
haemodialysis patients died by the end of the study (53.8%) with median survival 2.9
years (1.9 - 3.9), in contrast mortality rate among peritoneal dialysis patients was





















Peritoneal dialysis 25 3 12
haemodialysis 156 84 53.8 2.9 1.9 3.9
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Figure 5.24; Survival curve according to modality of treatment (p=0.001)
HD=haemodialysis, PD=peritoneal dialysis
5.7.7. Vascular access
In the analysis, 49.2% of patients started RRT using definitive access. Of patients
commencing on haemodialysis, 41% commenced with definitive access. Of those
known early to the renal unit more than half started haemodialysis with definitive
access (57.4% and 58.8% for 3 months and 6 months respectively) (Figure 5.25).
Haemodialysis patients who started dialysis with permanent access were younger
with median age 62 years (42-74), while those who started with temporary access





















Figure 5.25; Number of patients started with and without permanent access in
haemodialysis and peritoneal dialysis (HD+PD) and in haemodialysis (HD) patient only
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5.7.7.1. Comparison between access groups according to survival
Univariate analysis of the outcome according to access showed a significant
difference in mortality in all patients (haemodialysis and peritoneal dialysis patients
but excluding those who started RRT with pre-emptive kidney transplant) (Table
5.18). Patients who started dialysis with temporary access had increased risk of death
by 2.4 times higher than those who started RRT with permanent access
(76.3%vs.28%) at median follow up time 817 days (Figure 5.26). Univariate
analysis including only haemodialysis patients (Figure 5.27) showed that mortality
risk was 1.9 times higher in haemodialysis patient who started with temporary access
compared with patients who started with permanent access (67.3%vs.34.3%).
Access Number Number % dead Median 95% CI for Log
starting dead by by survival median survival rank




Access 89 25 28
No access 92 62 67.3 1.3 0.6 2.1
haemodialysis 0.0001
Access 64 22 34.3 3.7 3.2 4.1
No access 92 62 67.3 1.3 0.5 2.1
Table 5.18; Mortality difference between patients started with and without permanent access.
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Figure 5.26; Survival curve according to access in
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Figure 5.27; Survival curve according to access




Referral time was calculated as the number of days between the first recorded
biochemical result and the date of initiation of RRT. Referral times of 90 days or
more were considered as early referral. Referral times less than 90 days were defined
as late referral. Another consideration in the same way was done for a period of 6
months.
Most patients had been known to the renal unit before starting dialysis (72.1% for
over 3 months and 68.3% for over 6 months) (Figure 5.28). Patients referred late
were older than patients referred earlier (Figure 5.29).
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Figure 5.29; Age group in 10 years and referral to renal unit in 3 and 6 months
5.7.8.1. Comparison between referred groups according to outcome
Univariate analysis demonstrated a significant difference in survival between patients
who had or had not been referred to the renal unit at least 3 months (p=0.034) or 6
months (p=0.050) prior to starting dialysis (Table 5.19). The mortality rates of
referred patients were 43.1 % and 43.2% (median survival of 3.4 and 3.7 years) for 3
months and 6 months respectively. On the other hand the mortality rates for not-
referred patients were 61.2% for 3 months with median survival 1.9 year and 58.9%























Referred 132 57 43.1 3.4 2.8 4
Not-Referred 49 30 61.2 1.9 1.2 2.5
6 months 0.050
Referred 125 54 43.2 3.7 2.7 4
Not-Referred 56 33 58.9 2.1 0.3 3.9
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Figure 5.30; Survival curve for referral
at 3 months (p=0.034)
Figure 5.31; Survival curve for referral
at 6months (p=0.050)
5.8. Comparison between patient in the first year, second year and at end of the
study including and excluding 90 days mortality according to outcome
Univariate analysis of the patients in the first year, second year and at end of the
study (median follow up 817 days) including 90 days mortality showed that age,
comorbidity risk groups based on the 3 different comorbidity scores, initial access for
RRT, initial mode of RRT, initial serum albumin, initial serum cholesterol, and
initial CRP were all significantly associated with death within first year, second year
and at end of the study (Table 5.20, 5.21 and 5.22). The same univariate analysis
was repeated excluding those patients who died within the first 90 days revealed that
the same factors listed above were significantly associated with patient mortality.
Referral to dialysis at 3 months was associated with mortality at 2 years and at the
end of the study when first 90 days mortality was included. Referral at 6 months and
primary renal diagnosis were only significantly associated with mortality at the end
of the study (1/1/2007) if 90 days dead patients were included. Patients with primary
renal diagnoses of interstitial nephritis, multisystem disease, diabetic nephropathy,
and unknown cause of ESRD had worse survival than the reference
glomerulonephritis group. However, the highest mortality rate was among
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multisystem disease group 34.5%, while the best survival was among
glomerulonephritis and interstitial nephritis 25% (Table 5.22).
Univariate analysis of all coexisting illnesses at start of RRT when 90 days mortality
was included (Table 5.20, 5.21 and 5.22) revealed that congestive cardiac failure
and ischaemic heart disease were significantly associated with death in first year,
second year and at end of the study. Chronic pulmonary diseases and connective
tissue disease were significantly associated with mortality at second year and at end
of the study. Malignancy associated with mortality at two years whereas, peripheral
vascular disease at end of the study.
Patients' sex did not influence survival, nor did haemoglobin concentration, eGFR,
or urea concentration at time of initiating RRT.
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5.8.1. One year patient characteristics and univariate analysis
Cohort lyear survivors Dead by 1 year p value &
n=183 n=135 n=48 statistic test
Median age (years) (IQR) 65 (18-88) 62 (44-74) 71 (64-78) p=0.0001 M-W
Age>65 years 97 (52.7) 63 (46.7) 34 (70.8) p=0.004 x2
Permanent access (HD+PD) 89 (49.2) 82 (61.7) 7(14.6) p=0.022 x2
Access HD 64 (41) 58 (53.2) 6(12.8)
First Mode of RRT p=0.006 x2
Haemodialysis 156 (86.2) 109 (69.9) 47 (30.1)
Peritoneal dialysis 25 (13.8) 24 (96) 1 (4)
Mean Albumin (g/1) 33.6 SD 5.5 34.6 SD 5.5 30.7 SD 4.5 p=0.008 T-test
Mean cholesterol (mmol/1) 4.5 SD 1.2 4.6 SD 1.2 3.9 SD 1.1 p=0.002 T-test
Median CRP (mg/1) (IQR) 15 (5-49) 9 (5-35) 36(18-106) p= .001 M-W
Comorbid Conditions
Congestive cardiac failure 70 (38.3) 37 (27.4) 33 (68.8) p=0.0001 x2
Ischaemic heart disease 62 (33.9) 40 (29.6) 22 (45.8) p=0.0001 x2
Khan Score p=0.0001 x2
Low 37 (27.4) 37 (27.4) 0
Medium 53 (29) 43 (31.9) 10 (20.8)
High 93 (50.8) 55 (40.7) 38 (79.2)
Charlson Index p=0.0001 x2
CCI=0 43 (23.5) 42 (31.1) 1 (2.1)
CCI=1 39 (21.3) 32 (23.7) 7 (14.6)
CCI=2 34(18.6) 24(17.8) 10 (20.8)
CCI=3-7 67 (36.6) 37 (27.4) 30 (62.5)
Davies Score p=0.0001 X2
Davies=0 47 (25.7) 46 (34.1) 1(2.1)
Davies= 1 48 (26.2) 38 (28.1) 10 (20.8)
Davies=2 42 (23) 28 (20.7) 14 (29.2)
Davies=3-5 46 (25.1) 23 (17) 23 (47.9)
Table 5.20; Patient characteristics and univariate analysis of factors affecting mortality at 1 year, M-
W=Mann-Whitney Test, y2 = Chi square, IQR= inter-quartile range,
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5.8.2. Two years patient characteristics and univariate analysis
Cohort 2 year survivors Dead by 2year p value &
n=183 n=113 n=70
statistic test
Median age (years) (IQR) 65 (50-75) 59(42-71) 71 (64-78) p=0.0001 M-W
Age>65 years 97 (53) 49 (43.3) 48 (68.6) p=0.0001 x2
Referred 3 m 132 (72.9) 86 (78.2) 46 (64.8) p=0.048 x2
Referred 6 m 125 (69.1) 81 (73.6) 44 (62) p=0.097 x2
Permanent access 89 (49.2) 72 (65.5) 17 (23.9) p=0.0001 x2
(haemodialysis and peritoneal
dialysis)
Access haemodialysis 64 (41) 50 (56.8) 14 (20.6) p=0.0001 x2
First Mode of RRT p=0.003 x2
haemodialysis 156 (86.2) 88 (80) 84 (95.8)
Peritoneal dialysis 25 (13.8) 22 (20) 3 (4.2)
Mean Albumin (g/1) 33.6 35.3 30.9 p=0.0001 T-test
Mean cholesterol (mmol/1) 4.5 4.6 4.1 p=0.003 T-test
Median CRP (mg/1) (IQR) 15 (5-49) 7 (4-22) 34 (15-97) p= 0.0001 M-W
Comorbid Conditions
Congestive cardiac failure 70 (38.3) 24(21.4) 46 (64.8) p=0.001 x2
Ischaemic heart disease 62 (33.9) 28 (25) 34 (47.9) p=0.0001 x2
Malignancy 19(10.4) 6 (5.4) 13 (18.3) p=0.005 x2
Chronic pulmonary disease 24(13.1) 7 (6.3) 17 (23.9) p=0.001 x2
Connective tissue disease 16 (8.7) 5 (4.5) 11 (15.5) p=0.021 x2
Comorbidity p=0.0001 x2
Low 56 (30.6) 48 (42.5) 8 (11.4)
Medium 52 (28.4) 32 (28.3) 20 (28.6)
High 75 (41) 33 (29.2) 42 (60)
Table 5.21; Patient characteristics and univariate analysis of factors affecting mortality at 2.years M-
W=Mann-Whitney Test, x2 = Chi square, IQR= inter-quartile range,
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5.8.3. Patients characteristics and univariate analysis at end of the study
Cohort Survivors by Dead by p value &
1/1/2007 1/1/2007 statistic test
n=183 n=96 n=87
Median age (years) (IQR) 65 (50-75) 55 (40-68) 72 (64-78) p=0.0001 M-W
Age>65 years 97 (53) 34 (35.4) 63 (72.4) p=0.0001 x2
Referred 3 m 132 (72.9) 75 (56.8) 57 (43.2) p=0.031 x2
Referred 6 m 125 (69.1) 71 (56.8) 54 (43.2) p=0.050 x2
Permanent access (HD+PD) 89 (49.2) 64(68.1) 25 (28.7) p=0.0001 x2
Access haemodialysis 64 (41) 42 (58.3) 22 (26.2) p=0.0001 x2
First Mode of RRT p=0.0001 X2
Haemodialysis 156 (86.2) 72 (46.2) 84 (53.8)
Peritoneal dialysis 25 (13.8) 22 (88) 3(12)
Primary renal diagnosis p=0.024 x2
Glomerulonephritis 41 (22.4) 24 (25) 17 (19.5)
Interstitial Nephritis 34(18.6) 24 (25) 10(11.5)
Multisystem disease 52 (28.4) 22 (22.9) 30 (34.5)
Diabetic nephropathy 19(10.4) 12(12.5) 7(8)
Unknown 37 (20.2) 14(14.6) 23 (26.4)
Mean Albumin (g/1) 33.6 35.5 31.5 p=0.0001 T-test
Mean cholesterol (mmol/1) 4.5 4.7 4 p=0.0001 T-test
Median CRP (mg/1) (IQR) 15 (5-49) 8 (4-19) 31 (8-82) p= 0.0001 M-W
Comorbid Conditions
Congestive cardiac failure 70 (38.3) 17 (17.7) 53 (60.9) p=0.0001 x2
Ischaemic heart disease 62 (33.9) 19(19.8) 43 (49.4) p=0.0001 x2
Cerebrovascular disease 28(15.3) 8 (8.3) 20 (23) p=0.006 x2
Peripheral vascular disease 34 (18.6) 10(10.4) 24 (27.6) p=0.003 x2
Chronic pulmonary disease 24(13.1) 6 (6.3) 18(20.7) p=0.004 x2
Connective tissue disease 16(8.7) 4 (4.2) 12(13.8) p=0.021 x2
Khan Score p=0.0001 x2
Low 37 (20.2) 34 (35.4) 3 (3.4)
Medium 53 (29) 35 (36.5) 18 (20.7)
High 93 (50.8) 27 (28.1) 66 (75.9)
Charlson Index p=0.0001 x2
CCI=0 43 (23.5) 37 (38.5) 6 (6.9)
CCI=1 39 (21.3) 28 (29.2) 11 (12.6)
CCI=2 34(18.6) 15 (15.6) 19(21.8)
CCI=3-7 67 (36.6) 16(16.7) 51 (58.6)
Davies Score p=0.0001 X2
Davies=0 47 (25.7) 42 (43.8) 5 (5.7)
Davies=l 48 (26.2) 31 (32.3) 17(19.5)
Davies=2 42 (23) 14(14.6) 28 (32.2)
Davies=3-5 46 (25.1) 9 (9.4) 37 (42.5)
Table 5.22; Patient characteristics and univariate analysis of factors affecting mortality at end of the study,
M-W=Mann-Whitney Test, y2= Chi square, IQR= inter-quartile range.
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5.9. Multivariate analysis of patient mortality
The Cox regression model of survival analysis was used to identify independent
factors associated with death at the end of the study (median 817 days of follow up).
Firstly, including patients who died within 90 days, therefore survival analysis was
performed for 183 patients. Secondly, excluding those who died within the first 90
days of starting dialysis, survival analysis involved 170 patients.
The same analysis was done 4 times, because every analysis was performed using a
different comorbidity score (Charlson index, Khan Score, Davies score, and all
comorbid illnesses). All showed common results regarding initial serum cholesterol,
initial access for RRT, and age at start of RRT except for the Khan model as Khan
score depends on age.
The variables used in the multivariate analysis were age (except when Khan score
used), gender, referred in 3 months and 6 months periods, first mode of RRT, access
at initiation of RRT (haemodialysis and peritoneal dialysis), initial serum-
haemoglobin, albumin, cholesterol, CRP, and also eGFR, primary renal diagnosis,
and one of the comorbidity scores. The main outcome was 2 years patient survival
with binary description (1= death, 0 = live). Gender, referral to nephrology care,
access, and modality were also binary variables.
5.9.1. Charlson Index
In this analysis Charlson scores were divided into 4 groups to provide more statistical
power. Initial access for RRT was most significant factor; patients who started
dialysis with no permanent access had an increased risk of death by 2.9 times greater
than those who started dialysis with permanent access (for haemodialysis and
peritoneal dialysis). The initial serum cholesterol had a beneficial effect upon
survival; each lmmol/1 increase in serum cholesterol decreased the hazard of death
by 19%. Each additional year of patient age increased their chance of death by 3%.
The increase in Charlson score increased the odds of death, those scored 1 had 2.1
times increase in hazard of death compared with reference group with Charlson score
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of zero, this hazard increase to 3.4 times for those who scored 2 and over 5 times to
those who scored >2 (Table 5.23).
The analysis excluding those who died with in the first 90 days showed that each
additional year of patient age increased the risk of death by 2%, and patients who
started dialysis with temporary access had an increased hazard of death of 2.9% from
those who started RRT on permanent access. Patients not referred to nephrology care
at least 6 months before starting dialysis had increased hazard of death of 1.8 times
greater than those who had been referred. Charlson score, those who score 1 had 1.8
times increased odds of death from those who scored zero, that risk increased to 3.5
in those who scored 2 and 5.3 in those who scored >2 (Table 5.24).
Other variables analysed which did not contribute significantly to the multivariate
model were gender, first mode of RRT, serum albumin, GFR, haemoglobin, CRP,
and primary renal diagnosis.
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Age (years) 0.009 1.03 1.01 1.05
Access 0.0001 2.92 1.81 4.71
Cholesterol (mmol/1) 0.043 0.81 0.66 0.99
Charlson index
0 0.001 Ref -
1 2.1 0.75 5.85
2 3.42 1.28 9.15
>2 5.2 2.11 12.86
Table 5.23; Cox regression survival analysis Charlson Index model
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Age (years) 0.014 1.02 1.01 1.04
Access 0.0001 3.40 1.93 5.98
Referral after 6 months 0.031 1.86 1.05 3.26
Charlson index
0 0.000 Ref -
1 1.85 0.65 5.26
2 3.58 1.30 9.86
>2 5.31 2.12 13.31
Table 5.24; Cox regression survival analysis Charlson Index model excluding 90 days death
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5.9.2. Khan Score
Khan score stratifies patients into three risk groups (Low, medium and high)
according to comorbidity and age. The analysis using the Khan score showed that
factors associated with mortality were the same as when the Charlson index was
used. The only difference was the increased risk of death among Khan high risk
groups. The Khan score showed that odds of death are significantly increased by 6.5
times and over 13 times in the medium and high risk groups respectively, compared
with the low risk group (Table 5.25).
When those patients who died in the first 90 days were excluded, the analysis
showed the same results of Charlson score but with higher risk of death among Khan
Risk groups. Risk of death increased the by 6.5 times and 13.9 times in medium and
high risk groups respectively compared to the low risk group. Moreover, using Khan
score showed that Patients who started treatment on haemodialysis had a 3.5 greater
risk of death than those who started on peritoneal dialysis (Table 5.26).
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Access 0.0001 3.33 2.08 5.35
Cholesterol (mmol/1) 0.004 0.75 0.61 0.91
Khan score
Low risk group 0.0001 Ref -
Medium risk group 6.57 1.92 22.53
High risk group 13.17 4.11 42.17
Table 5.25; Cox regression survival analysis Khan score model.
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Access 0.0001 3.30 1.85 5.88
Referral at 6 months 0.008 2.14 1.21 3.77
Modality 0.041 3.54 1.05 11.93
Khan score
Low risk group 0.0001 Ref -
Medium risk group 6.59 1.90 22.78
High risk group 13.96 4.31 45.26
Table 5.26; Cox regression survival analysis Khan score model excluding 90 days death
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5.9.3. Davies score
In this analysis Davies scores were divided into 4 groups to provide more statistical
power. The Davies score showed the same results when Charlson index used, but the
risk of death was higher among Davies higher risk groups. Those who scored 1 had
3.9 times greater hazard of death compared with those with a Davies score of zero.
This hazard increased to 5.6 times for those who scored 2 and to 7.4 times to those
who scored >2 (Table 5.27).
When those who died in the first 90 days were excluded again the analysis showed
the same results as the Charlson model but the risk of death was higher among
Davies high risk groups. Risk of death increased by 4.8, 9.2 and 12.3 times higher in
patients with scores 1, 2 and >2 respectively compared to those who score zero. In
addition, patients who started on haemodialysis had a risk of death 3.6 greater than
peritoneal dialysis. Also each lmg/1 increase in CRP increased the hazard of death by
1% (Table 5.28).
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Age (years) 0.03 1.02 1.02 1.04
Access 0.0001 2.95 1.81 4.83
Cholesterol (mmol/1) 0.016 0.77 0.63 0.95
Davies Score
0 0.001 Ref -
1 3.96 1.39 11.34
2 5.60 2.01 15.66
>2 7.47 2.74 20.41
Table 5.27; Cox regression survival analysis Davies score model
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Access 0.002 2.62 1.44 4.77
Modality 0.039 3.60 1.06 12.21
CRP (mg/1) 0.029 1.01 1 1.02
Referral at 6 months 0.006 2.34 1.27 4.31
Davies Score
0 0.001 Ref -
1 4.82 1.71 13.56
2 9.22 3.45 24.66
>2 12.36 2.74 32.27
Table 5.28; Cox regression survival analysis Davies score model excluding 90 days death
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5.9.4. Comorbid conditions
In this analysis all the comorbid conditions that have been collected at the start of
dialysis were entered as independent factors instead of using a standard comorbidity
score. The analysis revealed that congestive cardiac failure as a comorbid disease
increased the odds of death by 2.5 times greater than those who started without
congestive cardiac failure. Also serum albumin had a beneficial effect upon survival;
each lmg/1 increase in serum albumin decreases the hazard of death by 4%. Patients
who were not referred at 6 months before starting dialysis had an increased risk of
death of 1.9 times than those who referred (Table 5.29).
Excluding patients who died in the first 90 days, the analysis showed the same results
as the analysis including 90 days patients except that ischaemic heart disease now
reached significance, increasing the hazard of death by 2.6 times greater in patients
started dialysis with ischaemic heart disease from those who started RRT without
ischaemic heart disease (Table 5.30). Cholesterol was no longer an independent risk
factor predicting mortality. Furthermore, higher serum albumin levels now were
associated with decreased mortality.
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Age (years) 0.0001 1.03 1.01 1.05
Access 0.0001 1.93 1.13 3.32
Cholesterol (mmol/l) 0.017 0.79 0.64 0.96
Albumin (g/1) 0.050 0.96 0.92 1.00
Referral 6 months 0.016 1.93 1.12 3.32
Congestive cardiac failure 0.0001 2.59 1.63 4.12
Table 5.29; Cox regression survival analysis all comorbid conditions model
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Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Age (years) 0.002 1.02 1.01 1.04
Access 0.0001 2.89 1.63 5.10
Referral in < 6 months 0.0001 2.84 1.55 5.21
Albumin (g/1) 0.002 1.02 1.01 1.04
Ischemic heart disease 0.048 1.62 1.01 2.62
Congestive cardiac failure 0.0001 2.48 1.52 4.05
Table 5.30; Cox regression survival analysis all comorbid conditions model excluding 90 days death
5.10. Hospitalisation
Hospitalization is a common occurrence in haemodialysis patients and the data on
hospitalisation for RRT patients are potentially informative about disease burden to
those patients and health services.
Patients with established renal disease are potentially subject to frequent hospital
admission during the course of their illness. This can be well seen in this study as the
number of patients who were not admitted to hospital in a period of two years was
only 13 (7.1%) (Figure 5.32). The maximum number of days spent in hospital was
497 days by one patient who died after he spent 650 days on RRT, meaning he had
spent 73.6% of his treatment time in hospital.
120-
100-
0.00 20.00 40.00 60.00 80.00 100.00
Percentage ofHospitalization
Figure 5.32; Histogram of hospitalisation percentage of patients who started RRT in 2003 and 2004
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5.10.1. Correlation of hospitalisation and continuous variables
Using Pearson Correlation to find any correlation between numbers of days spent in
hospital and other continuous variables (age, eGFR, albumin, CRP, cholesterol, Hb,
and urea) revealed similar associations as with mortality. The number of days spent
in hospital was significantly associated with age, CRP, and serum albumin. The
association with age and CRP was direct correlation (as age and CRP level increased
the number of days spent in hospital increased). However, with initial serum albumin
there was an inverse correlation (as serum albumin was low at the start of RRT the
days spent in hospital increased) (Table 5.31).
Age Serum albumin CRP
Days spent in hospital
Pearson Correlation 0.265 - 0.326 0.332
p-value 0.0001 0.0001 0.0001
Table 5.31; Pearson Correlations of hospitalisation
5.10.2. Comparison between groups according to percentage of time spent in
hospital
The percentage of time at risk (time from starting of RRT to either death or exactly
two years) spent in hospital was calculated for each patient as has been explained in
chapter 2. Kruskal Wallis test used to compare the groups (p-value<0.05 was
significant). The median percentage of time spent in hospital for all patients was
4.1% (0.9% - 13.9%) (Mean = 12.5%) and was dropped to 3.4 (0.7% - 10.7%) when
90 days mortality excluded (Mean = 9.3%).
Results showed that the percentage of time at risk spent in hospital was highest for
patients age >65 years. There was a significant difference in percentage of time at
risk spent in hospital between risk groups (as the comorbidity burden increased the
time spent in hospital was markedly increased) (Table 5.32).
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<65 years 86 47 2.8 in100o
>65 years 97 53 9.5 1.7-24.7
Charlson Index 0.005
CCI=0 43 23.5 2.3 0.8-4.3
CCI=1 39 21.3 2.4 0.6-5.4
CCI=2 34 18.6 7.8 0.9-19.4
CCI>2 67 36.6 10 2.8-25.4
Khan score 0.0001
Low 37 20.2 1.5 0.4 - 3.4
Medium 53 29 3.2 0.8 - 8.7
High 93 50.8 9.9 2.4-25.9
Table 5.32; hospitalisation percentage according to age and comorbidity
The percentage of time spent in hospital was significantly higher in female than male
(5.3% vs. 3%), and in haemodialysis patients compared with peritoneal patients
(4.3% vs. 1.9%). The analysis showed that patient who started RRT without
permanent access had a greater median percentage of time at risk spent in hospital
than those patients who started RRT with definitive access (11% vs. 1.5). The
percentage of time spent in hospital was highest for patients not-referred early to












Male 100 55 3 0.6-10
Female 83 45 5.3 2 - 20.2
First modality treatment 0.006
Peritoneal dialysis 25 13.8 1.9 vq1\DO
Haemodialysis 156 86.2 4.3 1.5-15.7
Initial access (HD+PD) 0.0001
Access 89 49.2 1.5 0.5-4.1
No access 92 50.8 11 3.5-28.8
Referral 3 months 0.0001
Referred 132 72.9 3.2 0.8-10
Not-referred 51 27.1 10.5 3.2- 10
Referral 6 months 0.0001
Referred 125 69.1 2.8 oi00©
Not-referred 58 30.9 9.4 3.2-30.2
Table 5.33; Hospitalisation percentage according to gender, modality, access and referral
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The median percentage of time spent in hospital was not significant by different
according to primary renal disease (Table 5.34).
Cases Cases Median % IQR Kruskal-




Primary renal diagnosis 0.273
Glomerulonephritis 41 22.2 3.2 1 - 14.9
Interstitial nephritis 34 18.6 3.4 lo
Multisystem disease 52 28.4 4.7 1.5-15.1
Diabetic nephropathy 19 10.4 2.2 0.4-9.3
Unknown 37 20.2 4.7 1.7-21.3
Table 5.34; Hospitalisation percentage according to primary renal diagnosis groups
5.11. Summary
The gross mortality of this incident RRT cohort was 26.2% at one year 38.2% at two
years and 47.5% at the end of the study. When deaths within the first 90 days of
treatment were excluded these mortality rates were 20.6%, 33.5% and 43.5%
respectively. The most common cause of mortality was cardiovascular disease
(40.7%) followed by infection (29.1%).
Univariate analysis of the first year, two years and at the end of the study including
and excluding 90 days mortality revealed that age, comorbidity, starting RRT with
definitive access, first treatment modality, initial serum albumin, initial serum
cholesterol and CRP were all associated with mortality.
Multivariate analysis with different comorbidity scores showed that age (except
when Khan score was used), comorbidity, initial access, initial serum cholesterol
were significantly associated with death. When the same analysis was carried out
with exclusion of those who died in the first 90 days initial serum cholesterol was no
longer significantly associated with death. However, no referral to renal unit at least
6 months prior starting dialysis was significantly associated with death in addition to
age, comorbidity, and initial access.
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Congestive cardiac failure and ischaemic heart disease were significant risk factors
for mortality when those patients who died within the first 90 days were included and
excluded.
Hospitalisation percentage was higher in more elderly patients, high co-morbidity
risk groups, female patients, patients started dialysis without access, haemodialysis
patients, and in patients who were not referred early.
This study has emphasized that age, comorbidity, initial access, initial serum
cholesterol were associated with survival of 2003 and 2004 patients receiving RRT
in RIE renal unit.
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5.12. Mortality of patients treated by haemodialysis
156 patients started RRT on haemodialysis with median age 65 years (IQR 54 to 76).
They had more comorbid conditions compared to 25 patients who started RRT on
peritoneal dialysis, who were also younger (median age 53 years and IQR 42 to 67).
Accordingly survival of haemodialysis patients will be analyzed separately in this
section.
5.12.1. Patient mortality
Of the 156 patients, 47 (30.1%) were dead by the end of one year 84 (53.8%) by the
end of the study. In order to make these figures more directly comparable with the
USRDS, 13 death within the first 90 days of RRT were excluded and the mortality at
the end of one year was 34 patients (23.8%) and 71 patients (49.7%) by the end of
the study (Table 5.35).




n % n %
90days 13 8.3% - -
6month 25 16% 12 8.4%
lyear 47 30.1% 34 23.8%
18months 58 37.2% 45 31.5%
2 years 67 42.9% 54 37.8%
End of study 84 53.8% 71 49.7%
Table 5.35; Mortality of haemodialysis patients receiving RRT
5.12.2. Causes of death
Infection was the leading cause of death in the first year 37%, followed by
cardiovascular 34.8%, others 21.7%, unknown 4.3% and malignancy 2.1%. At the
end of the study cardiovascular disease was the main cause of death 41%, followed
by infection 27.9%, others 16.9% unknown cause 9.6%, malignancy 4.8 % (Table
5.36).
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Cause of death One year End of the study
n % n %
Cardiovascular 16 34.8 34 41
Infection 17 37 23 27.9
Malignancy 1 2.2 4 4.8
Unknown 2 4.3 8 9.6
Others 10 21.7 14 16.9
Table 5.36; Cause of death including those who died in the first 90 days in haemodialysis patients at
one year and at end of the study
5.12.3. Comparison between patient including and excluding 90 days mortality
according to outcome at end of the study
Univariate analysis between survivors and dead haemodialysis patients including
those who died in the first 90 days revealed a significant difference in the following
data: age (those who survived to the end of the study were younger, median age 56
years), patients who started dialysis through permanent access showed better survival
(65.5%), patients who started haemodialysis with no comorbid conditions
(Khan=low, CCI=0 & Davies=0) are mainly survivors and as the comorbidity burden
increased the proportion of survivors decreased. Congestive cardiac failure,
ischaemic heart disease, cerebrovascular disease, peripheral vascular disease and
chronic pulmonary disease all showed a significant difference in survival. Survivors
had higher initial serum albumin (35.2 ± 5.4), initial serum cholesterol (4.5 ±1.1),
and lower levels of serum CRP (8mg/l). Primary renal diagnosis, gender and diabetes
did not show significant effect on survival of haemodialysis
Univariate analysis of haemodialysis patients excluding those who started dialysis at
first 90 days revealed similar results and therefore the data are not presented
separately.
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5.12.4. Multivariate analysis of patient mortality
5.12.4.1. Charlson index
The analysis showed that initial access had a significant impact on mortality as
patients who started without permanent access had increased hazard of death of 2.4
times greater than those who started with AVF or graft. Each additional year of
patient age increased their chance of death by 2%. Increases in Charlson score
increased the risk of death by 1.9, 3.3 and 5.8 times in CCI 1, 2 and >2 respectively,
compared with CCI of zero (Table 5.37). When the same analysis was done
excluding those who died within the first 90 days, survival was affected by type of
vascular access, CRP, referral 6 months previously, and comorbidity (Table 5.38).
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Age 0.038 1.02 1 1.04
Access 0.0001 2.42 1.47 3.96
CCI
0 0.0001 Ref -
1 1.91 0.68 5.35
2 3.38 1.21 9.43
>2 5.8 2.27 14.81
Table 5.37; Cox regression survival analysis Charlson Index model
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Access 0.002 2.54 1.47 4.57
Referral at 6 months 0.017 2.07 1.14 3.75
CRP 0.029 1.01 1 1.02
CCI
0 0.0001 Ref -
1 2.35 0.84 6.57
2 4.92 1.85 13.07
>2 8.6 3.63 20.79
Table 5.38; Cox regression survival analysis Charlson Index model excluding 90 days mortality
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5.12.4.2. Khan score
This analysis showed that access and serum cholesterol are significant predictors of
mortality. Each lmmol/1 increase in initial serum cholesterol decreased the hazard of
death by 22%. Patients in the medium and high risk groups had increased risk of
death by 6.4 and 13.6 times respectively, than low risk group (Table 5.39). The same
analysis excluding 90 days mortality showed that patients who started haemodialysis
with temporary access had risk of death by 3.3 times higher than those who started
with AV fistula/ graft. Patients who had not been referred 6 months prior to their first
haemodialysis session had 2.1 times higher risk of death than those who had been
referred. The risk of death was increased by 6.2 and 14.2 times greater in medium
and high risk Khan score groups compared with low risk group (Table 5.40).
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Access 0.0001 2.71 1.65 4.45
Cholesterol (mmol/1) 0.015 0.78 0.64 0.95
Khan
Low risk group 0.0001 Ref -
Medium risk group 6.49 1.87 22.54
High risk group 13.83 4.31 44.38
Table 5.39; Cox regression survival analysis Khan score model.
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Access 0.0001 3.31 1.85 5.92
Referral 6 months 0.009 2.15 1.21 3.81
Khan
Low risk group 0.0001 Ref -
Medium risk group 6.2 1.77 21.73
High risk group 14.28 4.39 46.43
Table 5.40; Cox regression survival analysis Khan score model excluding 90 days mortality
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5.12.4.3. Davies score
The analysis using Davies score including and then excluding those who died within
the first 90 days showed the same results as obtained when Charlson score was used
(Table 5.41 and 5.42)., except that cholesterol was an independent risk factor for
death when those who died within 90 days were included.
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Age 0.03 1.02 1.01 1.04
Access 0.0001 2.52 1.5 4.21
Cholesterol 0.033 0.79 0.64 0.98
Davies
0 0.0001 Ref -
1 5.58 2.02 15.41
2 9.2 3.48 24.31
>2 11.67 4.54 30.02
Table 5.41; Cox regression survival analysis Davies score model
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Access 0.0001 2.68 1.46 4.89
Referral 6 months 0.008 2.31 1.25 4.27
CRP 0.047 1.01 1 1.02
Davies
0 0.0001 Ref -
1 5 1.77 14.09
2 8.9 3.3 24.06
>2 11.93 4.55 31.25
Table 5.42; Cox regression survival analysis Davies score model excluding 90 days mortality
5.12.4.4. Comorbid conditions
All comorbid conditions that had been considered in this study had been entered in
this model separately to find the comorbid illness that had the most significant
impact on mortality. Congestive cardiac failure is the only comorbid condition that
had a significant influence on mortality of haemodialysis patients. Those who started
haemodialysis with congestive cardiac failure had increased risk of death by 2.2
times greater than who started without congestive cardiac failure (Table 5.43).
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Excluding those who died within the first 90 days of haemodialysis treatment the
analysis showed that congestive cardiac failure and ischaemic heart disease were
significant contributors to risk of mortality. Congestive cardiac failure and ischaemic
heart disease increased the risk of death by 2.6 and 1.7 times respectively (Table
5.44).
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Age 0.0001 1.03 1.01 1.04
Access 0.0001 2.26 1.37 3.74
Cholesterol 0.015 0.78 0.63 0.95
Congestive cardiac failure 0.0001 2.24 1.4 3.57
Table 5.43; Cox regression survival analysis all comorbid conditions model
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Age 0.002 1.03 1.01 1.05
Access 0.0001 2.34 1.48 3.96
CCF 0.0001 2.62 1.59 4.31
IHD 0.027 1.76 1.06 2.91
Table 5.44; Cox regression survival analysis all comorbid conditions model excluding 90 days
mortality
5.12.5. Summary of survival analysis of haemodialysis patients
The mortality of incident haemodialysis patients was 30.1% at one year and 53.8% at
end of the study which reduced to 23.8% and 49.7% when 90 days mortality was
excluded. The most common cause of death was cardiovascular 41%, followed by
infection 27.7%. Univariate analysis showed that age, comorbidity, initial access,
initial serum albumin, cholesterol and CRP were all associated with mortality at the
end of the study. Multivariate analysis revealed that when all factors were entered
together age, comorbidity, starting dialysis with permanent access, and initial serum
cholesterol were significantly associated with death at the end of the study. When all
comorbid conditions were entered as independent factors, congestive cardiac failure
135
is the only comorbid illness that was associated significantly with mortality in
haemodialysis patients. Ischaemic heart disease was a significant risk factor for
mortality of haemodialysis patient when 90 days mortality was excluded. Gender,
whether or not patients were referred early, and primary renal diagnosis did not
contribute significantly to the survival analysis.
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Chapter 6




Edinburgh showed 1 year survival below the 95th centile in the Renal Registry 2006
analysis of patients commencing dialysis in 2004. However, long term survival
figures are not significantly different from other units in Scotland.
Aim
To examine factors associated with survival in a detailed analysis of the cohort
commencing dialysis in south east Scotland in 2003 and 2004 and compare with a
prior cohort commencing dialysis from 1997 until 2000. These cohorts initiated RRT
before and after moving to a new hospital.
Method
183 patients started RRT in South East Scotland in 2003-2004, 156 haemodialysis,
25 peritoneal dialysis and 2 as pre-emptive transplants. Comorbidity was scored
according to the age and number of comorbid condition and patients stratified into 3
risk groups. Univariate and multivariate Cox regression was used to identify the
independent predictors of survival. The main outcomes were overall survival and
hospitalisation.
Results
Between the two studies the median age rose from 63 to 65 and take on rate from 83
to 91.5 patients per year (approximately from 113 to 120 patients per million
population per year) with all of the increase being in the Khan high risk group.
Mortality of the recent cohort was 7% at 90 days, 26% after at one year and 38% at
two years. In the previous cohort these figures are 9%, 21% and 37% respectively.
Multivariate analysis revealed that comorbidity group, permanent access, initial
serum albumin and initial serum cholesterol were independent predictors of
mortality. The median percentage of hospitalisation was halved in the recent study.
Conclusion
The 2 years survival rate was essentially unchanged between both studies despite
accepting older and more "high risk" patients in the recent study. Severity of
comorbidity is an important predictor of survival.
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6.2. Introduction
Survival is the ultimate outcome that can be used to compare the services between
different renal units. This chapter presents information about the outcomes being
achieved in the Royal Infirmary of Edinburgh Renal Unit in comparison with other
UK renal units according to UKRR report 2006 and with Scotland renal units
according to Scottish Renal Registry (SRR) reports 2002-2004. An incident cohort
study, which included 183 patients who started RTT in 2003 and 2004, was designed
to investigate about the survival changes (improvement, deterioration or no change)
in dialysis patients in the RIE renal unit in comparison with data has obtained from a
study conducted in 2001 in the RIE renal unit that included 249 incident patients who
started RTT between 1997 and 2000. In addition, to find the possible factors that
could be associated with patients' survival were determined.
The SRR report 2002-2004 includes data from all the Scottish Renal Units and
showed the survival of patients receiving RRT over a 10 year period. The
Crosshouse renal unit (XH) was used as a reference with a median survival time of
3.8 years. The graph shows very little difference in survival between all adult renal
units; the only exception was the Royal Hospital for Sick Children Glasgow (RHSC)
(paediatric renal unit) which had the best survival as expected. The risk of death at
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Figure 6.1; Survival by renal unit providing first RRT between 1995 and 2004
Courtesy of Scottish Renal Registry 2004
However, the funnel plot (Figure 6.2) presented in the UKRR annual report (2006)
shows one year survival of all renal units in UK with the mean survival of 87% and
dotted lines denoting 99% CI and 95% CI from the mean. The lowest survival in all
UK units was recorded in Plymouth (78.7%). Of all Scotland renal units the highest
was 88.3% in Aberdeen Royal Infirmary (ARI) and lowest was 81% in Dumfries and
Galloway (DGRI). The mean survival of Edinburgh renal unit was 82% just below
the 95% CI. This survival percentage gave Edinburgh the 4th lowest survival of all
UK renal units, but it was fairly typical of southern Scotland. However, the case was
different in 2007 UKRR report as the mean survival of Edinburgh renal unit rose to
86% but the survival of incident dialysis patients in Scotland was significantly lower
than in the rest of the UK.
Although Edinburgh's very low position seems likely to be a chance event on a
background of relatively poorer survival for all Scottish units; it was important to
examine this more closely
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Figure 6.2: Funnel plot of age-adjusted survival for 1 year after 90 days (2001 - 2004,4 year
cohort) each point is UK renal unit. From the UKRR report 2004.
Courtesy of Scottish Renal Registry 2004
Fortunately a study conducted in 2001 which included 249 incident adult patients
who started RRT between July 1997 and June 2000 (a cohort before the UKRR
report) was available to give us the opportunity to compare it with the survival of
patients who initiated dialysis in 2003 and 2004. This cohort was followed until 2006
hence this will be referred to as the 2006 cohort. The 2006 study involved a cohort
that was included in the 2006 UKRR report
The 2001 study included all adult patients who started RRT over a 3 year period
between 1997 and 2000. Mortality was related to comorbidity and age using a
modified Khan score (it is the same as the Khan score but with less comorbid
conditions congestive cardiac failure, chronic pulmonary disease and liver disease).
249 patients were classified into 3 groups according to Khan score. The number of
patients in each risk group with median age and survival percentage at 90 days, 1
year and 2 years are shown in Table 6.1. The study showed that overall two years
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survival was 63% and the outcomes were excellent for low and medium risk group
but the mortality of the high risk group was high, thought not different from
comparable studies (Edren).
Risk group number Median age Survival
90 days 1 year 2 years
Low risk 90 (36.1%) 49(17-69) 99 96 93
Medium 84 (33.7%) 71 (34-87) 92 76 63
High 75 (30.1%) 67 (34 - 87) 81 63 33
Overall 249 63 (17-87) 91 79 63
Table 6.1; Survival of RRT in Edinburgh (2001)
6.3. Methods
In this study, the data presented in chapter 5 is reanalysed in the same way of the
previous study in 2001 to permit direct comparisons. Unlike chapter 5 the follow up
period was exactly 2 years (minimum 7 days and maximum 730 days) or until death.
In the 2001 study only five comorbid diseases were collected (Table 6.2). Patients
were assigned to risk groups based on age and the number of comorbidities
(explained in the above section) Table 6.3
Comorbid diseases
1. Ischemic Heart Disease (Angina, Myocardial infarction, PTCA/CABG)
2. Cerebrovascular (TLA, CVA)
3. Peripheral vascular disease (intermittent claudication, amputation, PV bypass)
4. Diabetes
5. Visceral malignancy (not including skin cancer)
Table 6.2; Comorbid diseases included in 2001 study
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Risk groups
Low risk Age <70 years
Moderate risk Age 70-79 years
Age <70 years with one comorbidity out of 1,2,3,4
High risk Age >80 years
Any age with two comorbidities out of 1,2,3,4
Any age with visceral malignancy
Table 6.3; Classification of comorbidity risk groups
6.4. Frequency and distribution of patients in 2001 and 2006 studies
6.4.1. Age and Gender
The total number of patients involved in 2001 was 249 collected over 3 years
whereas in 2006 183 patients were collected in 2 years. Between two studies the
median age rose from 63 to 65 and take on rate from 83 to 91.5 patients per year
(approximately from 113 to 120 patients per million populations per year) Table 6.4.
The proportion of patients above 75 years was higher in 2006 (25.7%) compared
with 19.2% in the 2001 study. The gender proportions in both studies were almost
the same. The number of male patients was higher than female patients (Table 6.4).
The significance (P value) between age groups of both studies was not tested because
we lacked the detailed information of patients involved in 2001 study.
2001 2006
Age group
15-49 57 (22.8) 44 (24)
50-64 79 (31.8) 42 (23)
65-74 65 (26.2) 50 (27.3)
>75 48 (19.2) 47 (25.7)
Gender
Male 143 (57) 100 (54.6)
Female 106 (43) 83 (45.4)
Total 249 183
Table 6.4; Number and percentage of age group and gender in 2001 and 2006 studies
6.4.2. Modality
Haemodialysis was the dominant modality of treatment, 75.9% in 2001 and 85.2% in
2006 with the highest median age 64 years and 67 years respectively, followed by
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peritoneal dialysis, and pre-emptive transplant (Table 6.5). Chi square tests showed a
significant association between age group and mode of first RRT 2001 (p=0.014),
and in 2006 (p=0.05).
Modality 2001 2006
Number Median age (IQR) Number Median age (IQR)
Haemodialysis 189 64 156 67
(75.9%) (22 - 87) (85.2) (54 - 76)
Peritoneal 56 58 25 53
dialysis (22.5%) (17-80) (13.7%) (42.5 - 67)
Transplant 4 38.5 2 37 and 59
(1.6%) (17-55) (1.1%)
Table 6.5; Number, percentage and median age of patients in 2001 and 2006 according to modality of
treatment
6.4.3 Referral
Referred and not-referred to nephrology care was defined using the time from the
date of first biochemical test to the date of first RRT treatment. Patients were
classified as not-referred if this time was under 90 days. The proportion of referred








Table 6.6; the number and proportion of treatment type in 2001 and 2006 studies
Chi square tests showed a significant association (p=0.002) in 2001 and (p=0.005) in
2006 between referred/ not-referred and mode of first RRT with 70.2% and 80.6% of




Referred Not-referred Referred Not-referred
Haemodialysis 130 (70.2) 59 (92.2) 108 (80.6) 48 (97.9)
Peritoneal dialysis 51 (27.6) 5 (7.8) 24 (17.9) 1 (2.1)
Transplant 4 (2.2) 0 2(1.5) 0
Total 185 64 134 49
Table 6.7; First modality of RRT in relation to referral in 2001 and 2006 studies
There was no significant association between referred or not-referred treatment and
age group (Chi-Square test, p=0.654 for 2001, and p=0.107 for 2006) (Table 6.8).
Age group 2001 2006
referred Not-referred Referred Not-referred
15-49 44 (23.8) 13 (20.3) 35 (26.1) 9(18.4)
50-64 56 (30.3) 23 (35.9) 35 (26.1) 7(14.3)
65-74 51 (27.6) 14(21.8) 31 (23.2) 19(38.8)
>75 34(18.3) 14(21.8) 33 (24.6) 14 (28.5)
Total 185 64 134 49
Table 6.8; Age group in relation to referral in 2001 and 2006 studies
6.4.4. Primary Renal Disease
According to ERA-EDTA diagnosis codes for primary renal disease the new patients
were classified into 8 groups in 2001 study (Table 6.9) and 5 groups in 2006 study
(Table 6.10). The proportion of patients who started dialysis with diabetes were 20%
in the 2001 study and 24% in the 2006 study but only 14% and 19% were diagnosed
with diabetic nephropathy respectively.
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Primary renal diagnosis no % Median age
Primary glomerulonephritis 39 16 57
Interstitial nephritis 36 14.2 53
Familial /Hereditary. Renal diseases 29 12 53
Congenital diseases 2 0.8 24.5
Vascular diseases 54 21.6 71.5
Secondary glomerulonephritis/ systemic disease 47 18.6 63
Miscellaneous 8 3.2 62
Unknown 34 13.6 70.5
Table 6.9; Distribution and median age of new patients by primary renal disease in 2001 study
Primary Renal Diagnosis No % Median age (IQR)
Glomerulonephritis 41 22.4% 62 (41-71)
Interstitial Nephritis 34 18.6% 59 (42-70)
Multisystem Disease 52 28.4% 67 (56-79)
Diabetic Nephropathy 19 10.4% 61 (45-68)
Not known and Others 37 20.2% 74 (65-80)
Table 6.10; Distribution and median age ofnew patients by primary renal disease in 2006 study
6.5. Comparison of the Survival analysis between 2001 and 2006 studies
The extra patients commencing dialysis in the later study fall almost entirely in the
high risk group which has a higher median age than the earlier study. (Table 6.11)
Risk group No of cases & % Median age (min & max)
2001 2006 2001 2006
Low 90 (36) 56(31) 49(17-69) 42 (18-68)
Medium 84 (34) 52 (28) 71 (34-87) 69 (31 -84)
High 75 (30) 75 (41) 67 (34 - 87) 73 (39 - 88)
Total 249 183 63 (17 - 87) 65(18-88)
Table 6.11; Comparison of the patient number and median age according to risk groups between 2001
and 2006 studies
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Table 6.12 shows the outcome in the two studies:-
1. At 90 days the percentage of overall survival was slightly higher in 2006 than
2001 (93% vs. 91%) and according to risk groups the low and high risk groups
survival were slightly higher in 2006 than 2001.
2. At 1 year the overall survival was higher in 2001 than 2006 (79% vs. 74%),
3. The percentage of overall survival at 2 years was unchanged in both studies
(63% vs. 62%).
o The survival of low risk group in 2001 was higher than 2006 but most
importantly this apparent 7% survival difference was made by 1 dead
patient (the number of dead patients in 2001 was 7 out of 90 whereas in
2006 was 8 out of 56).
o The medium risk group survival was almost the same in both studies,
o Although in 2006 study the total number of patients was lower than 2001,
the same number of high risk group patients was recorded in both studies
(75 patients), making the proportion of high risk patients in 2006 higher
than in 2001. However the survival of high risk group in the 2006 study
was better than in the 2001 study (44% vs. 33%).The significant difference
between risk groups of both studies was not tested because we lack the
detailed information ofpatients included in 2001 study.
Risk
group
90 days 1 year 2 years
2001 2006 2001 2006 2001 2006
% no % no % no % no % no % no
Low 99 89 100 65 96 86 91 51 93 83 86 48
Medium 92 77 91 47 76 63 75 39 63 52 62 32
High 81 65 89 67 63 47 60 45 33 24 44 33
Total 91 231 93 170 79 196 74 135 63 159 62 113
Table 6.12; Comparison of survival percentage according to risk groups between 2001and 2006
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6.6. Comparison of hospitalisation between 2001 and 2006 studies
The median percentage of live time spent in hospital in 2006 study (time from
starting RRT to either death or exact 2 years) was calculated for each patient.
Kruskal Wallis test was used to compare the hospital data of 2001 (Table 6.13) with
2006 (Table 6.14) according to age group and risk groups (p value <0.05 was
significant).
The overall median percentage of time at risk spent in hospital in 2001 was 2 times
higher than in 2006 (8% vs. 4.1%). Hospitalisation was lower for all risk groups in
the recent study. The results showed that for both studies the percentage of time at
risk spent in hospital was highest for patients aged >75 (10.1% for 2001, and 11% for
2006). The percentage of time spent in hospital was increased markedly by risk
group (12% of time for high risk vs. 3.9% for low in 2001, and 10% for high risk vs.
2.2% for low in 2006). There were significant differences in percentage of time at
risk spent in hospital between age groups and risk groups.
patients Median IQR Kruskal-Wallis
test (p-value)
Age Group
15-49 57 3.4 1.4-7.6
0.002
50-64 79 7.4 3.2-18.6
65-74 65 8.5 3.3-23.4
>75 48 10.1 3.6-18.2
Risk Group
Low 90 3.9 1.4-7.4
0.0001
Medium 84 8.3 3.6-14.7
High 75 12 3.5-27.8
Table 6.13; Percentage of time at risk spent in hospital in 2001 study
patients Median IQR Kruskal-Wallis
test (p-value)
Age Group
15-49 44 1.8 0.6-4
0.0001
50-64 42 3.8 1.2-10.8
65-74 50 6.5 1.8-20.7
>75 47 11 1.5-25.9
Risk Group 0.0001
Low 56 2.2 0.6-4.4
Medium 52 4.6 1.5-13.2
High 75 10 1.9-23
Table 6.14; Percentage of time at risk spent in hospital in 2006 study
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6.7. Survival analysis of 2006 study at 2 years
The survival analysis in this chapter is different from chapter 5 regarding the period
of follow up as already explained in chapter 2. The survival results will show the
factors that associated with patients survival when the period of follow up is equal
for all patients (730 days) unless the patient died.
6.7.1. Univariate analysis
Univariate analysis including patients who died within the first 90 days, showed that
age, comorbidity based on modified khan score that used in the 2001 study, initial
access for RRT, initial mode of RRT, initial serum albumin, initial serum cholesterol,
and initial CRP were all significantly associated with death within two year of
starting dialysis (Table 6.15). The same univariate analysis was repeated excluding
those patients who died within the first 90 days revealed that the same factors listed
above were significantly associated with patient mortality (Table 6.16).
Univariate analysis of all coexisting illnesses at start of RRT revealed that congestive
cardiac failure, ischemic heart disease, chronic pulmonary disease and malignancy
were significantly associated with death in both analyses that included and excluded
patients who died in the first 90 days of starting RRT. Patients' sex did not influence
survival, nor did primary renal diagnosis, haemoglobin concentration, eGFR, or urea
concentration at time of initiating RRT.
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Cohort 2 year survivors Dead by 2year p value &
n=183 n=113 n=70
statistic test
Median age (years) (IQR) 65 (50-75) 59 (42-71) 71 (64-78) p=0.0001 M-W
Age>65 years 97 (53) 48 (42.9) 63 (69) p=0.0001 x2
Referral 3 m 132(72.9) 86 (78.2) 46 (64.8) p=0.048 x2
Referred 6 m 125 (69.1) 81 (73.6) 44 (62) p=0.097 x2
Access (HD+PD) 89 (49.2) 72 (65.5) 17 (23.9) p=0.0001 x2
Access haemodialysis 64 (41) 50 (56.8) 14 (20.6) p=0.0001 x2
First Mode of RRT p=0.003 x2
Haemodialysis 156(86.2) 88 (80) 84 (95.8)
Peritoneal dialysis 25 (13.8) 22 (20) 3 (4.2)
Primary renal diagnosis p=0.131 x2
Glomerulonephritis 41 (22.4) 28 (25) 13 (18.3)
Interstitial Nephritis 34(18.6) 25 (22.3) 9 (12.7)
Multisystem disease 52 (28.4) 28 (25) 24 (33.8)
Diabetic nephropathy 19(10.4) 13 (11.6) 6 (8.5)
Unknown 37 (20.2) 18 (16.1) 19 (26.8)
Mean Albumin (g/1) 33.6 35.3 30.9 p=0.0001 T-test
Mean cholesterol (mmol/1) 4.5 4.6 4.1 p=0.003 T-test
Median CRP (mg/1) (IQR) 15 (5-49) 7 (4-22) 34 (15-97) p= 0.0001 M-W
Comorbid Conditions
Congestive cardiac failure 70 (38.3) 24 (21.4) 46 (64.8) p=0.001 x2
Ischaemic heart disease 62 (33.9) 28 (25) 34 (47.9) p=0.0001 x2
Malignancy 19(10.4) 6 (5.4) 13 (18.3) p=0.005 x2
Chronic pulmonary disease 24(13.1) 7 (6.3) 17 (23.9) p=0.001 x2
Connective tissue disease 16 (8.7) 5 (4.5) 11 (15.5) p=0.021 x2
Comorbidity p=0.0001 x2
Low 56 (30.6) 48 (42.5) 8 (11.4)
Medium 52 (28.4) 32 (28.3) 20 (28.6)
High 75 (41) 33 (29.2) 42 (60)
y
Table 6.15: Patient characteristics and univariate analysis at two years, M-W=Mann-Whitney Test, x
= Chi square, IQR= inter-quartile range,
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Cohort 2 year survivors Dead by 2year p value &
of-▼HIIG n=113 n=57
statistic test
Median age (years) (IQR) 65 (48-74) 59 (42-71) 70 (62-77) p=0.0001 M-W
Age>65 years 88(51.8) 48 (42.9) 40 (69) p=0.001 i2
Access (HD+PD) 89 (53) 72 (65.5) 17 (29.3) p=0.0001 x2
Access Haemodialysis 64 (44.8) 50 (56.8) 14 (25.5) p=0.0001 X2
First Mode of RRT p=0.010x2
Haemodialysis 143 (85.1) 88 (80) 55 (94.8)
Peritoneal dialysis 25 (14.9) 22 (20) 3 (5.2)
Mean Albumin (mg/1) 33.8 35.3 31.7 p=0.0001 T-test
Mean cholesterol (mmol/1) 4.5 4.6 4.2 p=0.003 T-test
Median CRP (mg/1) (IQR) 13(5-47) 8 (4-22) 34(14-91) p= 0.0001 M-W
Comorbid Conditions
Congestive cardiac failure 59 (34.7) 24 (21.4) 35 (60.3) p=0.0001 x2
Ischaemic heart disease 55 (32.4) 28 (25) 27 (46.6) p=0.004 x2
Chronic pulmonary disease 22(13.1) 7 (6.3) 15 (25.9) p=0.0001 x2
Malignancy 17 (10) 6 (5.4) 11 (19) p=0.005 x2
Comorbidity p=0.0001 x2
Low 56 (32.9) 48 (42.5) 8 (14.1)
Medium 47 (27.6) 32 (28.3) 15 (26.3)
High 67 (39.4) 33 (29.2) 34 (59.6)
Table 6.16: Patient characteristics and univariate analysis at two years excluding 90 days deaths M-
W=Mann-Whitney Test, Chi square, IQR= inter-quartile range,
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6.7.2. Multivariate analysis of 2006 study
The independent variables used in the multivariate analysis were gender, first
modality of treatment, referral to nephrology care, definitive access, serum-,
albumin, urea, cholesterol, and CRP, primary renal diagnosis (based on ERA-EDTA
codes for renal disease), and comorbidity effect that evaluated by the same score that
has been used by 2001 study which stratifies patients into 3 risk groups (mild,
medium and high) depending on age and that is why age was not included in the
analysis. The main outcome was 2 years patient survival with binary description (1=
death, 0 = live). Gender, modality, treatment type were also a binary variables.
The analysis revealed that initial access for RRT was significantly (p=0.0001)
associated with survival as patients who started dialysis with no access have an
increased risk of death by 3.5 times greater than those who started dialysis with
permanent access including both haemodialysis and peritoneal dialysis patients.
Higher initial serum cholesterol had a beneficial effect upon survival; each lmmol/1
increase in serum cholesterol decreased the hazard of death by 28%. Each lg/1
increase in serum albumin decreased the hazard of death by 4%. Comorbidity risk
was significantly increased the risk of death by 2.6 times and 3.6 times in the
medium and high risk groups respectively, compared with the reference low risk
group (Table 6.17).
Variable significance Hazard ratio 95% CI for Hazard ratio
lower upper
Access 0.0001 3.5 1.93 6.52
Cholesterol 0.004 0.72 0.58 0.90
Albumin 0.049 0.96 0.92 0.98
Comorbidity 0.0001 Ref
Moderate risk group 2.61 1.16 6.22
Severe risk group 3.62 1.65 7.88
Table 6.17; Cox regression survival analysis of 2006 study
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Survival in Days
Figure 6.3: Two year Survival curve of incident patients started RRT
in RIE in 2003 and 2004.
6.8. Summary
Two years survival rate was essentially unchanged between both studies despite
accepting older and more "high risk" patients in the recent study. Severity of
comorbidity was an important predictor of survival. It is not apparent from this data
why Edinburgh along with most of the rest of Scotland, has poorer survival on RRT.
However the poorer survival of the background population seems likely to be
relevant. A reduction in hospitalisation was noted occurred across a period ofmoving
to a new hospital and multiple changes in working practices and in patient
supervision and audit policies.
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Chapter 7




Figure 7.1 illustrates the summary of univariate and multivariate results in chapters
4, 5 and 6. According to these results I will discuss individually the multivariate
independent factors that associated with patient survival, supported by the univariate
results. However before that a summary and limitations assessments of each chapter
are discussed.
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7.2. Summary and limitations of chapters 4, 5 and 6
7.2.1, Chapter 4
Despite this study having a cross sectional design, its results are like other survival
studies in that patient survival was influenced by age and burden of comorbid
illnesses, in addition to SGA and CRP. Presence of cerebrovascular disease and
peripheral vascular disease at the start of the study were the only contributory
illnesses to patient mortality. Hospitalisation percentage was markedly increased by
older age, high risk group, and malnourishment.
This study should be qualified by the possibility of selection bias during the initial
recruitment, it is possible that only those dialysis patients who were generally
healthier agreed to participate. However, the results of our study showed the one year
survival of our sample (122 patients) was similar to the one year overall survival of
all prevalent patients (298 patients) at the same hospital in the same year (87.7% vs.
87.4%).
The dietician team who initiated this study were aiming to find a nutritional
screening tool that was less time consuming, with the suggestion that a computer
based malnutrition screening tool could identify dialysis patients at risk of
malnutrition as accurately as subjective global assessment (SGA). However, survival
analysis of this study revealed that only SGA predicted survival out of other
numerical and measurable nutritional markers.
7.2.2. Chapter 5
This study addressed the factors that have negatively influenced survival and
increased hospital admission of patients starting RRT in Edinburgh in 2003 and
2004. Survival was affected by increased age, presence of comorbid conditions,
starting treatment with temporary access, and level of serum cholesterol. Out of all
comorbid conditions that were collected at the start of patient treatment, congestive
cardiac failure and ischaemic heart disease were the most important diseases that
affected patient survival. Hospitalisation was higher in old age, high risk patients,
females and those who started dialysis with temporary access
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The limitations of this study were; - the number of involved patients was small. The
proportion of peritoneal dialysis was also small which did not allow us to compare
between the two dialysis modalities.
The other limitation in this study is using Kaplan Meier method in comparing patient
survival on haemodialysis and peritoneal dialysis. There were very few patients
receiving peritoneal dialysis and therefore the results of the Kaplan-Meier analysis in
this context must be viewed with caution
A further potential limitation of the study is the possibility of lead time bias. This
kind of limitation may lead to differences between countries and renal centers in
measuring survival from the start of RRT. For example, apparent survival will be
longer if RRT is started at GFR=10 than in those who started with at GFR=5 as it is
measured from a time point earlier in the course of the disease. However, lead time
bias is unlikely a factor in this study because it is a single center study.
7.2.3. Chapter 6
The controversy created by the UKRR report on short term survival and SRR report
on long term survival of Edinburgh renal patients was unit investigated by comparing
the outcomes of patients started dialysis in 2003 and 2004 with the outcomes of a
previously conducted study in 2001 in the same renal unit. The comparison revealed
that overall survival was unchanged between both studies despite accepting older and
more high risk patients in 2006 study and there was a substantial reduction in
hospitalisation in 2006 study. Severity of comorbidity, serum albumin, serum
cholesterol and starting dialysis with permanent access were important predictors of
survival in patients started dialysis in 2003 and 2004.
There were several changes in practice between the two studies: the unit moved
hospitals and gained more nephrologists, more machines, there was a greater use of
high flux dialyzers and more rigorous audit was implemented particularly in the
haemodialysis services. However, we do not know for certain if these changes could
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explain the improvement in survival of high risk patients especially when we
consider the disappointing results from the HEMO study of no significant survival
advantages from using high rather than low flux dialyzers.
The limitation includes small number of patients with inadequate statistical power to
compare the high risk group in both studies.
7.3. Factors associated with survival
7.3.1. Age
The median age of the incident patients in Edinburgh has risen from 63 years (range
17- 87) in 2001 to 65 years (range 18-88) in 2006. Similarly, the median age of
incident dialysis patients in Scotland and the UK, has been increased from 63.9 and
63 years in 1998 to 65.5 and 65 years in 2007 respectively (Ansell et al., 2007).
The number of elderly patients requiring RRT has increased worldwide. In 1980,
USRDS reported that 28.5% of dialysis patients were > 65 years of age. In 2000, the
same age group had increased to 49.9% (USRDS 2007). The UKRR showed that the
percentage of new patients who are over 65 years of age has increased from 43% in
1987 to 51.2% in 2006 (Ansell et al., 2007). In Edinburgh 52.7% of patients who
started dialysis in 2003 and 2004 were > 65 years.
Age is the most powerful factor associated with survival in patients receiving RRT.
Multivariate analysis in chapter 4 and 5 showed that each additional year of patient
age increased the risk of death by 5% in prevalent patients and 3% in incident
patients. The UKRR (2005) reported that for every 10 year increase in patient age,
there is an increase in the hazard of death of 41% (Ansell et al., 2005).
The mortality rates of patients starting dialysis in 2003 and 2004 in Edinburgh were
7.7% at one year and 12% at two years in young patients (<65 years) compared with
18.6% at one year and 26.2% at two in old patients (> 65 years), However these
figures are much lower than reported from UK and US especially for old patients. In
2007, the UKRR reported the difference in mortality rates of new dialysis patients
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according to same age groups were 10% at one year and 16% at two years in young
patients whereas in old patients were 27% at one year and 45% at two years (Ansell
et al., 2007). In the 2007 USRDS report when patients who were dead in the first 90
days excluded, the mortality rates in younger patients were 10% at 1 year, and 18%
at two years but the mortality rates in patients > 65 years were 30% at one year and
48% at two years (USRDS 2007).
7.3.2. Comorbidity
Comorbid disease is well recognized as an important determinant of clinical
outcome, in terms of morbidity and mortality, for patients receiving RRT (Collins et
al., 1990; and Khan et al., 1998). Comorbid conditions were very common in
Edinburgh incident patients, 76% have one or more comorbid conditions. Congestive
cardiac failure and ischaemic heart disease were the most common conditions, seen
in 38% and 34% of patients respectively. The increased frequency of comorbidity
was reported by UKRR (2007) where 55% of all patients starting RRT between 2001
and 2006 in centres reporting to the UKRR have one or more comorbidities. The
most frequent comorbid diseases were diabetes 29% followed by ischaemic heart
disease 24% (Ansell et al., 2007).
Analyses of our study demonstrated that comorbidity was associated with increased
mortality at early (90 days), at one year and late at 2 years of follow up in dialysis
patients starting RRT in Edinburgh. Similar observation of comorbidity associated
with early mortality (90 days) has been publicized in a prospective study of 532
patients commencing RRT for ESRD in Scotland over one year, when comorbidity
was assessed using Khan score to classify patients into 3 risk groups. They found that
comorbidity was associated with early mortality (first 90 days) and patients in
medium and high comorbidity risk groups had early mortality rates of 2.2 and 4.7
times greater than those in the low-risk group (Metcalfe et al., 2000). Also similar
observations of comorbidity association with late mortality (2 years) were shown in
an observational study of 523 patients starting RRT in Scotland over a 1 year period,
followed for the first 2 years when Charlson index was used to group patients
according to comorbid conditions. They found increased comorbidity was a strong
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predictor of poor outcome. Patients who scored more than 2 on the Charlson scale
had 2.6 times the odds of death higher than those who started RRT with no comorbid
condition over 2 years (Metcalfe et al., 2003). The DOPPS study showed that
different comorbid conditions were associated with increased mortality among
haemodialysis patients (Goodkin et al., 2003).
The above observations of poorer outcomes influenced by presence of comorbid
disease at start of RRT is consistent with the UKRR (2006) that showed mortality
within 90 days of starting RRT was influenced by presence of ischaemic heart
disease, peripheral vascular disease, liver disease and malignancy. One year
mortality was associated with ischaemic heart disease, peripheral vascular disease,
cerebrovascular disease, diabetes, chronic obstructive pulmonary disease, liver
disease and malignancy (Ansell et al., 2006)
In chapter 5 comorbid conditions were assessed using three different comorbidity
scores (Charlson, Khan, and Davies). The 3 comorbidity scores performed equally in
predicting mortality, in agreement with van Manen and colleagues (2003). Therefore,
Charlson, Khan and Davies scores may all be used to predict patient survival.
7.3.3. Late Referral
The percentage of incident patients who started RRT in 2003 and 2004 that was
referred late (less than 90 days) was 28%. In developing countries, the proportion of
patients referred late for nephrology care is as high as 62% (Sesso et al., 1996) while
in developed countries it is ranges between 25% and 40% (Arora et al., 1999;
Schmidt et al., 1998; and Roubicek e al. 2000)). In 2007, UKRR reported that the
incidence of late referral (less than 90 days) ranged from 10 to 38% (Ansell et al.,
2007).
Late referral may be a reflection of suboptimal pre-ESRD care as many observational
studies showed that late referral associated with the following unfavourable
consequences (Ratcliffe et al. 1984; Jungers et al., 1993; Eadington et al., 1994;
Schmidt et al., 1998; and Roubicek et al., 2000): -
1. Poor control of blood pressure
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2. Lower eGFR
3. Anaemia and lower haemoglobin concentration
4. Renal bone disease with low concentration of calcium and phosphate
5. Poor nutritional status as measured with serum albumin and BMI
6. Metabolic acidosis
7. Emergency haemodialysis
8. Increase frequency of temporary access use
9. Increase rate of hospitalisation and health care cost
10. Reduced chance of receiving kidney transplantation
11. Lack of psychological preparation for RRT
The univariate analysis in chapters 5 and 6 and multivariate analysis in chapter 5
revealed that late referral was associated with increased mortality in patients starting
dialysis in 2003 and 2004. The increased mortality associated with late referral has
been reported in several observational studies. In a study of 3104 dialysis patients
showed that patients who referred late (<90 days) had 36% higher mortality rate
compared with those who had early referred to nephrology care. Excess mortality
among late referral was limited to the first 3 months of dialysis but not present
thereafter (Winkelmayer et al., 2003). A study which evaluated the impact of early
nephrology referral and pre-ESRD care on mortality risk in 2246 new dialysis
patients from USRDS found the mortality risks were higher for late referral (<4
months) compared with early referral patients (1.68 at one year and 1.23 at 2 years)
(Stack 2003). In a prospective study of 2195 incident dialysis patients, 33% were
referred late (<4 months). Late referral was associated with higher risk of death at
one year after initiation of dialysis compared with early referred patients (Kazmi et
al., 2004).
Patients who are referred late to nephrology care are reportedly to be those who are
older, sicker and with more comorbid disease. In 2007 the UKRR reported that
patients who were referred late were significantly older than referred earlier (median
age 67.7 vs. 64.8 years) and they had more comorbidity compared to those referred
earlier (Ansell et al., 2007). Khan and colleagues (1994) showed that increasing age
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and coexisting illnesses are more frequent in patients referred late. Also late referred
patients were observed to be unable to ambulate independently and to be
unemployed due to disability compared to patients who were referred early (Kazmi
et al., 2004).
In dialysis patients randomized control trials have shown different conclusions from
observational studies. For example the HEMO study which failed to show any
survival advantages of increasing dialysis dose beyond the recommended one, or
using high flux dialyzers instead of low flux. Another example is failure of
randomized controlled trials to show any benefits from normalisation of
haemoglobin values in dialysis patients. Despite the strong suggestion from
observational studies about late referral and increased mortality. It is possible that
early referral would not lead to predicted reduction in mortality, it would be difficult
to design a randomized controlled trial to evaluate whether the referral time effect on
survival of dialysis patients was due to confounding or causation.
7.3.4. Vascular Access
Out of patients who started RRT in 2003 and 2004, 49% started with definitive
access. Of patients who started on haemodialysis, 41% commenced with definitive
access. The UKRR (2006) reported that 51% of all patients started with definitive
access. However, only 37% of haemodialysis patients started with permanent access
(Ansell et al., 2006)
The analysis in chapters 5 and 6 demonstrated a significantly increased risk of death
in patients who received treatment via temporary access. The risk of death was 3
times higher in patients who started dialysis with temporary access compared with
those who started with permanent access. Similarly Polkinghorne and colleagues
(2004) tested the effect of access type on total mortality in 3749 incident
haemodialysis patients from ANZDATA Registry who commenced treatment from
1999 until 2002 and found that use of temporary access in incident haemodialysis
patients was associated with significant rise in total mortality. Interestingly, Allon
and associates (2006) found that changing the vascular access affected the risk of
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death in haemodialysis patients. Change from a catheter to AV access was associated
with a substantial decrease in mortality risk. The relative risks for mortality were 3.4
in patients who dialyzed with a catheter; 2.3 in patients switching from an AV access
to a catheter, and 1.3 in patients switching from a catheter to an AV access (Allon et
al., 2006).
The increased risk of death among individuals who are dialyzed through temporary
access could be explained by: -
First, Temporary access is associated with more frequent infection than permanent
access, and infection is associated with higher hospitalisation and mortality rates
(Churchill et al., 1992 and DOQI 1997d). A study of 7497 prevalent haemodialysis
patients from 279 haemodialysis treatment facilities showed that venous catheters
were associated with an increased risk of all-cause and infection-related mortality.
Patient characteristics independently associated with the presence of a catheter
included lower serum albumin, more severely impaired functional status, lower mean
URR (63%) compared to those dialyzed with fistula (69.5%) and lower mean blood
flow rate during dialysis (328.6 ml/min) compared to those dialyzed with a fistula
(418 ml/min) (Pastan et al., 2002). In 2005 the UKRR reported there was evidence of
an association between the use of venous catheters and morbidity judged by
hospitalisation and staphylococcus aureus infection (Ansell et al. 2005).
Second, venous catheters are associated with inadequate dialysis dose received in
haemodialysis patients. In 1996 the USRDS reported that the mean delivered dose
Kt/V for patients who started haemodialysis was 1.04 in those dialyzed via a venous
catheter and 1.14 in those dialyzed via AV fistula (USRDS 1996). An observational
study analyzed data from the USRDS on 5507 prevalent haemodialysis patients. It
found that venous catheters are correlated with increased mortality risk when
compared with permanent access. Dialysis dose measure by a single pool Kt/V was
about 10% lower for patients with venous catheter than those with AV access
(Dhingra et al., 2001). The inadequate dialysis dose could be a consequence of lower
blood flow defined by DOQI guidelines as less than 300 ml/min (DOQI, 2001b).
Pastan and colleagues (2002) found that venous catheters were associated with lower
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blood flow compared to AV access. The interrelation of venous catheter, reduced
blood flow and inadequate dialysis dose may play a role to increased mortality in
patients dialyzed via temporary access The relationship between mortality risk and
dialysis adequacy was discussed in chapter 1.
Third, the characteristics of those haemodialysis patients who were dialyzed through
venous catheter are different. They are older, sicker and have more frequent
comorbid conditions (congestive cardiac failure, ischaemic heart disease, peripheral
vascular disease, vascular disease, diabetes, and malignancy) that contribute to
increase the risk of mortality in those patients (Dhingra et al., 2001; and Di Iorio et
al., 2004).
Vascular access remains a key component for treatment of patients receiving
haemodialysis. International differences in outcomes for patient outcomes have been
suggested to be associated with vascular access type (Ansell et ah, 2006).
7.3.5. CRP
Previous studies have reported that elevated CRP level has been shown to be strongly
predictive of an increased risk of future myocardial infarction and predicts mortality
in apparently healthy people as well as in patients with established coronary heart
disease (Ridker et ah, 1998; and Morrow et ah, 1998; and Danesh et ah, 2004).
Higher CRP levels were also found in dialysis patients (Zimmermann et ah, 1999;
and Ortega et ah, 2002). The analysis of chapters 4, 5 and 6 showed that CRP was
associated with mortality in both incident and prevalent dialysis patients. Similarly,
many observational studies reported that CRP is a significant predictor of death in
dialysis patients (Iseki et ah, 1999; Yeun et ah, 2000; Kato et ah, 2001; Wanner et
ah, 2002).
The high mortality with increased CRP could be explained by atherosclerotic
cardiovascular disease being associated with inflammatory disorders. Inflammation
evidenced by high levels of CRP is closely related to high levels of atherogenic
vascular risk factors and cardiovascular death. Zoccali and colleagues (2000)
suggested that the association between inflammation and atherosclerosis is strong in
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dialysis patients and they have shown that CRP is independently associated with
intima media thickness and the number of atherosclerotic plaques in carotid arteries
of dialysis patients. Stenvinkel and collaborates (1999) showed a strong relationship
between elevated CRP levels and the thickness of intima media in predialysis
patients. Zimmermann and associates (1999) found that patients with elevated CRP
levels had significantly higher serum lipoprotein (a), higher plasma fibrinogen and
lower levels of HDL and serum albumin which is associated with increased overall
mortality and cardiovascular mortality.
On the other hand, recent experimental work claimed that CRP could be a direct
cause of death. Pepys and colleagues (2006) showed that therapeutic inhibition of
CRP is a promising new approach to cardio-protection. Administration of CRP
binding inhibitor [l,6-bis(phosphocholine)-hexane] to rats undergoing acute
myocardial infarction stopped the increase in infarct size and cardiac dysfunction
produced by injection of human CRP (Pepys et al., 2006).
7.3.6. Serum Albumin
Low albumin levels are powerful predictors of cardiovascular and all cause mortality
in haemodialysis patients (Lowrie et al., 1990; and Churchill et al., 1992). The serum
albumin concentration in dialysis patients changes with nutritional status and
inflammation through their effects on albumin synthesis and increased fractional
catabolic rate (Kaysen 2002).
Serum albumin as significant predictor of mortality was found in all univariate
analyses, but in multivariate analysis only in chapter 5 (when all comorbid conditions
were entered into the analysis instead of using single comorbid score) and chapter 6.
Each additional 1 g/1 in averaged attained albumin decreased the odds of death in the
first two years of treatment by 4%. The association between serum albumin and poor
prognosis is widely reported. The Canadian haemodialysis morbidity study showed
that patients with a low serum albumin level (<30g/l) at the start of haemodialysis
treatment had a higher probability of hospitalisation and infection related mortality
than did patients with higher serum albumin levels (Churchill et al., 1992). The
DOPPS study showed a highly significant association between low serum albumin
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levels and higher risk of death (Pifer et al., 2002). Also the CANUSA study (1996)
showed that low serum albumin levels were associated with an increased risk of
hospitalisation and mortality. Foley and colleagues (1996c) found hypoalbuminaemia
to be a major adverse prognostic factor in dialysis patients. Kaysen and co-workers
(2002) also showed a strong association between serum albumin and mortality in
haemodialysis patients.
7.3.7. Serum Cholesterol
In chapter 5 and 6 higher rather than lower serum cholesterol levels at the start of
dialysis provided significant survival advantages in patients started RRT in 2003 and
2004. Many prospective studies of dialysis patients have shown the same association
of elevated cholesterol levels with lower mortality. In a study of more than 12000
haemodialysis patients; Lowrie and Lew (1990) noted that mortality risk was
significantly lower at higher total cholesterol levels. Also Iseki and colleagues (2002)
enrolled 1167 chronic haemodialysis patients in a prospective study and showed that
low serum cholesterol level was an independent predictor of death in patients on
chronic haemodialysis and 5 years survival rates of patients who had high serum
cholesterol (>220 mg/dl [5.2 mmol/1]) were better than patients with lower serum
cholesterol (<140 mg/dl [3.3 mmol/1]). The high serum cholesterol and lower
mortality association is opposite to studies and clinical trials in the general population
as discussed in chapter 1.
The inverse association of reduced mortality with high levels of serum cholesterol
could be explained by;
First, it is likely to be due to inflammation and malnutrition, not to a protective effect
of high serum cholesterol. However, the mechanism by which systemic inflammation
and malnutrition may confound the association between cholesterol and mortality is
not entirely clear. A Prospective study of 823 haemodialysis patients by Liu and
colleagues (2004) used a stratification based on serum albumin, interleukin-6 and
CRP levels to evaluate patients with different nutritional and inflammatory status
separately. They found that low levels of serum cholesterol were associated with
increased mortality in patients with chronic inflammation, but in the absence of
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inflammation an elevated level of serum cholesterol was associated with increased
mortality, as in the general population.
Second, high cholesterol levels protect against infections, while low cholesterol
levels predispose to infections. The lipoprotein pool may serve as an effective
scavenger to bind with and neutralize the circulating lipopolysaccharides (bacterial
endotoxin) (Ravnskov 2003; Rauchhaus et al., 2000; and Niebauer et al., 1999). Low
levels of serum lipoproteins including cholesterol is common in dialysis patients so it
has been suggested that elevated levels of serum cholesterol provides a protective
effect from bacterial infection as an inhibitor of endotoxin (Kalantar-Zadeh et al.,
2004b; and Ravnskov 2004).
Third, presence of comorbid conditions can be associated with low cholesterol levels
and increased mortality (Neaton et al., 1992). Study by Iribarren and colleague
(1995) demonstrated that the presence of malignancy, liver disease, and other chronic
illnesses partially explains the inverse association of low cholesterol level and high
mortality.
7.3.8. Subjective Global Assessment (SGA) of nutritional status
Malnutrition is a common risk factor in dialysis patients and associated with
increased mortality (Hakim et al., 1993; Owen et al., 1993; Cianciaruso et al. 1995;
and CANUSA, 1996). The DOQI guidelines stress the significance of assessment of
nutritional status in dialysis patients (DOQI, 1997b). Methods to assess nutritional
status in dialysis patients range from simple anthropometric measurements to
complex tools (Nelson et al., 1990; Chertow et al., 1995). SGA was originally
developed to assess nutritional status in hospitalised post operative patients (Detsky
et al., 1987), but has been used in non kidney and kidney patients (Enia et al., 1993;
Kalantar-Zadeh et al., 1998).
SGA scoring can effectively discriminate malnourished dialysis patients from those
with normal nutrition (Cooper et al., 2002). More importantly, SGA has been shown
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to be a dependable predictor of poor outcome in dialysis patients (CANUSA 1996;
Chung et al., 2000; Pifer et al., 2002; and Hung et al., 2005).
The results in chapter 4 showed SGA was an independent nutritional factor that
predicted the overall mortality of prevalent dialysis patients at 2 years. The risk of
death was 2.4 and 5.1 times higher in moderately and severely malnourished patients
respectively, compared with the well nourished group. Similarly, The CANUSA
study of 680 peritoneal dialysis patients in 14 centers in Canada and the United
States showed the value of SGA in predicting survival. The SGA in the CANUSA
study was determined by the same method used in chapter 4. The CANUSA study
reported that 4.2% were severely malnourished, 51.2% had mild to moderate
malnutrition, and 44.6% were well nourished. In the study in chapter 4 severe, mild
to moderate and well nourished comprised 3.3%, 33.6% and 63.1% respectively. One
reason behind the increase in the proportion of well nourished patients in the study in
chapter 4 was because it included prevalent dialysis patients whereas the CANUSA
study included incident patients. However, patients included in chapter 4 were
representative to the real sample of dialysis population as it involved both
haemodialysis and peritoneal dialysis while CANUSA included only peritoneal
dialysis. The results of CANUSA study showed a 1 unit change in the SGA total
score was associated with 25% difference in the relative risk of death. In chapter 4
the SGA due to small sample size the mortality risk was tested using the well
nourished group as a reference. Mortality risk was more than 2 and 5 times higher in
moderate malnourished and severe malnourished respectively (CANUSA 1996).
Further support for the significance of using SGA in predicting survival of dialysis
patients came from the DOOPS study of 7719 haemodialysis patients. DOPPS study
used modified SGA (SGA method used in chapter 4 plus also points for energy level
and disease burden) to classify patients into one of 3 modified SGA groups:
normally, moderately or severely malnourished. This study showed that several
readily measurable nutritional indicators (serum albumin, serum creatinine and BMI)
together with SGA were significant predictors of mortality. The mortality risk was
increased by 33% and 5% in patients with severe and moderate malnutrition
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respectively than patients with normal modified SGA scores (Pifer et al., 2002).
However, the DOPPS study included only haemodialysis patients, and the inclusion
of patient reports about energy level and disease burden in the score raises questions
as to how accurate this modified SGA score is to assess the nutritional status
compared with the traditional SGA score. Unlike the DOPPS study out of all
nutritional markers entered in the analysis in chapter 4 only SGA was a significant
independent predictor of survival.
Although several interventions are available in treatment of malnutrition in
haemodialysis patients (e.g. dietary intake intervention, intradialytic parenteral
nutrition, nandrolone treatment), they are often of limited efficacy and not without
compliance problems and adverse effects. Recently, a multi national randomized
control trial conducted at 23 centers in 9 countries aimed to establish clinical proof of
the concept that human growth hormone treatment could improve of nutritional
status. This study, which included 139 maintenance haemodialysis patients who had
serum albumin levels <40 g/1, randomly assigned patients to 6 months of treatment
with placebo or 20, 35, or 50 ug/kg/pcr day human growth hormone. The study
showed that human growth hormone safely increases lean body mass, serum
albumin, serum HDL, and serum transferrin, reduces homocysteine and improves
health related quality of life in adult patients who are on maintenance haemodialysis
(Feldt-Rasmussen et al., 2007).
Practically, a randomized control study to evaluate the available nutritional markers
in predicting nutritional status and survival in dialysis patients will be the key to find
a standard method to assess the nutritional status of dialysis patients, especially when
some of the used nutritional indicators such as serum albumin, cholesterol and body
mass index has been shown inversely associated with survival in dialysis patients.
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7.3.9. Congestive Cardiac Failure
Congestive cardiac failure is the most difficult comorbid disease to assess in dialysis
patients. Echocardiography remains the gold standard method to assess congestive
cardiac failure. In this study the Scottish Renal Registry (SRR) comorbidity criteria
(appendix 5) were applied by one observer to assess congestive cardiac failure. The
analysis showed 38.3% and 14.8% of incident and prevalent dialysis patients
respectively, had congestive cardiac failure. In 2007, USRDS reported the percentage
of congestive heart failure in new dialysis patients increased from 30.6% in 1995 to
34.2% in 2006.
Cardiovascular disease is the most common cause of death in dialysis patients.
Congestive cardiac failure is a common presenting symptom of cardiovascular
disease in the dialysis population and is associated with systolic failure, left
ventricular hypertrophy and ischaemic heart disease (Parfrey et al., 1988). Moreover,
haemodialysis patients are known to have both a high prevalence and a high risk for
developing congestive cardiac failure (Foley et al., 2000; and USRDS 2002).
Presence of congestive cardiac failure at the beginning of RRT is a poor prognostic
indicator of mortality (Hutchinson et al., 1982).
Congestive cardiac failure was a strong predictor of mortality in the incident patients
who started their RRT in 2003 and 2004. In a prospective multicenter cohort study
which included 423 dialysis patients by Harnett and colleagues (1995) followed for a
mean of 41 months, the median survival of subjects with congestive cardiac failure at
baseline was 36 months compared to 62 months in subjects without congestive
cardiac failure. They also found that older age, hypertension, diabetes and ischaemic
heart disease were independent predictors for the presence of congestive heart failure
on initiation of RRT. Ischaemic heart failure, anaemia, hypoalbuminaemia and
hypertension were independent predictors for recurrence of heart failure in dialysis
patients (Harnett et al., 1995). The DOPPS study also showed the risk of death was
increased with cardiovascular comorbidities (heart failure and coronary artery
disease) (Goodkin et al., 2003).
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7.4. Hospitalisation
Measurements of hospitalisation in dialysis population are important outcome
predictors and provide information about the morbidity and the cost of treatment of
dialysis patients. The results in chapters 4, 5 and 6 demonstrated that prolonged
duration of hospitalisation was associated with older age, and comorbidity. Likewise,
in several observational studies the age was shown to be a significant risk factor for
increased hospital admissions as older patients (>60 years) had increased
hospitalisation rates (Carlson et al., 1984; and Serkes et al.1990). Rocco and
colleagues (1996) included 1572 incident dialysis patients and found that increased
age, comorbid condition (ischaemic heart disease, congestive cardiac failure,
peripheral vascular disease and diabetes) and low serum albumin were associated
with higher rates of hospitalisation. Athienites and colleagues (2000) found that
higher burden of comorbid conditions at the onset of treatment was strongly
correlated with a higher rate of hospitalisation and was an independent predictor of
mortality. Furthermore, several observational studies have demonstrated the strong
association between increased hospitalisation rates and the presence of several
comorbid illnesses in particular cardiovascular disease, congestive cardiac failure,
and diabetes (Murphy et al., 2000; Charytan et al., 1986; Serkes et al., 1990; and
Burton et al., 1989).
In our study comorbidity was assessed using Charlson, Khan and Davies comorbid
scores and all scores were significantly associated with increased hospitalisation
rates. Similar observations were reported in other studies. Chandna and colleagues
(1999) retrospective study included 292 dialysis patients and showed that age and
comorbidity assessed by Khan score were significant factors influencing
hospitalisation. Similarly the Charlson index of comorbidity has previously been
shown to be independently associated with length of hospital stay for patients
admitted with acute chest pain (Matsui et al., 1996) and after stroke (Monane et al.,
1996). Beddhu and collaborators (2002) showed that patients who are older and with
greater comorbidity assessed by the Charlson index have a greater risk of
hospitalisation and death. Fried and associates (2003) showed that the Charlson
comorbidity score was a significant predictor of hospitalisation and mortality.
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In chapter 4 SGA low score was associated with increased rates of hospital stay, the
rate of hospital admission was 1.9% and 5.3% higher in moderate and severe
malnourished groups compared with well nourished group. Similar results have been
reported in a prospective cohort study of nutritional markers and dialysis adequacy in
680 peritoneal dialysis in 14 centers in Canada and the United states (CANUSA)
which demonstrated that hospitalisation rate and mortality risk were increased with
worsened nutrition according to SGA and decreased serum albumin (CANUSA
1996).
Furthermore, with the aid of SGA for estimating nutritional status, the malnutrition
inflammation score has been developed. The malnutrition inflammation score
consists of SGA with 3 severity levels to assess nutritional state combined with
anthropometric and biochemical measurement. Kalantar-Zadeh and colleagues
(2004) have examined malnutrition inflammation score utility in predicting outcome
in 385 haemodialysis patients and showed that malnutrition inflammation score was
a good predictor of hospitalisation and mortality in haemodialysis patients.
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Conclusions
A clear definition for all comorbid conditions in particular congestive cardiac
failure is important if studies are to be comparable.
Measuring SGA provides significant additional information about prognosis
beyond the regular use of SGA as a nutritional tool.
The main factors that influenced prevalent patient survival were comorbidity,
nutritional status, age and CRP
The most important predictors of survival in patients starting RRT in 2003 and
2004 were age, comorbidity, initial access and initial serum cholesterol.
The major cause of mortality in both incident and prevalent patients was
cardiovascular disease, followed by infection.
Hospitalisation was good predictor of outcome in incident and prevalent dialysis
patients. Hospital admission was increased in old, high risk and malnourished
patients.
Two year survival rate was essentially unchanged between 2001 and 2006
cohorts despite accepting older and more high risk patients in the more recent
study. Hospitalisation was halved in the recent cohort, the reduction noted
occurred across a period of moving to a new hospital and multiple changes in
working practices and in patient supervision and audit policies.
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Recommendations
The conclusions and observations obtained in this study make it possible to suggest
policies and areas for further studies.
• SGA should be assessed for all patients at the time of commencing RRT. In
Chapter 4 out of all nutritional parameters only SGA was independently
found to be associated with survival.
• A randomized controlled trial is needed to evaluate the long term effect of
interventional nutritional methods in dialysis patients, because malnutrition is
highly prevalent in dialysis patients and potentially reversible.
• Early referral to nephrology care might help avoid the disadvantages of late
referral that have been reported in many observational studies. But the scale
of benefit from this may not as high as hoped. Nevertheless it is worth
referring patients because of the advantages listed in chapter 7.
• Commencing dialysis with permanent vascular access. The increased
mortality associated with temporary access in incident dialysis patients in the
Edinburgh Renal Unit suggests that the type of access employed may have
subsequent implications for survival that provide an additional reason for
aggressive pursuit of starting dialysis with permanent access.
• Adopting a method of recording comorbidity (standardized comorbidity
score) uniformly in a straightforward manner and with clear definitions of the
co-morbid conditions, in particular congestive cardiac failure, so that survival
statistics can be meaningfully compared between patients in different renal
units.
• Long term follow up of the 2003 and 2004 cohort to assess the survival of
those patients in 5 and 10 years will be valuable.
• Multicenter studies to evaluate factors associated with survival in dialysis
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Appendix 1: Comorbidity scoring system













Moderate to severe renal failure (excluded in our study)
Diabetes with end organ damage
Any tumour (solid tumour without metastases diagnosed in past 5 years)
Leukaemia (acute and chronic and Polycythemia vera)
Lymphoma (includes Hodgekins, Waldenstroms, Myeloma,
lymphosarcoma)
3 Moderate or severe liver disease (cirrhosis, portal hypertension, varicies)
6 Metastatic solid tumours
HIV
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Appendix 1.2: Khan score
Grade-0 (low risk) Age<70 years and no comorbid disease
Grade-1 (medium risk) Age 70-80 years, or <70 years age with any one of the
following: Angina, previous myocardial infarction,
cardiac failure, chronic obstructive airway disease,
pulmonary fibrosis, or liver disease (cirrhosis, chronic
hepatitis), peripheral vascular and cerebrovascular
diseases or <70 with diabetes mellitus
Grade-2 (high risk) Age>80 years, or <80 years with two or more organ
dysfunction, cardiopulmonary disease, visceral
malignancy, or 70-80 years with diabetes or
cardiopulmonary disease.
Appendix 1.3: Davies score
Conditions






Other significant pathology (chronic pulmonary diseases)
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Appendix 2: ERA-EDTA Primary Renal Diagnosis Codes and Groupings
Group 1 Primary Glomerulonephritis
10 Glomerulonephritis histologically NOT examined
11 Focal segmental glomerulosclerosis with nephrotic syndrome in children
12 IgA nephropathy (proven by immunofluorescence, not 85)
13 Dense deposit disease, membranoproliferative GN; type II (proven by
immunofluorescence and/or electron microscopy)
14 Membranous nephropathy
15 membranoproliferative GN; type I (proven by immunofluorescence and/or
electron microscopy - not code 84 or 89)
16 Crescentic (extracapilliary) glomerulonephritis (type 1,11, III)
17 Focal segmental glomerulonephritis with nephrotic syndrome in adults
19 Glomerulonephritis; histologically examined, not given above
Group 2: Interstitial Nephropathies
20 Pyelonephritis cause not specified
21 Pyelonephritis associated with neurogenic bladder
22 Pyelonephritis due to congenital obstructive uropathy with/without vesico-
ureteric reflux
23 Pyelonephritis due to acquired obstructive uropathy
24 Pyelonephritis due to vesico-ureteric reflux without obstruction
25 Pyelonephritis due to urolithiasis
29 Pyelonephritis due to other cause
30 Interstitial nephritis (not pyelonephritis) due to other cause, or unspecified
(not mentioned
31 Interstitial nephropathy due to analgesic drugs
32 Interstitial nephropathy due to cis-platinum
33 Interstitial nephropathy due to cyclosporin A
34 Lead induced interstitial nephropathy
39 Drug induced interstitial nephropathy not mentioned above
40 Cystic kidney disease - type unspecified
41 Polycystic kidneys; adult type (dominant)
42 Polycystic kidneys; infantile (recessive)
43 Medullary cystic disease; including nephronophthisis
49 Cystic kidney- disease - other specified type
50 Hereditary/Familial nephropathy - type unspecified




59 Hereditary nephropathy - other specified type
61 Oligomeganephronic hypoplasia
63 Congenital renal dysplasia with/without urinary tract malformation
66 Syndrome of agenesis of abdominal muscles (Prune Belly)
92 Gout nephropathy (urate)




























Group 3; Multisystem Diseases
Renal vascular disease - type unspecified
Renal vascular disease due to malignant hypertension (No PRD)
Renal vascular disease due to hypertension (No PRD)
Renal vascular disease due to polyarteritis
Wegeners Granulomatosis
Ischaemic renal disease / cholesterol embolisation
Glomerulonephritis related to liver cirrhosis
Cryoglobulinaemic glomerulonephritis
Renal vascular disease - due to other cause (not given above and not code
84-88)






Haemolytic uraemic Syndrome (including Moschcowitz Syndrome)
Multi-system disease - other (not mentioned above)




Traumatic or surgical loss of kidney
Group 4: - Diabetes
Diabetic glomerulosclerosis or diabetic nephropathy
Group 5: - Not Known and Other
Chronic renal failure; aetiology uncertain/unknown/unavailable
Renal hypoplasia (congenital) - type unspecified
Other identified renal disorders
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Appendix 3: ERA-EDTA Cause of Death Codes
00 Cause of Death uncertain/not determined
11 Myocardial ischaemia and infarction
12 Hyperkalaemia
13 Haemorrhagic pericarditis
14 Other causes of cardiac failure
15 Cardiac arrest, cause unknown







24 Haemorrhage from graft site
25 Haemorrhage from vascular access or dialysis circuit
26 Haemorrhage from rupture vascular aneurysm (not codes 22,23)
27 Haemorrhage from surgery (not codes 23,24,26)
28 Other haemorrhage (not codes 23-27)
29 Mesenteric infarction
29 Mesenteric infarction
31 Pulmonary infection (bacterial)
32 Pulmonary infection (viral)
33 Pulmonary infection (fungal or protozoal)




38 Generalized viral infection
39 Peritonitis (not code 70)
41 due to Hepatitis B virus
42 due to other viral Hepatitis
43 due to drug toxicity
44 Cirrhosis-not viral
45 Cystic liver disease
46 Liver failure-cause unknown
51 Patient refused further treatment
52 Suicide
53 Therapy ceased for any other reason
61 Uraemia caused by graft failure
62 Pancreatitis
62 Pancreatitis
63 Bone marrow depression
64 Cachexia
66 Malignant disease possibly .induced by immunosuppression, therapy
67 Malignant disease except those of 66
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69 Dementia
70 Sclerosing (or adhesive) peritoneal disease
70 Sclerosing (or adhesive) peritoneal disease
71 Perforation of peptic ulcer
71 Perforation of peptic ulcer
72 Perforation of colon
72 Perforation of colon
81 Accident related to treatment
82 Accident unrelated to treatment
99 Other cause of death please specify
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Appendix 4: Evaluation form for Subjective Global Assessment
Medical History
Weight changes
□ Usual dry weight: kg
□ Current dry weight: kg
□ (Weight 3 months ago: kg %)
□ Weight 6 months ago: kg
□ Overall change in past 6 months: kg % SGA score 1: Weight change
% change over past 6 months:
□ gain or <5% loss
□ 5-10% loss
□ >10% loss
Severe Mild Moderate Normal
1 2 3 4 5 6 7
Change in the past 2 weeks:
□ increase □ no change □ decrease
Dietary intake
□ no change:
□ adequate intake □ inadequate intake
□ change:
□ increase □ decrease
„ ... . . SGA score 2: Dietary intake & GIT symptoms
Overall duration: weeks
Severe Mild Moderate Normal
^uange in pieviuus u liiuuuis.
□ yes □ no
changes in the past 2 weeks:
□ yes □ no
1 2 3 4 5 6 7
Gastrointestinal Symptoms




□ Biceps □ Triceps SGA score 3 & 4: : Physical Examination
Subcutaneous fat
□ Triceps □ Chest □ Eyes
□ Perioral □ Interosseous □ Palmar
Severe Mild Moderate Normal
1 2 3 4 1 2 3
Oedema
□ Hands □ Sacral □ lower extremity
Overall SGA Classification
severe moderate mild normal
1 2 3 4 5 6 7
C B A
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Appendix 5: Scottish Renal Registry (SRR) comorbid conditions
Comorbid conditions
Congestive Cardiac Failure (CCF) Clinical diagnosis of CCF prior to starting RRT.
Echocardiogram Evidence
Angiographic Evidence
Fluid overload may be difficult to exclude and where
reasonable clinical doubt exist CCF should be
recorded.
Myocardial Infarction (MI) Diagnosis of MI at any time prior to date of starting
RRT.
Based on clinical history and either diagnostic ECG
changes or diagnostic biochemical indices.
Peripheral vascular disease Clinical history of intermittent claudication.
Angiographic evidence of peripheral artery atheroma.
Chronic Pulmonary disease Clinical diagnosis based upon pulmonary function
tests or pulmonary imaging
Foot ulcer Any cause of foot ulceration except venous eczema.
Diabetic foot ulcer, ischaemic foot ulcer included.
Malignancy Skin basal cell carcinoma excluded
All solid organ and haematological malignancies
included.
Serum albumin at start of RRT
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